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A Toxicological Profile for chloroethane was released in December 1989. This edition supersedes any 
previously released draft or final profile. 
Toxicological profiles are revised and republished as necessary, but no less than once every three years. 
For information regarding the update status of previously released profiles, contact ATSDR at: 
Agency for Toxic Substances and Disease Registry
 
Division of Toxicology/Toxicology Information Branch
 








The toxicological profiles are developed in response to the Superfund Amendments and 
Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive 
Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This 
public law directed ATSDR to prepare toxicological profiles for hazardous substances most 
commonly found at facilities on the CERCLA National Priorities List and that pose the most 
significant potential threat to human health, as determined by ATSDR and the EPA. The availability 
of the revised priority list of 275 hazardous substances was announced in the Federal Register on 
November 17, 1997 (62 FR 61332). For prior versions of the list of substances, see Federal Register 
notices dated April 29, 1996 (61 FR 18744); April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 
41280); October 26, 1989 (54 FR 43619); October 17,199O (55 FR 42067); October 17, 1991 (56 FR 
52166); October 28, 1992 (57 FR 48801); and February 28, 1994 (59 FR 9486). Section 104(i)(3) of 
CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for 
each substance on the list. 
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QUICK REFERENCE FOR HEALTH CARE PROVIDERS 
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and 
interpretation of available toxicologic and epidemiologic information on a substance. Health care 
providers treating patients potentially exposed to hazardous substances will find the following 
information helpful for fast answers to often-asked questions. 
Primary Chapters/Sections of Interest 
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for 
educating patients about possible exposure to a hazardous substance. It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the 
general health effects observed following exposure. 
Chapter 2: Health Effects: Specific health effects of a given hazardous compound are reported by 
route of exposure, by type of health effect (death, systemic, immunologic, reproductive), and by length of 
exposure (acute, intermediate, and chronic). In addition, both human and animal studies are reported  in 
this section. 
NOTE: Not all health effects reported in this section are necessarily observed in 
the clinical setting. Please refer to the Public Health Statement to identify general 
health effects observed following exposure. 
Pediatrics: Four new sections have been added to each Toxicological Profile to address child health 
issues:
 
Section 1.6 How Can (Chemical X) Affect Children?
 
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)?
 
Section 2.6 Children’s Susceptibility
 
Section 5.6 Exposures of Children
 
Other Sections of Interest:
 
Section 2.7 Biomarkers of Exposure and Effect
 
Section 2.10 Methods for Reducing Toxic Effects
 
ATSDR Information Center 
Phone: l-800-447-1544 (to be replaced by l-888-42-ATSDR in 1999)
 
or 404-639-6357 Fax: 404-639-6359
 
E-mail: atsdric@cdc.gov Internet: http://atsdrl.atsdr.cdc.gov:8080
 
The following additional material can be ordered through the ATSDR Information Center: 
Case Studies in Environmental Medicine: Taking an Exposure History--The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure 
history is provided. Other case studies of interest include Reproductive and Developmental 
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 
Toxicity; and numerous chemical-specific case studies. 
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Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials incident. 
Volumes I and II are planning guides to assist first responders and hospital emergency department 
personnel in planning for incidents that involve hazardous materials. Volume III-Medical Management 
Guidelines for Acute Chemical Exposures-is a guide for health care professionals treating patients exposed 
to hazardous materials. 
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances. 
Other Agencies and Organizations 
The National Centerfor Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the 
workplace. Contact: NCEH, Mailstop F-29,4770 Buford Highway, NE, Atlanta, GA 30341-3724 
• Phone: 770-488-7000 • FAX: 770-488-7015. 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on 
occupational diseases and injuries, responds to requests for assistance by investigating problems of 
health and safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue, SW, 
Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. 
Taft Laboratory, Mailstop C-19,4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800­
35-NIOSH. 
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for 
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212. 
Referrals 
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of 
clinics in the United States to provide expertise in occupational and environmental issues. Contact: 
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 z Phone: 202-347-4976 • FAX: 
202-347-4950 • e-mail: aoec@dgs.dgsys.com • AOEC Clinic Director: 
http://occ-env/med.mc.duke.edu/oem/aoec.htm. 
The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and environmental 
medicine. Contact: ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-228­
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THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:
 
1 . Health Effects Review. The Health Effects Review Committee examines the health effects chapter 
of each profile for consistency and accuracy in interpreting health effects and classifying end points. 
2 . Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, 
and makes recommendations for derivation of MRLs. 
3 . Data Needs Review. The Research Implementation Branch reviews data needs sections to assure 




A peer review panel was assembled for chloroethane. The panel consisted of the following members: 
1. Dr. Martin Alexander, Cornell University, Ithaca, NY. 
2. Dr. Syed GhiasUddin, Toxicologist, Indiana Department of Environmental Management,  Indianapolis, IN. 
3. Dr. Shane Que Hee, UCLA School of Public Health, Los Angeles, CA. 
These experts collectively have knowledge of chloroethane’s physical and chemical properties, 
toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and 
quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer 
review specified in Section 104(1)( 13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended. 
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers’ comments and determined which comments will be included in the profile. A listing of the peer 
reviewers’ comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a 
list of unpublished documents cited are also included in the administrative record. 
The citation of the peer review panel should not be understood to imply its approval of the profile’s final 











1. PUBLIC HEALTH STATEMENT 
This public health statement tells you about chloroethane and the effects of exposure. 
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the 
nation These sites make up the National Priorities List (NPL) and are the sites targeted for long-term 
federal cleanup activities. Chloroethane has been found in at least 282 of the 1,467 current or former 
NPL sites. However, the total number of NPL sites evaluated for this substance is not known. As 
more sites are evaluated, the sites at which chloroethane is found may increase. This information is 
important because exposure to this substance may harm you and because these sites may be sources 
of exposure. 
When a substance is released from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment. This release does not always lead to 
exposure. You are exposed to a substance only when you come in contact with it. You may be 
exposed by breathing, eating, or drinking the substance or by skin contact. 
If you are exposed to chloroethane, many factors determine whether you’ll be harmed. These 
factors include the dose (how much), the duration (how long), and how you come in contact with 
it. You must also consider the other chemicals you’re exposed to and your age, sex, diet, family 
traits, lifestyle, and state of health. 
1.1 WHAT IS CHLOROETHANE? 
Chloroethane, also called ethyl chloride, is a colorless gas at room temperature and pressure, with 
a characteristically sharp odor. People can smell chloroethane in the air at levels above 4 parts 
CHLOROETHANE 2 
1. PUBLlC HEALTH STATEMENT 
chloroethane in a million parts of air by volume (ppm). It can be smelled in water at levels above 0.02 
parts chloroethane in a million parts of water (ppm). In pressurized containers, chloroethane exists as 
a liquid. However, the liquid evaporates quickly when exposed to air. It catches fire easily and is very 
dangerous when exposed to heat or flame. Chloroethane does not occur naturally in the environment. 
It is present in the environment as a result of human activity. 
In the past, the largest single use for chloroethane was for the production of tetraethyl lead, which is a 
gasoline additive. However, production of chloroethane has decreased dramatically as a result of 
stricter government regulations controlling lead in gasoline. Other applications include use in the 
production of ethyl cellulose, dyes, medicinal drugs, and other commercial chemicals, and use as a 
solvent and refrigerant. It is used to numb skin prior to medical procedures such as ear piercing and 
skin biopsies, and it is used in the treatment of sports injuries. 
1.2 WHAT HAPPENS TO CHLOROETHANE WHEN IT ENTERS THE 
ENVIRONMENT? 
Most of the chloroethane released to the environment ends up as a gas in the atmosphere, while much 
smaller amounts enter groundwater as a result of passage through soil. Once in the atmosphere, 
chloroethane breaks down fairly rapidly by reaction with substances in the air. It takes about 40 days 
for half of any given amount of chloroethane that is released to the atmosphere to disappear. In 
groundwater, chloroethane changes slowly to ethanol and a chloride salt as a result of reaction with 
water. In addition, some types of bacteria present in the water may break down chloroethane to 
smaller compounds. However, not enough is known about chloroethane to be sure if this occurs or 
how long it may remain in groundwater. For more information, see Chapters 3,4, and 5. 
1.3 HOW MIGHT I BE EXPOSED TO CHLOROETHANE? 
Humans can be exposed to chloroethane from environmental, occupational, and consumer sources. 
During the mid-to-late 1970s and the early 1980s chloroethane was detected in samples of outdoor 
air. Air samples collected in urban and suburban areas contained 
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chloroethane at an average level of 41-140 parts of chloroethane in a trillion parts of air (ppt; 
1 ppt is l,000,000 times less than 1 ppm). Rural air samples contained less than 5 ppt. Current 
levels of chloroethane in the air are expected to be even lower than levels found in the past 
because of the sharp decrease in chloroethane production in the United States and the decrease in 
chloroethane release. Occurrences of chloroethane in air can be attributed to releases from 
factories that manufacture or use chloroethane; evaporation from some landfills, solvents, 
refrigerants, and anesthetics; and releases in fumes from the burning of plastics and other materials 
found in trash. Based on the limited amount of information available on the occurrence of 
chloroethane in drinking water, it can be concluded that extremely low levels of chloroethane may 
occur in some drinking water supplies as a result of formation during chlorination, contamination of 
rivers and lakes used as drinking water supplies, or seepage into groundwater resulting from storage 
of chemical wastes or disposal at waste sites. However, there is not enough information available to 
indicate what levels of chloroethane occur in drinking water under these circumstances. No data were 
located that indicate that chloroethane is found in food. 
Exposure may also result from contact with various consumer products including some solvents, 
paints, and refrigerants. People may be exposed to chloroethane through skin contact as the 
result of its use as an agent to numb skin before ear piercing, before skin biopsy, as a treatment 
for sports injury, and for other medical reasons. Occupational exposure may result from 
inhalation or skin contact. Workers who may be exposed to chloroethane include physicians, 
nurses, and other medical workers, automobile mechanics, office machine mechanics, household 
appliance and accessory installers, assemblers, professional painters, heavy-equipment mechanics, 
diesel mechanics, plumbers, and pipe fitters. According to a National Institute for Occupational 
Safety and Health (NIOSH) survey conducted between 1981 and 1983, au estimated 49,212 workers 
in the United States were exposed to chloroethane in the workplace. More recent data are not 
available to determine how many workers might be exposed to chloroethane per year in the United 
States. For further information, see Chapter 5. 
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1.4 HOW CAN CHLOROETHANE ENTER AND LEAVE MY BODY? 
Chloroethane can enter the body when a person breathes air containing chloroethane vapor. 
Chloroethane may also enter the body through the skin, although most of it quickly evaporates 
from the skin’s surface. When a person drinks water containing chloroethane, it enters the body 
through the digestive tract. After chloroethane enters the body, it may leave the body through the 
lungs. Some chloroethane may also be changed to acetate, which is normally found in the body. 
Other chemicals formed from chloroethane leave the body in the urine. 
People who happen to be near hazardous waste sites containing chloroethane are most likely to be 
exposed to the compound by breathing potentially contaminated air. People may also be exposed 
to chloroethane by drinking potentially contaminated water. See Chapter 2 for more information. 
1.5 HOW CAN CHLOROETHANE AFFECT MY HEALTH? 
To protect the public from the harmful effects of toxic chemicals and to find ways to treat people 
who have been harmed, scientists use many tests. 
One way to see if a chemical will hurt people is to learn how the chemical is absorbed, used, and 
released by the body; for some chemicals, animal testing may be necessary. Animal testing may 
also be used to identify health effects such as cancer or birth defects. Without laboratory animals, 
scientists would lose a basic method to get information needed to make wise decisions to protect 
public health. Scientists have the responsibility to treat research animals with care and 
compassion. Laws today protect the welfare of research animals, and scientists must comply with 
strict animal care guidelines. 
Brief exposure to high levels of chloroethane vapor can produce temporary feelings of drunkenness, 
and at still higher levels, lack of muscle coordination and unconsciousness. Adults have felt dizzy and 
have suffered decreased reaction times as a result of inhaling chloroethane. They have 
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also experienced stomach cramps, nausea, vomiting, and eye irritation after breathing high 
concentrations of chloroethane for a short time. 
Workers who breathed chloroethane vapors for 1.5 to 3 years (levels of chloroethane unknown) 
had significantly decreased defensive responses against illness. Inhalant abusers who intentionally 
breathe chloroethane vapors at much higher concentrations than those found in any work environment 
or near any hazardous waste site have experienced these neurological effects. Long term abuse of 
high chloroethane concentrations causes the most adverse effects of chloroethane exposure, namely, 
those to the nervous system. In the worst recorded cases of chloroethane abuse by sniffing, the 
abusers have had severe symptoms including jerking eye movements, an inability to control muscles 
in voluntary movements, difficulty in speaking clearly, an inability to perform finger tapping 
exercises, sluggish lower limb reflexes, seizures, difficulties in walking, disorientation, short-term 
memory loss, and hallucinations affecting their sight and hearing. In one case, damage to motor and 
sensory nerves occurred. 
Human patients have died after breathing chloroethane concentrations high enough to induce 
anesthesia. Dogs have suffered irregular heart rhythms, followed by death, when given anesthetic 
doses of chloroethane. Due to the risk of accidental death, chloroethane is no longer medically 
used as a general anesthetic during major surgery. Chloroethane can, however, be applied to the 
skin in the form of chloroethane spray as a numbing agent prior to minor surgery. If this spray is 
applied for too long, frostbite can result. Some adults have had allergic reactions to the 
chloroethane spray while others experienced mild pain after being sprayed for 10 seconds. 
Studies have shown that chloroethane can enhance the effects of alcohol in rats. It is unknown if 
similar interactions between chloroethane and alcohol occur in humans. 
It is not known whether chloroethane produces cancer in humans. However, long-term exposure 
to high levels of chloroethane vapor has been shown to produce cancer in mice. There have been 
no animal or human studies involving the ability of chloroethane to cause cancer when either eaten or 
applied to the skin. The International Agency for Research on Cancer (IARC) has reviewed 
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the information available concerning the abiIity of chloroethane to cause cancer. They concluded 
that chloroethane is not classifiable as to its carcinogenicity in humans. See Chapter 2 for more 
information. 
1.6 HOW CAN CHLOROETHANE AFFECT CHILDREN? 
This section discusses potential health effects from exposures during the period from conception 
to maturity at 18 years of age in humans. Potential effects on children resulting from exposures of 
the parents are also considered. 
There are no known unique exposure pathways by which children may be exposed to chloroethane. 
In children, there have been few recorded reports of exposures to chloroethane or adverse health 
effects resulting from this exposure. Brief inhalation exposure of children to very high 
concentrations of chloroethane has resulted in stimulation of certain nerves followed by a decrease in 
heart rate. One teenager died from lung paralysis during general anesthesia with chloroethane.  In 
addition to these health effects seen specifically in children, the observed adverse effects of 
chloroethane exposure in adults are also expected in children. It is unknown whether children differ 
from adults in their susceptibility to health effects from chloroethane exposure. 
We do not know whether chloroethane exposure can affect development in humans. There is not 
enough information to know whether chloroethane affects development in animals. Only one 
developmental study has been done in animals. This study with mice showed that exposure to 
high levels of chloroethane during pregnancy delayed bone development in the offspring. 
We do not know whether chloroethane or its breakdown products within the body can reach and 
cross the mother’s placenta into her developing baby. One study has shown that chloroethane can 
be found in mother’s milk, but we do not know if the mothers were exposed to the compound by 
breathing it, eating it, or having it sprayed on their skin. 
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1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO
 CHLOROETHANE? 
If your doctor finds that you have been exposed to significant amounts of chloroethane, ask if 
children may also be exposed. When necessary your doctor may need to ask your state 
Department of Public Health to investigate. 
Little information exists concerning the concentrations of chloroethane that might be present in 
drinking water. However, past data indicate that chloroethane is not a frequent contaminant in 
drinking water, and therefore the risk to families from drinking water containing chloroethane is 
low. 
Chloroethane is found in common household products such as paints, solvents, air fresheners, and 
deodorant sprays. Inhaling or ingesting toxic amounts of chloroethane from these products is 
possible. Therefore, household products such as these should be stored out of reach of young 
children to prevent accidental poisonings. Always store household chemicals in their original 
labeled containers; never store household chemicals in containers children would find attractive to eat 
or drink from, such as old soda bottles. Keep your Poison Control Center’s number by the 
phone. 
Sometimes older children sniff household chemicals in an attempt to get high. Chloroethane is 
sold in drug paraphernalia shops as Ethyl Gaz, Ethyl Four Star, Black Jac, and Maximum Impact. 
Your children may be exposed to chloroethane by inhaling products containing it and are putting 
their health at serious risk if they do so. Talk with your children about the dangers of sniffing 
chemicals. 
When household products that contain chloroethane are used properly and are not abused, the 
concentrations of chloroethane within them are not high enough to pose a risk of significant 
exposure to children. 
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The tendency of chloroethane to evaporate upon contact with air makes it highly unlikely that the 
compound could be taken home on the parents’ work clothes. 
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN
      EXPOSED TO CHLOROETHANE? 
Although there are complex analytical tests that chemists use to measure chloroethane in the 
blood, milk, or urine, there are no commonly used medical tests available to determine whether or 
not a person has been exposed to chloroethane. A breath test to determine exposure may be 
possible but is not commonly used. 
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT
      MADE TO PROTECT HUMAN HEALTH? 
The federal government develops regulations and recommendations to protect public health. 
Regulations can be enforced by law. Federal agencies that develop regulations for toxic 
substances include the Environmental Protection Agency (EPA), the Occupational Safety and 
Health Administration (OSHA), and the Food and Drug Administration (FDA). Recommendations 
provide valuable guidelines to protect public health but cannot be enforced by law.  Federal 
organizations that develop recommendations for toxic substances include the Agency for Toxic 
Substances and Disease Registry (ATSDR) and the National Institute for Occupational Safety and 
Health (NIOSH). 
Regulations and recommendations can be expressed in not-to-exceed levels in air, water, soil, or 
food that are usually based on levels that affect animals, then they are adjusted to help protect 
people. Sometimes these not-to-exceed levels differ among federal organizations because of 
different exposure times (an 8-hour workday or a 24-hour day), the use of different animal studies, or 
other factors. 
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Recommendations and regulations are also periodically updated as more information becomes 
available. For the most current information, check with the federal agency or organization that 
provides it. Some regulations and recommendations for chloroethane include the following: 
Chloroethane levels in the workplace are regulated by QSHA. The occupational exposure limit 
for an g-hour work day of a 40-hour work week is 1,000 ppm. The EPA requires industry to 
report discharges or spills of 100 pounds or more. See Chapter 7 for more information. 
1.10 WHERE CAN I GET MORE INFORMATION? 
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department or 
Agency for Toxic Substances and Disease Registry 
Division of Toxicology 
1600 Clifton Road NE, Mailstop E-29 
Atlanta, GA 30333 





ATSDR can also tell you the location of occupational and environmental health clinics. 
These clinics specialize in recognizing, evaluating, and treating illnesses resulting from 
exposure to hazardous substances. 
* To order toxicological nrofnes. contact 
National Technical Information Service
 








2. HEALTH EFFECTS 
2.1 INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective of the toxicology of chloroethane. It 
contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health. 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure-inhalation, 
oral, and dermal; and then by health effect-death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects. These data are discussed in terms of three exposure 
periods-acute (14 days or less), intermediate (15-364 days), and chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated in figures.  The points 
in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-observed-adverseeffect levels 
(LOAELs) reflect the actual doses (levels of exposure) used in the studies. LOAELS have been classified into “less 
serious” or “serious” effects. “Serious” effects are those that evoke failure in a biological system and can lead to 
morbidity or mortality (e.g., acute respiratory distress or death). “Less serious” effects are those that are not expected 
to cause significant dysfunction or death, or those whose significance to the organism is not entirely clear. ATSDR 
acknowledges that a considerable amount of judgment may be required in establishing whether an end point should be 
classified as a NOAEL, “less serious” LOAEL, or “serious” LOAEL, and that in some cases, there will be insufficient 
data to decide whether the effect is indicative of significant dysfunction. However, the Agency has established 
guidelines and policies that are used to classify these end points. ATSDR believes that there is sufficient merit in this 
approach to warrant anattempt at distinguishing between “less serious” and “serious” effects. The distinction 
between “less serious” effects and “serious” effects is considered to be important because it helps the users of the 
profiles to identify levels of exposure at which major health effects start to appear LOAELs or NOAELs should also 
help in 
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determining whether or not the effects vary with dose and/or duration, and place into perspective the 
possible significance of these effects to human health. 
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user’s perspective. Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure associated 
with more subtle effects in humans or animals (LOAEL) or exposure levels below which no adverse 
effects (NOAELs) have been observed. Estimates of levels posing minimal risk to humans (Minimal Risk 
Levels or MRLs) may be of interest to health professionals and citizens alike. 
Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) of chloroethane are 
indicated in Table 2- 1 and Figure 2-l. 
Estimates of exposure levels posing minimal risk to humans (Minimal Risk Levels or MRLs) have been 
made for chloroethane. An MRL is defined as an estimate of daily human exposure to a substance that is 
likely to be without an appreciable risk of adverse effects (noncarcinogenic) over a specified duration of 
exposure.  MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of effect 
or the most sensitive health effect(s) for a specific duration within a given route of exposure. MRLs are 
based on noncancerous health effects only and do not consider carcinogenic effects. MRLs can be derived 
for acute, intermediate, and chronic duration exposures for inhalation and oral routes. Appropriate 
methodology does not exist to develop MRLs for dermal exposure. 
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques. Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs. As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development 
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis.  As these kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be revised. 
A User’s Guide has been provided at the end of this profile (see Appendix B). This guide should aid in the 
interpretation of the tables and figures for Levels of Significant Exposure and the MRLs. 
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2.2.1 Inhalation Exposure 
Some of the data on the health effects of chloroethane following inhalation exposure were taken from a 
study by Troshina (1966). This report does not provide an adequate description of experimental methods 
or results. Consequently, the results of the study are not included in Table 2-l or plotted in Figure 2-l as 
levels of significant exposure. 
2.2.1.2 Death 
Use of chloroethane as a general anesthetic has occasionally resulted in the death of human patients 
(Konietzko 1984; Kuschinsky 1970; Lawson 1965; Lehman and Flury 1943). In the years between 1945 
and 1964, there were 71 deaths attributed to chloroethane inhalation in the United Kingdom (Dawkins 
1964). Only chloroform has been blamed for more anesthetic deaths than chloroethane (Lawson 1965). 
Death from respiratory paralysis (Kuschinsky 1970) and toxic injury to the heart (Lehman and Flury 1943) 
have been reported following anesthesia with chloroethane. Death of a man following abuse of 
chloroethane has also been reported (Yacoub et al. 1993). Although the blood concentration of 
chloroethane was 65 mg/dL in this man shortly after death, the study authors believed that because of 
resuscitation attempts for about 65 minutes, concentrations of chloroethane resulting in death were 
actually greater than the measured concentration. Levels of significant exposure are not reported in Table 
2- 1 or plotted in Figure 2- 1 because concentrations of chloroethane lethal to humans are not known. 
Mortality produced by inhalation of high concentrations of chloroethane vapor has been studied 
quantitatively in animals. The minimum lethal concentration of chloroethane in a 2-hour exposure study in 
mice was 56,860 ppm (Lazarew 1929). In another 2-hour exposure test, the minimum lethal concentration 
was 54,948 ppm in rats and mice (Troshina 1966). In this case, death was probably caused by 
asphyxiation. Exposure to 19,000 ppm chloroethane for 4 hours did not produce mortality in rats or mice 
(NTP 1989). The lethal concentration of chloroethane increased as the duration of exposure decreased in 
guinea pigs exposed to chloroethane concentrations ranging from 0 to 241,000 ppm for 5 minutes to 13.5 
hours (Sayers et al.1929). Exposure to 20,000 ppm chloroethane for 9 hours was not lethal to guinea pigs 
in this study. Death was reported during or after exposure of guinea pigs to 40,000 ppm for 9 hours (2/6), 

















2. HEALTH EFFECTS 
Studies in which animals were repeatedly exposed to chloroethane for 14 days or less did not report deaths 
resulting from inhalation of this compound. No mortality was reported in rats exposed to 436 ppm 4 
hours/day for 8 exposures in 10 days (Gohlke and Schmidt 1972; Schmidt et al. 1972), in mice exposed to 
4,843 ppm 23 hours/day for 11 days (Landry et al. 1987, 1989), in rats and dogs exposed to 9,980 ppm 6 
hours/day, 5 days/week for 2 weeks (Landry et al. 1982) or in rats and mice exposed to 19,000 ppm 6 
hours/day, 5 days/week for 2 weeks (NTP 1989). 
Mortality was not increased significantly by chloroethane exposure in studies of intermediate duration 
(15-364 days). Mortality was not observed in rats or mice exposed to chloroethane at 19,000 ppm 
6 hours/day, 5 days/week for 13 weeks (NTP 1989). At 10,000 ppm, 1 male mouse died. No discussion 
was provided on whether or not this death was exposure related. Therefore, this death is not included in 
Table 2-l or Figure 2- 1. 
In a chronic inhalation study, rat survival was not reduced compared to controls following exposure to 
15,000 ppm chloroethane 6 hours/day, 5 days/week for 1102 weeks (NTP 1989). The concurrent controls, 
however, had abnormally low survival rates after week 90 of the study. Survival was significantly reduced 
in mice following exposure to 15,000 ppm chloroethane for 100 weeks; the effect was found in males after 
330 days and in females after 574 days (NTP 1989). An ascending urinary tract infection may have 
contributed to the reduced survival in male mice. The decreased survival in female mice was attributed to 
uterine cancer. 
All LOAEL values from each reliable study for death in each species and duration category are recorded in 
Table 2-l and plotted in Figure 2-l. 
2.2.1.2 Systemic Effects 
The highest NOAEL values and all LOAEL values from each reliable study for systemic effects in each 
species and duration category are recorded in Table 2-l and plotted in Figure 2-l. The results of the study 
by Troshina (1966) were not used as levels of significant exposure because experimental methods and 
results were not described in sufficient detail. 
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Respiratory Effects. Chloroethane in combination with nitrous oxide and oxygen was used to 
maintain anesthesia in human patients previously made unconscious by administration of either 
thiopentone (thiopental), nitrous oxide, or a mixture of nitrous oxide, chloroethane, and oxygen (Cole 
1956). A concentration of 20,000 ppm chloroethane was initially required to maintain anesthesia, but this 
could slowly be reduced to as low as 5,000 ppm in some cases. Respiration usually remained smooth and 
even, but some cases of tachypnea were seen. Respiratory rate was stimulated in 16 of 23 patients tested in 
a second similar study using 36,000 ppm chloroethane (Cole 1967). This study was not reported in Table 
2-l or plotted in Figure 2- 1 as a NOAEL or LOAEL for the acute respiratory effects of chloroethane in 
humans because the compound was administered in conjunction with other anesthetic agents. Respiratory 
paralysis was reported to be the cause of death of a 14-year-old child who died during anesthesia with 
chloroethane (Kuschinsky 1970). A level of significant exposure was not based on this report because the 
concentration of chloroethane administered was not known. 
Studies in animals also indicate that inhalation of chloroethane may affect respiration. Exposure to 10 ppm 
chloroethane for 10 minutes had no consistent effect on the respiratory rate of rabbits (Watanabe 1983). 
This study was not used as the basis for a NOAEL because changes in respiratory rate occurred, even 
though no trend was found. Inhalation of 20,000 ppm chloroethane for 9 hours resulted in only very mild 
tissue changes, but congestion, hemorrhage, and edema were found in the lungs of guinea pigs that died 
following exposure to 40,000 ppm or more (Sayers et al. 1929). 
Hypertrophic bronchial tubes and interstitial pneumonia were found in rats given eight 4-hour exposures to 
436 ppm chloroethane; however, these effects were also present to a lesser extent in controls (Gohlke and 
Schmidt 1972). Consequently, these results were not considered to be indicative of adverse respiratory 
effects produced by chloroethane. The only other respiratory effect reported by this study was a mild 
transitory increase in relative lung weight, which was also not considered adverse (Schmidt et al. 1972). 
Absolute and relative lung weights were not affected in rats or mice exposed to chloroethane at 15,000 
ppm 6 hours/day for 5 days (Fedtke et al. 1994a). Histopathological changes were not observed in the 
respiratory tracts of mice exposed to chloroethane at 4,843 ppm 23 hours/day for 11 days (Landry et al. 
1987,1989).  Histopathological examinations of respiratory organs and tissues were performed following 
inhalation of chloroethane for 6 hours/day, 5 days/week for 2 weeks at a concentration of 9,980 ppm in 
rats and dogs (Landry et al. 1982) and 19,000 ppm in rats and mice (NTP 1989). No effects were reported 
in either study 
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The NTP (1989) study is limited in that organs of only 3 of 10 exposed rats and 3 of 10 exposed mice were 
examined microscopically. Therefore, this study is not presented in Table 2-l or Figure 2-l for respiratory 
effects. 
In an intermediate-duration study, inhalation of 19,000 ppm cbloroethane for 13 weeks (6 hours/day, 
5 days/week) failed to produce lesions in the respiratory tissue of rats or mice as documented by complete 
histopathological examinations (NTP 1989). Inhalation of 216 ppm chloroethane for 6 months (4 
hours/day, 6 days/week) caused thickening of the alveolar septa in the lungs of rats; the effect was 
produced by an increase in the number of macrophages (Troshina 1966). No respiratory effects were 
reported at 22.7 ppm. 
Chronic exposure to 15,000 ppm chloroethane for approximately 2 years (6 hours/day, 5 days/week) had 
no non-neoplastic histopathological effects on the respiratory system in rats or mice (NTP 1989). 
Cardiovascular Effects. There is some evidence that inhalation of chloroethane has cardiovascular 
effects in humans. Vagal stimulation followed by direct depression of cardiac tissues was reported in 
children exposed briefly to high concentrations of chloroethane (Bush et al. 1952). This study was not 
reported in Table 2-l or plotted in Figure 2-l because the effective concentration of chloroethane was not 
reported. A mixture of chloroethane, nitrous oxide, and oxygen was used to maintain anesthesia in patients 
previously made unconscious by administration of thiopentone (thiopental), or nitrous oxide, or the 
mixture described above (Cole 1956). A concentration of 20,000 ppm chloroethane was initially required 
to maintain anesthesia, but this could slowly be reduced to concentrations as low as 5,000 ppm in some 
cases. Pulse rate remained strong and no clinically detectable arrhythmias or changes in heart rate were 
observed. A similar study using 36,000 ppm chloroethane found increased systolic blood pressure and 
pulse rate in 16 of 25 patients tested, but again no cardiac arrhythmias were detected (Cole 1967). This 
study was not reported in Table 2-l or plotted in Figure 2- 1 as a NOAEL or LOAEL for the acute 
cardiovascular effects of chloroethane in humans because the compound was administered in conjunction 
with other anesthetic agents. 
The cardiovascular effects of chloroethane have also been studied in animals. In dogs, acute exposure to 
anesthetic concentrations of chloroethane resulted in cardiac irregularities, including ventricular 
tachycardia and asystole (Haid et al. 1954; Morris et al. 1953). Chloroethane also sensitized the heart to 
the effects of epinephrine (Haid et al. 1954; Morris et al. 1953). Bush et al. (1952) found that cardiac 
depression occurred in dogs given anesthetic doses of chloroethane. This depression was initially due to 
stimulation of the vagus 
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nerve and occurred within 2 minutes of the onset of anesthesia. Direct depression of the cardiac tissue 
followed and was succeeded by ventricular fibrillation and asystole, which resulted in death. None of the 
above studies are presented in Table 2-1 or plotted in Figure 2-l because effective chloroethane 
concentrations were not reported. 
Rabbits exposed to 10 ppm chloroethane for 10 minutes did not experience consistent changes in blood 
pressure or heart rate (Watanabe 1983). Although changes in these variables did occur, this study was not 
used as the basis for a NOAEL because no trend was found. The occurrence of undescribed “vascular 
disarrangements” was reported in rats and mice killed by exposure to over 54,948 ppm chloroethane for 2 
hours (Troshina 1966). Degeneration of heart muscle was found in guinea pigs that died following 
exposure to 40,000 ppm chloroethane for 9 hours (Sayers et al. 1929). No effects were reported at lower 
concentrations. 
Multiple-exposure studies of acute duration reported no significant cardiovascular effects. Rat heart weight 
was not affected by eight 4-hour exposures to 436 ppm chloroethane over a 10-day period (Schmidt et 
al.1972). When histopathological examination of rats and dogs exposed to 9,980 ppm chloroethane for 2 
weeks (6 hours/day, 5 days/week) was done, no cardiovascular effects were found (Landry et al. 1982). 
Changes in heart weights and microscopic changes in the heart were not observed in mice exposed to 
chloroethane at 4,843 ppm 23 hours/day for 11 days (Landry et al. 1987,1989). Microscopic examination 
of the heart in 3 of 10 rats and 3 of 10 mice exposed to chloroethane at 19,000 ppm 6 hours/day, 5 
days/week for 2 weeks, did not reveal any effects (NTP 1989). Because histopathological examinations 
were completed on only a few animals, this study is not presented in Table 2-l and Figure 2-l for 
cardiovascular effects. 
Inhalation of 19,000 ppm chloroethane 6 hours/day, 5 days/week for 13 weeks, had no histopathological 
effect on the cardiovascular system of rats or mice (NTP 1989). Arterial blood pressure 24 mmHg below 
controls was reported in rats exposed 4 hours/day, 6 days/week for 6 months, to 2 16 ppm chloroethane 
(Troshina 1966). No effects on blood pressure were noted at 22.7 ppm. 
In the only chronic inhalation study of chloroethane, histopathological examinations of the heart did not 
reveal any effects in rats or mice exposed to 15,000 ppm 6 hours/day, 5 days/week for approximately 2 
years (NTP 1989). 
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Gastrointestinal Effects. Gastrointestinal effects have been reported in humans exposed to 
chloroethane by inhalation. Sayers et al. (1929) reported that mild abdominal cramps occurred in healthy 
human subjects who inhaled 2 breaths of 40,000 ppm chloroethane or 2-4 breaths of 20,000 ppm 
chloroethane. Exposure to 33,600 ppm chloroethane caused nausea and vomiting in human subjects after 
approximately 8 minutes; subjects exposed to 25,000 ppm did not become nauseated even after 21 minutes 
(Davidson 1925).  Vomiting occurred in 10 of 23 patients who were anesthetized with 36,000 ppm 
chloroethane combined with nitrous oxide and oxygen (Cole 1967). A LOAEL was not reported in Table 
2-l or plotted in Figure 2-l because chloroethane was administered in conjunction with other anesthetic 
agents. 
Gastrointestinal effects in animals were studied by necropsy and histopathological examination. 
Congestion of the intestines was found in guinea pigs that died following exposure to 80,000 ppm for up to 
4.5 hours (Sayers et al. 1929). Chloroethane concentrations below 40,000 ppm did not produce 
gastrointestinal effects in this study. 
Exposure to 9,980 ppm chloroethane for 2 weeks had no histopathological effects on the gastrointestinal 
organs of rats or dogs (Landry et al. 1982). Histopathological changes were not observed in the 
gastrointestinal tracts of mice exposed to chloroethane at 4,843 ppm 23 hours/day for 11 days (Landry et 
al.1987, 1989), or in rats or mice exposed to 19,000 ppm 6 hours/day, 5 days/week for 2 weeks (NTP 
1989). The NTP (1989) study is not presented in Table 2-l or Figure 2-l for gastrointestinal effects because 
histopathological examinations were completed on only 3 of 10 exposed rats and 3 of 10 exposed mice. 
No gastrointestinal effects were found by histopathological examination in longer term studies. 
Chloroethane concentrations of 19,000 ppm for 13 weeks (6 hours/day, 5 days/week) in rats and mice and 
15,000 ppm for approximately 2 years (6 hours/day, 5 days/week) in rats and mice (NTP 1989) were all 
without effect on this organ system. 
Hematological Effects. There was a single report of a hematological effect following chloroethane 
inhalation in humans. A human subject exposed to 33,600 ppm chloroethane developed cyanosis within 
8.5 minutes but only when the chloroethane was not mixed with oxygen (Davidson 1925). Therefore, this 
effect was probably due to lack of oxygen, and this result was not used as the basis for a LOAEL. 
No effects on hematologic parameters (packed cell volume, hemoglobin, red blood cell counts, platelet 
counts, differential leukocyte counts, mean corpuscular volume, mean corpuscular hemoglobin) were 
noted in 
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mice exposed to chloroethane at 4,843 ppm 23 hours/day for 11 days (Landry et al. 1987, 1989), or in rats 
or dogs exposed to 9,980 ppm 6 hours/day, 5 days/week for 2 weeks (Landry et al. 1982). Hematologic 
effects were not examined in other inhalation studies of chloroethane. 
Musculoskeletal Effects. No studies were located regarding musculoskeletal effects in humans 
following inhalation exposure to chloroethane. 
Histopathological examination of muscle and bone following exposure of mice to chloroethane at 4,843 
ppm 23 hours/day for 11 days did not reveal any effects (Landry et al. 1987, 1989). Histopathologic 
changes in muscle and bone were also not observed in rats or dogs exposed to chloroethane at 9,980 ppm 6 
hours/day, 5 days/week for 2 weeks (Landry et al. 1982). Rats and mice exposed to 15,000 ppm 
chloroethane 6 hours/day, 5 days/week for approximately 2 years, were also examined; no increase in the 
occurrence of bone lesions was found (NTP 1989). The National Toxicology Program (NTP) studies of 
shorter duration did not include examination of bone or muscle tissue. 
Hepatic Effects. In a case report of a woman who sniffed chloroethane (about 200-300 ml/day) for 
4 months, an enlarged liver and mild transient disturbance of liver function which was not further 
described were noted (Hes et al. 1979). The woman had previously used other drugs but was reported to be 
free of addiction for 2 years before starting to use chloroethane. Moderately elevated serum alanine 
aminotransferase was observed in a man who abused chloroethane for 30 years (Nordin et al. 1988). 
During the 4 months before the man was examined he inhaled at least 100 ml/day chloroethane (Nordin et 
al. 1988).  This subject also had a history of alcohol and sedative abuse, so it is not known for certain if the 
liver effects were a result of the chloroethane abuse. 
Hepatic effects in animals have been studied by a number of researchers. A single 5minute exposure to an 
unspecified concentration of chloroethane produced an increase in the ratio of adenosine 
triphosphate/adenosine diphosphate (ATP/ADP) in the livers of mice (Oura et al. 1966). The effective 
concentration of chloroethane in this study was not reported, so no level of significant exposure was 
determined. Pale appearance, edema, congestion, and degeneration were seen in the livers of guinea pigs 
exposed to at least 20,000 ppm chloroethane for up to 9 hours (Sayers et al. 1929). Liver non-protein 
sulfhydryl (NPSH) concentration was reduced in both rats and mice following a single 6-hour exposure to 
chloroethane concentrations of 9,980 ppm for rats and 4,000 ppm for mice, but the study authors 
considered this effect to 
CHLOROETHANE 35 
2. HEALTH EFFECTS 
be more adaptive than toxicologic since the change was small and no associated liver lesions were found 
(Landry et al. 1982). 
Following 5 daily 6-hour exposures to chloroethane at 15,000 ppm, glutathione levels in the liver were 
reduced in male rats but not in female rats or in mice of either sex (Fedtke et al. 1994b). Liver weights 
were not affected in rats or mice following 5 daily 6-hour exposures to chloroethane at 15,000 ppm 
(Fedtke et al.1994a). 
Serum amino transaminase activity (alanine and aspartate), liver enzyme activity, lipid content, 
histopathology, and liver weight were not significantly altered in rats given eight 4-hour exposures to 
436 ppm chloroethane (Gohlke and Schmidt 1972; Schmidt et al. 1972). Histopathological effects were 
reported but apparently only in groups pre-treated with ethanol. It did not appear that significant tissue 
changes occurred in rats exposed to chloroethane alone. Mice exposed to 4,843 ppm chloroethane 23 
hours/day for 11 days had increased relative liver weight and slightly increased hepatocellular vacuolation 
(Landry et al. 1987, 1989). The study authors considered these effects to be mild and not indicative of 
significant toxicity. No changes in liver weight were noted in mice exposed to chloroethane at 4,946 ppm 
6 hours/day on gestation days 6-15 and sacrificed on gestation day 18 (Scortichini et al. 1986). There was 
a slight increase in relative liver weight in male rats exposed to 3,980 ppm or more for 6 hours/day, 5 
days/week for 2 weeks, but since no other hepatic effects were reported, this effect was not thought to 
indicate significant liver toxicity (Landry et al. 1982). There were no hepatic effects in dogs exposed to 
9,980 ppm chloroethane 6 hours/day, 5 days/week for 2 weeks (Landry et al. 1982). No significant 
hepatotoxicity was observed in rats or mice examined histopathologically following exposure to 19,000 
ppm chloroethane 6 hours/day, 5 days/week for 2 weeks (NTP 1989). The NTP (1989) study is not 
presented in Table 2-l or Figure 2-l for hepatic effects because histopathological examinations were 
completed on only 3 of 10 exposed rats and 3 of 10 exposed mice. 
Liver weight and histopathologic changes in the liver were not observed in mice exposed to 15,000 ppm 
chloroethane 6 hours/day for 21 days (Bucher et al. 1995). Relative liver weights were significantly 
(p<0.05) increased in male rats but not female rats or mice of either sex exposed to 19,000 ppm 
chloroethane 6 hours/day, 5 days/week for 13 weeks (NTP 1989). Because histopathological changes were 
not observed, the increased relative liver weight is not considered adverse. Interference with hepatic 
function in rats, as indicated by reduced hippuric acid elimination following sodium benzoate loading, 
occurred following both a 60-day exposure to 5,305 ppm chloroethane and a 6-month exposure to 216 
ppm (Troshina 1966). Fatty 
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degeneration of hepatocytes also occurred following a 6-month exposure to 216 ppm chloroethane 
(Troshina 1966). 
Chronic exposure to 15,000 ppm chloroethane 6 hours/day, 5 days/week for approximately 2 years, 
produced no increase in the incidence of non-neoplastic hepatic lesions in rats or mice (NTP 1989). 
Renal Effects. No studies were located regarding renal effects in humans following inhalation 
exposure to chloroethane. 
Inhalation of chloroethane has been shown to produce renal effects in animals. Pale appearance, 
congestion, and degeneration were seen in the kidneys of guinea pigs exposed to 40,000 ppm or more for 
up to 9 hours (Sayers et al. 1929). No effects were found following exposure to 20,000 ppm for 9 hours. 
Exposure to 436 ppm chloroethane for 4 hours/day for 8 days had no effect on rat kidney histopathology, 
fat content, or weight (Gohlke and Schmidt 1972; Schmidt et al 1972). Inhalation of 4,843 ppm 23 
hours/day for 11 days did not produce renal effects detectable by serum chemistry analysis or 
histopathological examination in mice (Landry et al. 1987, 1989). Absolute and relative kidney weights 
were not affected in rats or mice exposed to 15,000 ppm chloroethane for 5 daily 6-hour exposures (Fedtke 
et al. 1994a). Blood urea nitrogen (BUN) was decreased slightly in female rats following inhalation of at 
least 3,980 ppm for 2 weeks (Landry et al. 1982). However, the study authors did not consider this effect 
to be toxicologically significant since BUN is not a direct indicator of toxicity and no associated 
pathological lesions were found.  No other renal effects were found in rats or dogs exposed to 9,980 ppm 
chloroethane 6 hours/day, 5 days/week for 2 weeks (Landry et al. 1982). Histopathological examination of 
3 of 10 exposed rats and 3 of 10 exposed mice showed no evidence of nephrotoxicity after exposure to 
19,000 ppm 6 hours/day, 5 days/week for 2 weeks (NTP 1989). Because of the small number of animals 
examined microscopically, this study is not presented in Table 2-l or Figure 2-l for renal effects. 
Exposure to 19,000 ppm chloroethane 6 hours/day, 5 days/week for 13 weeks, had no effect on the 
occurrence of kidney lesions in rats or mice (NTP 1989). Inhalation of chloroethane for 6 months 
increased urinary amino acid levels in the rat (Troshina 1966). The concentration at which this effect 
occurred is not stated. Therefore, a concentration is not presented in Table 2-l or Figure 2-l. 
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Chloroethane vapor at a concentration of 15,000 ppm produced signs of mild nephrotoxicity in mice 
exposed 6 hours/day, 5 days/week for 100 weeks (NTP 1989). There was an increase in the incidence of 
scattered foci of tubular regeneration and minimal glomerulosclerosis in treated female mice, while treated 
male mice exhibited only slight enlargement of renal tubular cell nuclei. No renal effects were found in 
rats exposed to 15,000 ppm chloroethane 6 hours/day, 5 days/week for 102 weeks (NTP 1989). 
Endocrine Effects. No studies were located regarding endocrine effects in humans following 
inhalation exposure to chloroethane. 
No effects on thyroid weight, thyroid histopathology, or adrenocorticotropic hormone activity were noted 
in rats exposed to 436 ppm chloroethane 4 hours/day for 8 exposures over 10 days (Gohlke and Schmidt 
1972;Schmidt et al. 1972). Histopathologic changes were not observed in the adrenals, pancreas, 
parathyroid, pituitary, or thyroid glands of mice exposed to 4,843 ppm chloroethane 23 hours/day for 11 
days (Landry et al. 1987, 1989), or rats or dogs exposed to 9,980 ppm chloroethane 6 hours/day, 5 
days/week for 2 weeks (Landry et al. 1982). Microscopic examination of the adrenals, pancreas, 
parathyroid, pituitary, and thyroid glands from 3 of 10 rats and 3 of 10 mice exposed to 19,000 ppm 
chloroethane 6 hours/day, 5 days/week for 2 weeks, did not reveal any effects (NTP 1989). Because 
histopathological examinations were completed on only a few animals, this study is not presented in Table 
2-l and Figure 2-l for endocrine effects. 
Histopathologic changes were not observed in the adrenals, pancreas, parathyroid glands, pituitary, or 
thyroid glands of rats or mice exposed to 19,000 ppm chloroethane 6 hours/day, 5 days/week for 13 
weeks, or those exposed to 15,000 ppm 6 hours/day, 5 days/week for approximately 2 years (NTP 1989). 
Dermal Effects. No studies were located regarding dermal effects in humans following inhalation 
exposure to chloroethane. 
Dermal effects following inhalation exposure to chloroethane were not reported in animal studies. No 
histopathological effects on the skin were found in mice exposed to 4,843 ppm 23 hours/day for 11 days 
(Landry et al. 1987, 1989); in rats or dogs exposed to 9,980 ppm 6 hours/day, 5 days/week for 2 weeks 
(Landry et al. 1982); or rats or mice exposed 6 hours/day, 5 days/week to 19,000 ppm for 2 weeks (NTP 
1989), 19,000 ppm for 13 weeks (NTP 1989), or 15,000 ppm for approximately 2 years. The 2-week NTP 
(1989) study is not presented in Table 2-1 or Figure 2-B for dermal effects because histopathological 
examinations were completed on only 3 of 10 exposed rats and 3 of 10 exposed mice. 
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Ocular Effects. Mild eye irritation occurred in volunteers exposed briefly to 40,000 ppm 
chloroethane (Sayers et al. 1929). No eye irritation was reported followmg exposure to 20,000 ppm. 
Additional reports of eye irritation in humans during exposure to cbloroethane vapor were not identified. 
Histopathological examinations of the eyes did not reveal any effects in mice exposed to 4,843 ppm 
chloroethane 23 hours/day for 11 days (Landry et al. 1987,1989), or in rats or dogs exposed to 9,980 ppm 
chloroethane 6 hours/day, 5 days/week for 2 weeks (Landry et al. 1982). Ophthalmoscopic examination of 
the eyes of the chloroethane-exposed dogs also did not reveal any effects. 
Body Weight Effects. No studies were located regarding body weight effects in humans following 
inhalation exposure to chloroethane. Body weight gain was not significantly affected by exposures to 
15,000 ppm chloroethane for 5 daily 6-hour exposures in rats or mice (Fedtke et al. 1994a); to 436 ppm 4 
hours/day for 8 of 10 days in rats (Schmidt et al. 1972); to 4,843 ppm 23 hours/day for 11 days in mice 
(Landry et al. 1987, 1989); to 9,980 ppm 6 hours/day, 5 days/week for 2 weeks, in rats or dogs (Landry et 
al.1982); or 19,000 ppm 6 hours/day, 5 days/week for 2 weeks, in rats or mice (NTP 1989). Exposure to 
4,946 ppm chloroethane 6 hours/day on gestation days 6-l 5 did not affect body weight gain of pregnant 
mice (Scortichini et al. 1986). 
Following longer duration exposures to chloroethane, body weight gain was not significantly affected in 
rats or mice by exposures to 19,000 ppm 6 hours/day, 5 days/week for 13 weeks, or 15,000 ppm 6 
hours/day, 5 days/week for approximately 2 years (NTP 1989). Body weight gain of 62 g less than 
controls was reported in rats exposed to 216 ppm chloroethane for 6 months (Troshina 1966). Because 
experimental methods were not described in detail, the Troshina (1966) study is not presented in Table 2-l 
or Figure 2-l. 
2.2.1.3 Immunological and Lymphoreticular Effects 
One study of immunological effects in humans exposed to chloroethane was found. Troshina (1966) 
compared the leukocyte phagocytic activity of 25 workers who may have been exposed to chloroethane 
vapors for 1.5-3 years with that of 25 control workers and found a significant decrease in phagocytic 
activity in the exposed workers. Levels of chloroethane in the plant were not reported. This study was not 
used as the source of a LOAEL value because it did not contain an adequate description of either methods 
or results. 
There were no reliable reports of immunological effects in animals after inhalation of chloroethane. 
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Rat spleen and thymus weight were not affected by exposure to 436 ppm chloroethane for 4 hours/day for 
8 days (Schmidt et al. 1972). White blood cell counts were also unaffected in this study (Schmidt et al. 
1972). Histological changes in the thymus, spleen, and lymph nodes were not observed in mice exposed to 
4,843 ppm chloroethane 23 hours/day for 11 days (Landry et al. 1987,1989). There were no 
compoundrelated effects on organs or tissues of the immune system after exposure to 9,980 ppm 6 
hours/day, 5 days/week for 2 weeks, in rats or dogs (Landry et al. 1982), 19,000 ppm 6 hours/day, 5 
days/week for 2 weeks, in rats or mice (NTP 1989), 19,000 ppm 6 hours/day, 5 days/week for 13 weeks, in 
rats or mice (NTP 1989), or 15,000 ppm 6 hours/day, 5 days/week for approximately 2 years, in rats or 
mice (NTP 1989). 
Slightly congested or anemic spleens were observed in guinea pigs exposed to 40,000 ppm chloroethane 
for 90 minutes (Sayers et al. 1929). Reduced leukocyte phagocytic activity was reported in rats following 
both 60-day exposure to 5,305 ppm chloroethane and 6-month exposure to 2 16 ppm (Troshina 1966). 
These concentrations were not used as levels of significant exposure, however, because no experimental 
details were provided. 
The highest NOAEL values for immunological effects from each reliable study in each species and 
duration category are recorded in Table 2- 1 and plotted in Figure 2- 1. 
2.2.1.4 Neurological Effects 
There are numerous reports of neurological effects in humans exposed to chloroethane by inhalation. 
Marked dizziness was reported in volunteers who were given 3 breaths of 20,000 ppm chloroethane 
(Sayers et al. (1929). A subjective feeling of intoxication and decreased reaction times were reported in 
persons during exposure to 13,000 ppm for 12 minutes (Davidson 1925). At 19,000 ppm, slight 
intoxication was recorded within 1 minute of exposure. This effect progressed to distinct intoxication and 
mild analgesia within 12 minutes. At higher concentrations, more pronounced effects appeared, such as 
slight incoordination within 15 minutes at 25,000 ppm and marked incoordination within 8 minutes at 
33,600 ppm. Inhalation of 33,600 ppm chloroethane in oxygen produced unconsciousness in 13-17 
minutes (Davidson 1925). The number of subjects exposed at each concentration was not clearly stated in 
this study, and there was no discussion regarding how long it took for the subjects to recover fully from 
the effects of chloroethane. 
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Chloroethane, combined with nitrous oxide and oxygen, was used to maintain anesthesia in patients 
previously made unconscious by administration of either thiopentone (thiopental), nitrous oxide, or a 
mixture of nitrous oxide, chloroethane, and oxygen (Cole 1956). A concentration of 20,000 ppm 
chloroethane was initially required to maintain anesthesia, but this could slowly be reduced to as low as 
5,000 ppm in some cases. Anesthesia could be maintained up to an hour using chloroethane in this 
manner. In a similar study using 36,000 ppm chloroethane, the length of time required to recover from 
anesthesia varied from 3 to 15 minutes in 33 subjects (Cole 1967). This result was not used as a level of 
significant exposure because chloroethane was administered in combination with other anesthetic agents. 
Unconsciousness is not the only neurological effect reported in humans following exposure to anesthetic 
concentrations of chloroethane. Anesthetic concentrations of chloroethane also produced vagus nerve 
stimulation leading to cardiac depression in subjects studied by Bush et al. (1952). A LOAEL was not 
taken from this study because the effective concentration of chloroethane was not reported. As indicated in 
Section 2.2.1.2, gastrointestinal effects (nausea, vomiting, mild abdominal cramps) have been reported in 
people recovering from chloroethane anesthesia (Cole 1967). Because these effects are thought to have a 
neurological basis, the NOAEL and LOAEL associated with the gastrointestinal effects in humans in the 
Davidson (1925) study are also presented in Table 2-l and plotted in Figure 2-l under neurological effects. 
A woman who inhaled chloroethane daily as a narcotic for 4 months had several signs and symptoms 
indicating cerebellar dysfunction. A neurological examination revealed ataxia, nystagmus (rapid eye 
movement), scanning dysarthria (imperfect speech articulation), dysdiadochokinesia (inability to perform 
alternating movements) of the arm, and sluggish lower limb reflexes (Hes et al. 1979). After 1 month 
without chloroethane, her neurological condition returned to normal. The woman had previously used 
other drugs but was reported to be free of addiction for 2 years before starting to use chloroethane (Hes et 
al. 1979). In a second case of chloroethane abuse, neurological signs and symptoms observed during the 
withdrawal period included a grand mal seizure, ataxia, difficulties in walking, disorientation, short-term 
memory impairment, and visual hallucinations (Nordin et al. 1988). Electroneurography indicated 
neuropathy of motor and sensory neurons (Nordin et al. 1988). Because it provided a euphoric effect, this 
male subject had abused chloroethane for about 30 years, and during the 4 months before he was admitted 
to the hospital, inhaled at least 100 ml/day. This subject also had a history of alcohol and sedative abuse, 
although no ethanol was in his breath on hospital admission. After approximately 6 weeks, the 
neurological and mental changes regressed without any residual symptoms. The study authors indicated 
that it was not possible to determine if the nervous system effects were toxic effects of chloroethane or 
withdrawal 
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symptoms. Levels of significant exposure were not based on these reports because the effective 
concentration of chloroethane was not reported. 
Only one study of chloroethane exposure in an industrial setting was found. Seventy-six workers in a butyl 
rubber plant possibly exposed to chloroethane vapors for 2 months to 3 years were examined; 
approximately half had autonomic nervous system dysfunction in the form of intensified parasympathetic 
tonus (Troshina 1966). The study author indicated that autonomous nervous system function was 
measured with a battery of tests, including Ashner’s test, a synapse test, and a white spot test, but 
additional details were not provided.  Concentrations of chloroethane in the plant were not reported. 
Neurological effects of chloroethane inhalation have also been studied in animals. Guinea pigs exposed to 
20,000 ppm chloroethane were unsteady, sluggish, and dizzy during a 9-hour exposure (Sayers et al. 
1929).  Those exposed to 40,000 ppm were unsteady and dizzy after 3 minutes of exposure. At higher 
concentrations (>51,000 ppm), these effects were seen after shorter exposure durations, and more severe 
effects were found such as inability to stand, lying on the side, convulsions, and unconsciousness. Two-
hour inhalation of 54,948 ppm produced nervous excitation and convulsions followed by narcosis in mice 
and rats (Troshina 1966). Respiratory paralysis also occurred in some cases, leading to death. 
Histopathological examination revealed degeneration of nerve cells in the medulla oblongata and 
subcortical stratum of the brain (Troshina 1966). In dogs, concentrations of chloroethane that produced 
anesthesia also produced stimulation of the vagus nerve and, consequently, cardiac depression (Bush et al. 
1952). Premeditation with anticholinergic drugs inhibited vagal stimulation (Bush et al. 1952). Muscle 
twitching and tremors have also been observed in dogs during chloroethane anesthesia (Morris et al. 
1953). LOAELs were not taken from these studies because the effective concentrations of chloroethane 
were not reported. 
There were few reports of neurological effects in studies of longer duration. Brain histopathology and 
weight in the rat were unaffected by eight 4-hour exposures to 436 ppm chloroethane (Gohlke and 
Schmidt 1972; Schmidt et al. 1972). Slight lethargy was observed in rats, and hyperactivity was observed 
in 1 of 2 dogs exposed to 9,980 ppm chloroethane 6 hours/day, 5 days/week for 2 weeks (Landry et al. 
1982). Brain weight and brain or peripheral nerve histopathology were not affected. Evaluation of the dogs 
for gait, posture, cranial nerve reflexes, postural reactions, spinal cord reflexes, muscle tone, and pain 
perception also did not reveal any chloroethane-related effects (Landry et al. 1982). When mice received 
11 days of near-continuous exposure to 4,843 ppm chloroethane, no neurological effects were found by 
function testing or histopathological examination (Landry et al. 1987, 1989). No compound-related 
neurological effects were 
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found in histopathological examinations of rats and mice exposed to 19,000 ppm chloroethane 6 
hours/day, 5 days/week for 2 or 13 weeks (NTP 1989). No increase in the occurrence of non-neoplastic 
lesions was found in nervous system organs or tissues following exposure of rats and mice to 15,000 ppm 
chloroethane 6 hours/day, 5 days/week for approximately 2 years (NTP 1989). This study did, however, 
report hyperactivity of female mice during the daily exposure period. A temporary increase in the 
threshold of electrodermal excitability occurred in rats after 60 days of exposure to 5,305 ppm, but not 
after 6 months of exposure to 216 ppm (Troshina 1966). 
The highest NOAEL values and all LOAEL values from each reliable study for neurological effects in 
each species and duration category are recorded in Table 2-l and plotted in Figure 2-l. The results of the 
study by Troshina (1966) were not used as levels of significant exposure because experimental methods 
and results were not described in sufficient detail. 
2.2.1.5 Reproductive Effects 
No studies were located regarding reproductive effects in humans following inhalation exposure to 
chloroethane. 
Several studies investigated reproductive endpoints in animals. In dogs anesthetized with chloroethane, 
high concentrations resulted in decreased uterine motility and muscle tonus (Van Liere et al. 1966). This 
study was not used as the basis for a LOAEL because the effective concentration of chloroethane was not 
reported.  In addition, the relevance of this endpoint to other reproductive effects is unclear. No effects on 
uterine weights were observed in rats exposed to 15,000 ppm chloroethane 6 hours/day for 5 days (Fedtke 
et al. 1994a). Compared to unexposed controls, absolute and relative uterine weights were decreased by 
approximately 35% in mice exposed to 15,000 ppm chloroethane 6 hours/day for 5 days (Fedtke et al. 
1994a). Significant decreases in uterine glutathione levels were observed in both rats and mice (Fedtke et 
al. 1994b). The decreases in glutathione in the uterus were greater than the decreases in glutathione 
observed in the liver, lungs, and kidneys. A small increase in the average duration of the estrous cycle was 
observed in mice exposed to 15,000 ppm chloroethane 6 hours/day for 21 days (Bucher et al. 1995). 
Before the exposure, estrous cycle duration was 5.15±0.15 days, while during the exposure, estrous cycle 
duration was 5.52±0.19 days. Measurement of serum estradiol and progesterone did not reveal any 
consistent statistically significant changes attributable to chloroethane exposure. 
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Testes weights were not affected in rats exposed to 436 ppm chloroethane 4 hours/day for 8 days during a 
l0-day time period (Schmidt et al. 1972). Sperm motility in rats was reduced after exposure to 
chloroethane for 6 months (Troshina 1966). At 22.7 ppm, the effect subsided after the exposure period 
ended, but at 216 ppm no recovery occurred during the month after exposure. Methods and results were 
inadequately reported in this study, so it was not used for a LOAEL. 
Histopathological changes in reproductive organs were not observed in mice exposed to 4,843 ppm 
chloroethane 23 hours/day for 11 days (Landry et al. 1987, 1989), or in rats and dogs exposed to 9,980 
ppm chloroethane 6 hours/day, 5 days/week for 2 weeks (Landry et al. 1982). Microscopic examination of 
the reproductive organs of 3 of 10 rats and 3 of 10 mice exposed to 19,000 ppm chloroethane 6 hours/day, 
5 days/week for 2 weeks, did not reveal any effects (NTP 1989). Because histopathological examinations 
were completed on only a few animals, this study is not presented in Table 2-l or Figure 2-l for 
reproductive effects. No compound-related histopathological changes were found in the reproductive 
organs of rats or mice exposed to 19,000 ppm chloroethane 6 hours/day, 5 days/week for 13 weeks, or to 
15,000 ppm 6 hours/day, 5 days/week for approximately 2 years (NTP 1989). 
No effects on the number of live and dead fetuses or on the number and position of resorption sites were 
observed in mice exposed to 4,946 ppm chloroethane 6 hours/day on gestation days 6-15 (Scortichini et al. 
1986). Additional studies of reproductive outcome in animals following inhalation exposure to 
chloroethane were not identified. 
The highest NOAEL values and all LOAEL values from each reliable study for reproductive effects in 
each species and duration category are recorded in Table 2-l and plotted in Figure 2-l. 
2.2.1.6 Developmental Effects 
No studies were located regarding developmental effects in humans following inhalation exposure to 
chloroethane. 
Only one study of the developmental effects of chloroethane in animals was found. In mice, 6-hour 
inhalation exposure to 4,946 ppm chloroethane on gestation days 6-15 resulted in minimal evidence of 
fetotoxicity (Scortichini et al. 1986). A small, statistically significant (p=0.05) increase in the incidence of 
foramina of the skull bones (small centers of unossified bone) was observed. This effect was observed in 
5,4,4, and 
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23% of the litters at 0, 491, 1,504, and 4,946 ppm, respectively. An increase in supernumerary ribs was 
also found, although this effect was not indicated as statistically significant. The incidences of litters with 
supernumerary ribs were 9,4, 19, and 18% at 0, 491, 1,504, and 4,946 ppm, respectively. No effects were 
observed on maternal body or liver weights, reproductive parameters, fetal body weight, or the incidence 
of external or visceral malformations in the fetuses The NOAEL and LOAEL for fetotoxic effects in mice 
are recorded in Table 2-l and plotted in Figure 2-l 0 Based on the NOAEL of 1,504 ppm for developmental 
effects in mice (Scortichini et al. 1986), an acute-duration inhalation MRL of 15 ppm was calculated, as 
described in the footnote to Table 2-1. 
2.2.1.7 Genotoxic Effects 
No studies were located regarding genotoxic effects in humans following inhalation exposure to 
chloroethane. 
Chloroethane did not increase the number of micronuclei in bone marrow cells or affect DNA synthesis in 
mice exposed nose-only to 25,000 ppm chloroethane 6 hours/day for 3 days (Ebert et al. 1994). The 
investigators indicated that the exposure concentration used in this study was about 66% of the 
flammability limit and that it was the highest concentration that could be safely administered. 
Other genotoxicity studies are discussed in Section 2.5. 
2.2.1.8 Cancer 
No studies were located regarding cancer in humans following inhalation exposure to chloroethane. 
A study of the carcinogenicity of chloroethane vapor in animals has been completed. Inhalation exposure 
to 15,000 ppm chloroethane 6 hours/day, 5 days/week for 102 weeks, produced evidence of 
carcinogenicity in both male and female rats (NTP 1989). The combined incidence of skin 
trichoepitheliomas, sebaceous gland adenomas, and basal cell carcinomas was 10% (5/50) in treated male 
rats and 0% (0/50) in concurrent controls. This increase was statistically significant when compared to the 
mean historical inhalation control incidence of 0.7% (n=300) and the historical untreated control incidence 
of 2% (n=1,936). It is reasonable to combine incidence data of these neoplasms because they are 
morphologically similar (all are epithelial tumors arising from the epidermis or associated structures). 
Malignant brain astrocytomas were found in 6% (3/50) of the treated female rats and 0% (0/50) of the 
concurrent controls. This increase was statistically significant 
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compared to the historical inhalation control incidence of 0.3% (n=297) and the historical untreated glial 
cell tumor incidence of 1.2% (n=l,969). All three affected rats died before the end of the study and it was 
suggested that the brain tumors may have been the cause of death. The NTP (1989) concluded that this 
study provides equivocal evidence of the carcinogenicity of chloroethane in both male and female rats. A 
CEL of 15,000 ppm for rats is reported in Table 2-1 and plotted in Figure 2-l. 
There was a highly significant increase in the incidence of uterine carcinomas of endometrial origin in 
female mice exposed to 15,000 ppm chloroethane 6 hours/day, 5 days/week for 100 weeks (NTP 1989). 
These tumors, which were highly malignant and metastasized to a wide variety of organs, were found in 
86% (43/50) of treated females and 0% (0/49) of concurrent controls. In addition, there was a significant 
increase in hepatocellular carcinomas, which occurred in treated female mice at an incidence of 15% 
(7/48) and concurrent controls at 6% (3/49). A significant increase in the occurrence of lymphomas in 
treated female mice was discounted because concurrent control values were abnormally low compared to 
historical control values. In males, the combined incidence of alveolar and bronchiolar adenomas was 17% 
(8/48), a significant increase compared to the 6% (3/50) incidence in concurrent controls. The combined 
incidence of adenomas and carcinomas was 21% (10/48) in exposed mice and 10% (5/50) in concurrent 
controls. The study authors concluded that this study provides clear evidence of the carcinogenicity of 
chloroethane in female mice but that the study was inadequate for male mice because of low survival. A 
CEL of 15,000 ppm for mice is reported in Table 2- 1 and plotted in Figure 2- 1. 
2.2.2 Oral Exposure 
No studies were located regarding the following effects in humans or animals after oral exposure to 
chloroethane. 
2.2.2.1 Death 
2.2.2.2 Systemic Effects 
2.2.2.3 Immunological and Lymphoreticular Effects 
2.2.2.4 Neurological Effects 
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2.2.2.5 Reproductive Effects 
2.2.2.6 Developmental Effects 
2.2.2.7 Genotoxic Effects 
Genotoxicity studies are discussed in Section 2.5. 
2.2.2.6 Cancer 
No studies were located regarding cancer in humans or animals after oral exposure to chloroethane. 
2.2.3 Dermal Exposure 
2.2.3.1 Death 
No studies were located regarding death in humans or animals following dermal exposure to chloroethane. 
2.2.3.2 Systemic Effects 
No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological, hepatic, 
renal, or ocular effects in humans or animals following dermal exposure to chloroethane. 
Musculoskeletal Effects. No studies were located regarding musculoskeletal effects in humans 
following dermal exposure to chloroethane. 
One study investigated the musculoskeletal effects of dermally applied chloroethane in animals. 
Chloroethane sprayed onto a l-2-cm2 area on the thighs of rats until the skin was blanched produced local 
infiltration and disintegration of muscle fibers (Kenig 1956). This study, available only as an abstract, was 
not used as the basis for a LOAEL because the effective dose of chloroethane was not reported and few 
experimental details were provided. 
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Dermal Effects. Dermally applied chloroethane is used as a local anesthetic in humans (Nielsen 
1980; Noble 1979; Ott 1969; Van Ketel 1976). When sprayed on the skin, chloroethane rapidly evaporates 
and causes the skin to freeze, which produces a numbing sensation. It is used for procedures such as skin 
biopsy and ear piercing that require short periods of surface anesthesia in a small area (Ott 1969). It is also 
used topically to relieve pain in facial muscles during physical therapy for those suffering from 
temperomandibular pain and dysfunction syndrome (also known as temperomandibular joint syndrome, or 
TMJ) (Marbach 1996). When used as a topical anesthetic, chloroethane is usually applied for 30 seconds 
or less. Symptoms of frostbite can result from prolonged exposures. Three children who had their earlobes 
sprayed with chloroethane for several minutes all developed chemical frostbite on their ears and necks 
(Noble 1979). This report was not used as the basis for a LOAEL because the effective dose of 
chloroethane was not reported.  As discussed in Section 2.2.3.3, humans can develop dermal contact 
sensitivity reactions to chloroethane (Bircher et al. 1994; Kriechbaumer et al. 1998; Van Ketel 1976). 
Dermal effects have also been reported in animals Chloroethane has the same topical anesthetic qualities 
in animals as it does in humans (Dobkin and Byles 1971). Chloroethane applied to a l-2-cm2 area on the 
thighs of rats until the skin was blanched produced edema in the subcutaneous tissue of the application site 
(Kenig 1956). This study, available only as an abstract, was not used as the basis for a LOAEL because the 
effective dose of chloroethane was not reported and few experimental details were provided. 
2.2.3.3 Immunological and Lymphoreticular Effects 
Dermal exposure to chloroethane can result in contact sensitivity. Patch tests performed on two patients 
with eczema were strongly positive for chloroethane, while a third patient suffered an eczematous reaction 
after the use of chloroethane as a local anesthetic, indicating that allergy to chloroethane can occur. Patch 
tests on 15 control volunteers were negative (Van Ketel 1976). A punch biopsy taken from a woman with 
a positive patch test to chloroethane revealed observations consistent with a T-cell-mediated allergic 
reaction (Bircher et al. 1994). Microscopic examination showed marked spongiosis and a 
lymphohistocytic infiltrate. There was a marked dermal infiltrate of CD3+ T cells (pan T cells), with a 
predominance of CD4+ T cells (helper/suppressor cell subtypes). Most of the cells expressed lymphocyte 
function-associated antigen. A considerable number of CDl+ Langerhans cells were also found in the 
epidermis. 
No studies were located regarding immunological and lymphoreticular effects in animals following dermal 
exposure to chloroethane. 
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2.2.3.4 Neurological Effects 
Mild pain was reported when chloroethane was sprayed on a small area of 1 hand each of 40 women 
(Selby and Bowles 1995). The chloroethane was sprayed for 10 seconds, from a height of 20 cm. This 
procedure was used as analgesia for venous cannulation, a procedure that was reported to be more painful 
without pretreatment with chloroethane. 
There is one study of the neurological effects of dermally applied chloroethane in animals. Rats were 
sprayed with chloroethane until their skin was blanched, and examination of the nerve fibers at the site of 
application (a 1-2-cm2 area of the thigh) revealed thickening of the fibers and swelling of the Schwann cell 
nuclei (Kenig 1956). These effects subsided within 10 days of application. This study, available only as an 
abstract, was not used as the basis for a LOAEL because the effective dose of chloroethane was not 
reported and few experimental details were provided. 
No studies were located regarding the following effects in humans or animals following dermal exposure 
to chloroethane. 
2.2.3.5 Reproductive Effects 
2.2.3.6 Developmental Effects 
2.2.3.7 Genotoxic Effects 
Genotoxicity studies are discussed in Section 2.5. 
2.2.3.8 Cancer 
No studies were located regarding cancer in humans or animals after dermal exposure to chloroethane. 
2 . 3 TOXICOKINETICS 
Chloroethane is readily absorbed following inhalation exposure. Data regarding the absorption of 
chloroethane following oral exposure were not identified. Based on physical properties, a dermal flux rate of 
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0.99 mg/cm2 hour has been estimated. Partition coefficients indicate that chloroethane, once absorbed, 
would have a greater affinity for fat than for muscle or the liver. 
The metabolism of chloroethane has not been studied in humans. In rats and mice, the two major pathways 
of chloroethane metabolism are the production of acetaldehyde by cytochrome P450, and conjugation of 
chloroethane with glutathione to form S-ethyl-glutathione. Acetaldehyde is rapidly metabolized to acetic 
acid.  The glutathione metabohtes are further metabolized to S-ethyl-L-cysteine in mice, and S-ethyl-N­
acetyl-L-cysteine in both rats and mice. Glutathione conjugate metabolites of chloroethane are excreted in 
the urine, while unmetabolized chloroethane is exhaled. 
2.3.1 Absorption 
2.3.1.1 Inhalation Exposure 
Chloroethane is readily absorbed through the lungs in humans and animals (Konietzko 1984; Lehman and 
Flury 1943; Torkelson and Rowe 1981). The rapidity of anesthesia in humans and animals following 
inhalation exposure supports this contention (Dobkin and B yles 197 1; Finer 1966; Lawson 1965). Human 
subjects were exposed to about 5 mg 38Cl-labeled chloroethane for 30 seconds by taking 1 breath through 
the mouth and then holding it for 30 seconds (Morgan et al. 1970). Approximately 18% of the 
radioactivity was exhaled in the first 2 breaths indicating that about 82% was retained. 
No data are available to indicate that absorption of chloroethane would be different in children as 
compared to adults. Exposure to chloroethane is most likely via inhalation. Since infants and adolescents 
breathe more air per kilogram than adults, it is possible that children could inhale more chloroethane 
relative to their body weight than adults. However, infants have less developed alveoli than adults, which 
may result in a smaller surface area for absorption (NRC 1993). 
2.3.1.2 Oral Exposure 
No studies were located regarding absorption in humans or animals following oral exposure to 
chloroethane. 
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2.3.1.3 Dermal Exposure 
A dermal flux rate of 0.99 mg/cm2/hour was estimated based on the physical properties of chloroethane 
(Fiserova-Bergerova et al. 1990). Based on physical properties, the study authors considered chloroethane 
to have no significant dermal absorption potential. No quantitative studies were located regarding 
absorption in humans or animals following dermal exposure to chloroethane. 
2.3.2 Distribution 
Partition coefficients for human blood and serum measured in vitro at 40 °C were 1.9 for blood/air and 1.2 
for serum/air (Morgan et al. 1970). A blood/air partition coefficient for humans of 2.69±0.2 has also been 
determined in vitro at 37°C (Gargas et al. 1989). Rat tissue/air partition coefficients of 38.6±0.7, 
4.08±0.39, 3.61±0.32, and 3.22±0.68 for fat, blood, liver, and muscle, respectively, suggest that 
chloroethane has a higher affinity for fat than for blood, liver, or muscle (Gargas et al. 1989). These 
partition coefficients were determined in vitro at 37 °C using tissues from F344 rats. 
No concrete data are available to indicate that distribution of chloroethane is different in children. 
Physical-chemical properties of chloroethane indicate that it would be readily soluble in fat. In the 
newborn and young infant, fat tissue is relatively scarce (15% of body weight; Morselli et al. 1980) as 
compared to an adult, indicating that distribution of lipophilic chloroethane will differ in infants and young 
children relative to adults. In addition, infants and younger children have much more total body and 
extracellular water relative to body weight than adults (Altman and Dittmer 1974), indicating that 
distribution of water-soluble compounds, such as chloroethane metabolites, will differ in children as 
compared with adults (Morselli et a1.1980). 
The brain of a child is much larger, relative to body weight, than in the adult (Guzelian et al. 1992). 
Further, cerebral blood flow is greater, relative to brain weight, in the child than in the adult (Guzelian et 
al. 1992). Therefore, chloroethane present in the blood after exposures (such as inhalation) will more 
readily reach the brain of a child due to this increased blood flow. Since the central nervous system is the 
target organ for chloroethane’s narcotic effects, the larger relative brain size of the child indicates that a 
child might experience a much larger exposure dose relative to body weight than an adult. 
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It is unknown if chloroethane can reach and cross the placenta or its precursors. However, based on 
physical-chemical characteristics of the compound, it is likely that it can. In addition, it is known that 
some chloroethane metabolites such as ethanol (Guzelian et al. 1992), can cross the placental barrier. 
One study to date (Pellizari et al. 1982) determined that chloroethane does enter the milk of a lactating 
woman and can be detected. However, this study did not qluantify the chloroethane in milk, few women 
were tested, and the route of exposure to chloroethane was not determined. Therefore, it is impossible to 
estimate what percentage of exposed nursing mothers would be expected to excrete the compound in milk 
and what the significance of the compound in mother’s milk would be for a nursing infant. 
No data are available to indicate that females store chloroethane or its metabolites in their tissues. Data 
indicate that chloroethane is rapidly cleared within the body; therefore, it is unlikely that any of the 
compoundwould be stored in tissues, and it would not likely be available to be mobilized at a later time 
during pregnancy or lactation. 
No data are available concerning the possibility of chloroethane entering into and adversely affecting 
parental germ cells. 
2.3.2.1 Inhalation Exposure 
No studies were located regarding distribution in humans or animals following inhalation exposure to 
chloroethane. Reviews of the effects of chloroethane (Konietzko 1984; Lehman and Flury 1943) provide 
some general information about the distribution of chloroethane. The species in which the information was 
obtained was not stated. In the blood, approximately 75% of the chloroethane is bound to red blood cells, 
and 25% is in the plasma (Konietzko 1984). The highest concentration of chloroethane in the animal body 
was found in fatty tissue around the kidney, and the lowest was found in the cerebrospinal fluid 
(Konietzko 1984). The brain was said to accumulate a concentration two times that of the blood. Lehman 
and Flury (1943) reported that chloroethane content in the brain and medulla oblongata was especially 
high. 
2.3.2.2 Oral Exposure 
No studies were located regarding distribution of chloroethane in humans or animals following oral 
exposure. 
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2.3.2.3 Dermal Exposure 
No studies were located regarding distribution of chloroethane in humans or animals following dermal 
exposure. 
2.3.3 Metabolism 
No studies were located regarding metabolism of chloroethane by humans.  A review indicates that a small 
amount of chloroethane was metabolized to ethanol via dechlorination in animals following administration 
of high anesthetic doses (Konietzko 1984). The species was not identified. 
Less than 0.5% of the dose was dechlorinated by rat liver microsomes in vitro (Van Dyke and Wineman 
1971). 
The metabolic rates for chloroethane were estimated for male F344 rats using a gas uptake method 
(Gargas et al. 1990). The rats were exposed to an initial concentration of 100, 535, 1,200, or 2,350 ppm, 
and the disappearance of the gas was studied for about 5 hours. A physiologically based pharmacokinetic 
(PBPK) model that assumed metabolism occurred exclusively in the liver was used to analyze the data. 
The metabolism of chloroethane was best described by a combination of a saturable pathway and a first-
order pathway. The Vmaxc which is the maximum velocity (Vmax) scaled for a 1-kg animal, was determined 
to be 4 mg/hour (to calculate a Vmax for an animal of any body weight [body weight in kg] use Vmax = 
Vmaxc[BW]0.7). The rate constant for the saturable pathway (Km was estimated to be 0.1 mgL. The first-
order rate constant, kfc which is the rate constant (Kf scaled for a l-kg animal, was 1 hr-1 (to calculate a kf 
for any body weight use kf = kfc[BW]-0.3). 
The proposed metabolic pathways for chloroethane in rats and mice (Fedtke et al. 1994b) are shown in 
Figure 2-2. The two major pathways are the production of acetaldehyde by cytochrome P450, and 
conjugation of chloroethane with glutathione to form S-ethyl-glutathione. The metabolism of chloroethane 
to acetaldehyde was studied in vitro using livers from rats and mice exposed to chloroethane at 0 or 15,000 
ppm 6 hours/day for 5 days (Fedtke et al. 1994a). The amounts of acetaldehyde detected ranged from 26.9 
to 49.3% of the chloroethane metabolized, depending on pre-exposure to chloroethane, for the individual 
microsome preparations from rats and mice. The investigators found that exposure to chloroethane 
induced its own metabolism by approximately 100% in mice and female rats, with no effect in male rats. 
Based on 
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studies using specific P450 enzyme inducers and inhibitors, the investigators concluded that the P450 
enzyme DE1 (CYP2El) was responsible for chloroethane metabolism. CYP2E1 also metabolizes alcohols, 
aldehydes, and ketones, and plays a role in gluconeogenesis within the body (Vieira et al. 1996). 
Acetaldehyde is rapidly metabolized to acetic acid by aldehyde dehydrogenase. Therefore, increased 
acetaldehyde relative to normal levels was not detected in the serum of chloroethane-exposed rats or mice 
(15,000 ppm), or in the urine of exposed rats (Fedtke et al. 1994a). Small increases in acetaldehyde were 
detected in the urine of chloroethane-exposed mice. Acetaldehyde concentrations in the urine of male and 
female mice were 7.9-20.3 and 0-l 8.1 µmol/L, respectively, in unexposed mice, and 15.4-70.1 and 11.6­
17 µmol/L, respectively, in chloroethane-exposed mice. Except for the approximately threefold greater 
metabolism of chloroethane in mice compared to rats, there was little difference between the species. The 
study authors concluded that the production of acetaldehyde from chloroethane was unlikely to have a role 
in the induction of uterine carcinomas in mice. 
Glutathione levels were studied in rats and mice exposed to chloroethane at 0 or 15,000 ppm 6 hours/day 
for 5 days (Fedtke et al. 1994b). The animals were sacrificed immediately after the last exposure. 
Compared to controls, glutathione concentrations were significantly (p<0.05) decreased in the livers of 
male rats, in the kidneys of female rats, in the lungs of both sexes of rats and mice, and in the uteri of both 
rats and mice. The decreases in glutathione levels were most dramatic in the uterus, in which levels were 
approximately two-thirds lower than in controls. In vitro studies of chloroethane conjugation to 
glutathione, using liver cytosolic fractions from control and chloroethane-exposed rats and mice, indicated 
that the conjugation was catalyzed by glutathione-S-transferase enzymes (Fedtke et al. 1994b). 
Glutathione conjugation rates, in nmol chloroethane conjugated/minute mg protein, were greater in mice 
(0.71±0.19 in males; 1.01±0.19 in females) than in rats (0.17±0.19 in males; 0.16±0.03 in females). 
Chloroethane exposure had no effect on these rates in rats and slightly decreased the rates in mice. When 
urine was analyzed for glutathione metabolites, S-ethyl-N-acety-L-cysteine was detected in both rats and 
mice. S-Ethyl-L-cysteine was detected only in the urine of mice. The total amount of glutathione 
metabolites excreted during the 5-day exposure period was about fivefold higher in mice than in rats. The 
study authors concluded that rats completely metabolize S-ethyl-L-cysteine to more hydrophilic 
metabolites before urinary excretion, while these metabolic pathways were not available to the same extent 
in mice under the conditions of this study. 
No data are currently available to indicate that the metabolism of chloroethane is different in children 
when compared to adults; however, some of the enzymes in the chloroethane metabolism scheme 
belong to enzyme 
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families that are developmentally regulated to some extent either in humans or animals. Chloroethane is 
metabolized by both cytochrome P450 and by glutathione S-transferase. Studies have shown that liver 
glutathione S-transferase activities are low in prepubertal male and female rats, but as the rats reach sexual 
maturity (at around 30-50 days of age), glutathione-conjugating activity toward dichloronitrobenzene is 
two to threefold higher in males than females (Lamartiniere and Lucier 1983). The difference in 
glutathione S-transferase activity was dependent on pituitary secretions. Further research on 
hypophysectomized male and female rats revealed that growth hormones may contribute to the 
establishment of glutathione S-transferase activities (Lamartiniere 1981). No data are available to indicate 
that glutathione S-transferase activity is developmentally or sexually expressed in humans. 
After glutathione conjugation of chloroethane, three other enzymes convert the conjugate to a more 
hydrophilic form to be excreted by the body. These enzymes are γ-glutamyltranspeptidase, cysteinyl 
glycinase, and N-acetyltransferase, NAT (Amdur et al. 1991). These three enzymes convert elatively 
hydrophobic glutathione conjugates to their respective mercapturic acids, which can be excreted more 
readily.  There are two N-acetyltransferase enzyme families, NAT1 and NAT2. Of these enzymes, only 
NAT2 is developmentally regulated. It is unknown which NAT enzyme metabolizes chloroethane; 
therefore, it is unknown whether chloroethane is developmentally regulated by this metabolic pathway. 
Studies have shown that the other enzyme metabolizing chloroethane, cytochrome P45OIIEl (CYP2El), is 
developmentally regulated in humans (Vieira et al. 1996). This enzyme is not detectable from livers of 
fetuses at 14-40 gestational weeks. However, the level of the protein rises sharply in the first day after 
birth ( 1 unit/mg protein) and continues to increase until it reaches adult values in children from 1 to 10 
years of age, approximately 5 units/mg protein (Vieira et al. 1996). 
2.3.4 Elimination and Excretion 
2.3.4.1 Inhalation Exposure 
Excretion of chloroethane by the lungs is rapid in humans and animals (Adriani 1986; Konietzko 1984; 
Lehman and Flury 1943; Torkelson and Rowe 1981). In humans exposed briefly by inhalation to 
chloroethane, 30% of the retained dose was excreted in the breath within 1 hour (Morgan et al. 1970). 
Excretion over a longer period of time could not be measured because of the short half-life of the 38Cl 
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radioisotope used in this study. Morgan et al. (1970) found that the rate of excretion of radioactivity in the 
urine of humans was very slow (i.e., <0.01% per minute) I hour after inhalation. 
Small increases in acetaldehyde were detected in the urine of chloroethane-exposed mice but not rats 
(Fedtke et al. 1994a). Acetaldehyde concentrations in the urine of male and female mice were 7.9-20.3 and 
0-l 8.1 µmol/L, respectively, in unexposed mice, and 15.4-70.1 and 11.6-17 µmol/L,respectively, in 
chloroethane-exposed mice. Acetaldehyde is rapidly metabolized to acetic acid; therefore it would be 
difficult to detect in whole animal studies. Glutathione conjugates have also been detected in the urine of 
rats and mice exposed to chloroethane (Fedtke et al. 1994b). Rats excreted the more hydrophilic S-ethyl­
N-acetyl-L-cysteine, while mice excreted both S-ethyl-N-acetyl-L-cysteine and S-ethyl-L-cysteine. During 
the 5 days that rats and mice were exposed to chloroethane at 15,000 ppm for 6 hours/day, the total 
amount of glutathione metabolites excreted in the urine was about fivefold higher in mice than in rats. 
2.3.4.2 Oral Exposure 
No studies were located regarding excretion of chloroethane and metabolites in humans or animals 
following oral exposure. 
2.3.4.3 Dermal Exposure 
No studies were located regarding excretion of chloroethane and metabolites in humans or animals 
following dermal exposure. 
No data are available to indicate that excretion of chloroethane is different in children, 
2.3.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic 
(PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994). PBPK models are also called biologically based tissue dosimetry models. 
PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985). Physiologically based 
pharmacodynamic 
CHLOROETHANE 57 
2. HEALTH EFFECTS 
(PBPD) models use mathematical descriptions of the dose-response function to quantitatively describe the 
relationship between target tissue dose and toxic end points. 
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to delineate 
and characterize the relationships between: (1) the external/exposure concentration and target tissue dose 
of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen et al. 1987; Andersen 
and Krishnan 1994). These models are biologically and mechanistically based and can be used to 
extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from route to 
route, between species, and between subpopulations within a species. The biological basis of PBPK 
models results in more meaningful extrapolations than those generated with the more conventional use of 
uncertainty factors. 
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model 
representation, (2) model parametrization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994). In the early 1990s validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters. The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes. Solving these differential and algebraic equations 
provides the predictions of tissue dose. Computers then provide process simulations based on these 
solutions. 
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems. If the uptake and disposition of the chemical substance(s) is adequately 
described, however, this simplification is desirable because data are often unavailable for many biological 
processes. A simplified scheme reduces the magnitude of cumulative uncertainty. The adequacy of the 
model is, therefore, of great importance, and model validation is essential to the use of PBPK models in 
risk assessment. 
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994). 
PBPK models provide a scientifically-sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species. 
Figure 2-3 shows a conceptualized representation of a PBPK model. 
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If PBPK models for chloroethane exist, the overall results and individual models are discussed in this 
section in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species 
extrapolations. 
See Section 2.3.3 for discussion of a study that used a PBPK model to estimate the metabolic parameters 
for chloroethane in rats (Gargas et al. 1990). This study was not used for risk assessment, tissue dosimetry, 
or dose, route, or species extrapolation. Therefore, it is not discussed in this section. 
There are no PBPK models for children, fetuses, pregnant women, infants or lactating women, or any 
other appropriate age group with which to make predictions concerning the pharmacokinetics of 
chloroethane in humans. In addition, these models are lacking in animals. 
2.4 MECHANISMS OF ACTION 
The exact mechanism of action for chloroethane toxicity has not been defined. It is generally accepted 
that chloroethane’s ability to target the central nervous system and the heart is based on its 
physicalchemical characteristics and similarity to other volatile halogenated organics with anesthetic 
properties.  These currently accepted beliefs do not suggest that differences exist between children and 
adults in regards to the mechanism of toxicity of chloroethane. 
2.4.1 Pharmacokinetic Mechanisms 
Because chloroethane is a small lipophilic compound, simple diffusion accounts for its absorption across 
membranes, and its higher affinity for lipids determines its distribution. A review regarding the kinetics of 
chloroethane indicates that 75% of the compound in blood is bound to red blood cells, and 25% is in 
plasma (Konietzko 1984). This is consistent with the lipophilic nature of chloroethane. The metabolism of 
chloroethane has been studied in vitro using liver microsomal preparations from rats and mice (Fedtke et 
al. 1994a).  The observations that inhibitors of the P450 enzyme IlEI reduce chloroethane metabolism, and 
that inducers of P450 IIEI enhance metabolism of the compound to acetaldehyde, provide evidence that 
P450 IIEI is the principal P450 enzyme involved in the metabolism of chloroethane. In vitro studies using 
hepatic cytosolic fractions from the livers of rats and mice have shown that the conjugation of 
chloroethane with glutathione is catalyzed by glutathione -S-transferase enzymes (Fedtke et al. 1994b). In 
mice, both S-ethyl-N-acetyl-L-cysteine and S-ethyl-L-cysteine are formed and excreted in the urine, while 
in rats, only S-ethyl-N-acetyl-L-cysteine is formed and excreted in the urine. 
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2.4.2 Mechanisms of Toxicity 
Chloroethane has a general anesthetic effect when inhaled at high concentrations by humans and animals. 
The anesthetic effect is thought to be produced by the compound itself. Although the specific mechanism 
of action is unknown, it is generally believed that chloroetbane’s ability to induce anesthesia is related to 
the solubility of the compound in oils or fats. The lipophilicity of the nonpolar compound suggests that 
chloroethane is dissolved within and acts upon the lipid layer of cellular membrane or the hydrophobic 
areas of specific membrane-bound cellular proteins (Goodman and Gilman 1993). This hypothesis is 
supported by the findings of Balasubramanian and Wetlaufer (1966) who showed that chloroethane and 
other volatile anesthetics produced reversible structural changes in globular proteins in vitro. They 
proposed that the anesthetic activity of these compounds may be a result of their ability to produce 
structural changes in protein or lipoprotein structures. 
Volatile anesthetics affect voltage-gated calcium channels (Langmoen et al. 1995). Using a guinea pig 
heartlung preparation, Doring (1975) found that volatile general anesthetics including chloroethane 
interfere with the calcium-mediated process of excitation-contraction coupling leading to a reduction in 
high energy phosphate (ATP) utilization. Extra calcium, cardiac glycosides, or β-adrenergic 
catecholamines did not reverse the effects. Doring (1975) indicated that, because of their lipophilic nature, 
volatile anesthetics may alter the lipid arrangement of the transverse tubule walls, resulting in permanent 
impairment of excitationcontraction coupling. In studies using chloroform, Doring (1975) was able to 
show ultrastructural changes in the transverse tubules, especially vacuolization and dilatation Electron 
microscopic examinations of hearts similarly exposed to chloroethane were not presented, but 
chloroethane would be expected to act in a manner similar to chloroform. 
Chloroethane has been shown to have cardiotoxic effects in several studies (Bush et al. 1952; Cole 1967; 
Haid et al. 1954; Morris et al. 1953). At levels adequate to induce anesthesia, chloroethane sensitizes the 
heart to the effects of catecholamines (Haid et al. 1954; Morris et al. 1953). Catecholamine release can be 
induced by euphoria and excitement resulting from the effects of chloroethane on the central nervous 
system (Benowitz 1992). The myocardium can be sensitized to the effects of the catecholamines. This 
sensitization, along with asphyxia and hypoxia, which can also result from high concentrations of inhaled 
chloroethane, can cause arrhythmias, which can result in death (Benowitz 1992). It is possible that 
chloroethane and similar solvents may depress atrioventricular nodal conduction, causing atrioventricular 
block. Bradyarrhythmias 
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(abnormally slow hearth rhythms) may then occur to prevent ventricular arrhythmias, or asystole (lack of 
electrical or mechanical activity in the heart) may result. 
Analysis of structure-activity relationships predicts that chloroethane is carcinogenic. The alerting 
substructure is the Cl-CH2 group, which results in chloroethane being an alkylating agent and a mutagen to 
Salmonella (Tennant and Ashby 1991). It is not known why chloroethane does not cause respiratory 
cancers following inhalation exposure, or why it acts as a selective carcinogen resulting in uterine tumors 
in mice.  Based on a lack of differences in P450 metabolism of chloroethane between rats and mice, 
decreased uterine glutathione levels in rats and mice following chloroethane exposure, and the urinary 
excretion of S-ethyl-Lcysteine in mice but not rats, Fedtke et al. (1994b) suggested that uterine tumor 
production is a result of the glutathione conjugation pathway, rather than a result of chloroethane 
metabolism by P450 enzymes. The study authors did not state which compound in the glutathione 
conjugation pathway was responsible for the carcinogenic effect of chloroethane. 
2.4.3 Animal-to-Human Extrapolations 
The metabolism of chloroethane has not been studied in humans. Therefore, it is not possible to determine 
which species of animal is the most appropriate model for humans exposed to chloroethane. Studies by 
Fedtke et al. (1994a, 1994b) indicate that compared to rats, mice have a greater capacity to metabolize 
chloroethane by both the P450 and glutathione conjugation pathways. 
2.5 RELEVANCE TO PUBLIC HEALTH 
Issues relevant to children are explicitly discussed in 2.6 Children’s Susceptibility and 5.6 Exposures of 
Children. 
Overview 
Although chloroethane has been used as a general anesthetic in humans, very little is known about the 
effects of inhalation exposure to lower concentrations. The concentrations required to produce anesthesia, 
approximately 40,000 ppm, are near the explosion limit of this compound. Chloroethane is also used as a 
local anesthetic in humans. When chloroethane is sprayed on the skin, it rapidly evaporates and causes the 
skin to freeze, producing a numbing sensation. Oral exposure of humans to chloroethane has not been 
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studied. Because chloroethane is a gas, substantial oral exposure of humans to this compound is not 
expected. 
Animal studies regarding the effects of chloroethane are predominantly focused on the inhalation route of 
exposure. At high concentrations for short periods of time, chloroethane clearly results in neurological 
effects producing unsteadiness followed by unconsciousness. A number of toxicity studies have not clearly 
identified a target organ of toxicity for chloroethane (Eandry et al. 1982, 1987,1989; NTP 1989). 
One target of chloroethane toxicity in animals exposed to high concentrations is the uterus. Chloroethane 
has been shown to decrease uterine weight by 35% in mice exposed to 15,000 ppm chloroethane 6 
hours/day for 5 days (Fedtke et al. 1994a). Significant decreases in uterine glutathione levels were also 
observed in both rats and r-nice (Fedtke et al. 1994b). Chloroethane has also been shown to produce 
uterine cancer in mice but not rats exposed to 15,000 ppm chloroethane for approximately 2 years (NTP 
1989). The relevance of these uterine effects in animals to humans is not known. 
In addition to uterine effects, limited studies of reproduction and development in mice have shown effects. 
A small increase in the average duration of the estrous cycle was observed in mice exposed to 15,000 ppm 
chloroethane 6 hours/day for 21 days (Bucher et al. 1995). Before the exposure, estrous cycle duration was 
5.15±0.15 days, while during the exposure, estrous cycle duration was 5.52±0.19 days. Measurement of 
serum estradiol and progesterone did not reveal any consistent statistically significant changes attributable 
to chloroethane exposure. Evidence of fetotoxicity, a statistically significant increase in small centers of 
unossified bones of the skull, was observed in the offspring of mice exposed to 4,946 ppm chloroethane 
during gestation days 6-15 (Scortichini et al. 1986). Further studies are needed to confirm the reproductive 
and developmental toxicity of chloroethane and to determine that the effects are observed in another 
species in addition to mice. 
Chloroethane is an alkylating agent and is mutagenic to Samonella (NTP 1989). Chloroethane has not 
been shown to cause genotoxic effects in in vivo assays in mice (Ebert et al. 1994). In a single high-
concentration (15,000 ppm) study, chloroethane clearly caused uterine cancer in female mice, with 
equivocal evidence of carcinogenicity in rats (increased skin tumors in male rats and astrocytomas in the 
brains of female rats) (NTP 1989). Because only one concentration was tested, it cannot be determined 
whether or not the carcinogenic effect of chloroethane is a high-concentration phenomenon. 
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Minimal Risk Levels for Chloroethane 
Inhalation MRLS 
•	 An MRL of 15 ppm has been derived for acute-duration inhalation exposure (14 days or less) to 
chloroethane. 
This MRL is based on the developmental study by Scortichini et al. (1986) in which minimal 
fetotoxicity (a significant increase in the incidence of foramina of the skull bones) was observed in the 
offspring of mice exposed to 4,946 ppm chloroethane during gestation days 6-15. Fetotoxicity was not 
observed at 1,504 ppm, the NOAEL concentration that serves as the basis of the MRL. No additional 
developmental studies of chloroethane were identified. 
Intermediate- and chronic-duration inhalation MRLs were not derived. The only concentration that 
resulted in adverse effects in longer duration studies was 15,000 ppm (NTP 1989). At this concentration in 
studies of about 2 years in duration, hyperactivity, renal effects, and decreased survival were observed in 
mice. In 13-week studies, no adverse effects were observed in rats or mice at 19,000 ppm (NTP 1989). 
Since the acuteduration inhalation MRL is based on a concentration much lower than those resulting in 
effects in longer duration studies, it should also be protective for intermediate- and chronic-duration 
inhalation exposure. 
Oral MRLS 
Oral data concerning the effects of chloroethane were not identified. Therefore, no oral MRLs were 
derived. 
Death. Acute inhalation of high concentrations of chloroethane vapor is lethal to humans (Dawkins 
1964; Konietzko 1984; Kuschinsky 1970; Lawson 1965; Lehman and Flury 1943; Yacoub et al. 1993) and 
animals (Lazarew 1929; Sayers et al. 1929; Troshina 1966). Death appears to be caused by asphyxiation, 
as well as effects on the heart and nervous system. The nervous system seems to be involved because 
neurological effects such as unsteadiness, loss of muscle coordination, and unconsciousness precede death 
in animals.  Similar effects are seen in humans exposed to chloroethane. In addition, effects such as 
respiratory paralysis and cardiac depression, which have been reported during chloroethane exposure in 
both humans and animals, are at least partly neurological in origin. For example, cardiac depression can be 
caused by stimulation of the vagus nerve or by direct effect on the cardiac tissue. Bush et al. (1952) found 
that in dogs anesthetized with chloroethane, cardiac depression occurred first by vagal stimulation and 
then by direct effect on the heart.  Upon overdose, the dogs died from cardiac arrest. Most human deaths 
caused by chloroethane were the result of overdose while under anesthesia. There is also one report of a 
death following abuse of chloroethane 
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(Yacoub et al. 1993). The specific level of exposure that causes death in humans is not known, but it 
probably exceeds 40,000 ppm, which is the concentration that was typically used to produce clinical 
anesthesia. Chloroethane is no longer used as a general anesthetic in the United States. 
The long-term survival of mice was reduced by chronic exposure to 15,000 ppm chloroethane vapor (NTP 
1989). An ascending urinary tract infection may have contributed to the reduced survival in male mice. 
The decreased survival in female mice was attributed to uterine cancer. Decreased survival was not 
observed in rats, but control survival was abnormally low for this species which obscured the results (NTP 
1989). There is no evidence that humans would respond to chronic chloroethane exposure in a manner 
similar to the mouse, but these data suggest the possibility that sub-anesthetic concentrations of 
chloroethane may be potentially hazardous to humans if inhaled for an extended period of time. 
Reliable information regarding death of humans or animals following oral consumption of chloroethane 
was not found. Because chloroethane is a gas, accidental oral exposure to doses of chloroethane large 
enough to result in deaths is highly unlikely. Although no studies of the acute lethality of dermally-applied 
chloroethane were located, it is unlikely that brief dermal exposure is lethal to humans since chloroethane 
is in widespread use as a topical anesthetic, and reports of accidental death from this use were not found. 
Further, as previously discussed, chloroethane is expected to evaporate quickly from the skin since its 
standard state is a gas. Therefore, it is unlikely to remain on the skin long enough to be absorbed at a dose 
that would result in death. 
Systemic Effects. The systemic effects of chloroethane, which is a gas, have not been studied by the 
oral route of exposure. Few studies regarding dermal exposure to chloroethane were identified. Therefore, 
in the following discussion, unless stated otherwise, exposure is via inhalation. 
Respiratory Effects. When used as a general anesthetic, chloroethane sometimes increases the respiratory 
rate of humans (Cole 1956, 1967). Respiratory paralysis was reported to be the cause of death of a 14-year 
old who died during anesthesia (Kuschinsky 1970). Mild lung effects have also been reported in animals 
exposed to very high concentrations of chloroethane for short periods of time (Gohlke and Schmidt 1972; 
Sayers et al. 1929). Histopathological changes in the lungs of animals were not observed in studies of 
longer duration (Landry et al. 1982, 1987,1989; NTP 1989). 
CHLOROETHANE 65 
2. HEALTH EFFECTS 
The exposure concentrations (up to 19,000 ppm) used in the inhalation studies are much higher than one is 
likely to encounter in occupational settings or in the vicinity of hazardous waste sites. Therefore, 
respiratory effects resulting from chloroethane exposure are highly unlikely. 
Cardiovascular Effects. Chloroethane has been shown to interfere with cardiac function in animals when 
inhaled at anesthetic concentrations. Cardiac depression, ventricular tachycardia, ventricular fibrillation, 
asystole, and sensitization to endogenous and exogenous epinephrine have all been observed in 
dogsanesthetized with chloroethane (Bush et al. 1952; Haid et al. 1954; Morris et al. 1953). Severe, 
irreversible, contractile failure of the heart occurred in a guinea pig heart-lung preparation after exposure 
to chloroethane vapor, and elevated ratios of ATP/ADP and creatine-P/inorganic-P were found in the 
heart, indicating that a reduction in high-energy phosphate utilization had taken place (Doring 1975). 
These results, together with the previously reported finding of cardiac depression in humans exposed 
briefly to high concentrations of chloroethane (Bush et al. 1952), suggest that high levels of chloroethane 
vapor in the air may be potentially hazardous to humans because of effects on the heart. Longer studies at 
lower concentrations have not reported any histopathological changes in the heart (Landry et al. 1982, 
1987,1989; NTP 1989).  Cardiovascular effects are unlikely to occur at concentrations of chloroethane 
normally found at occupational settings or in the environment, including hazardous waste sites. 
Gastrointestinal Effects. Abdominal cramps and nausea have been reported by persons exposed to 
chloroethane at very high concentrations for short periods of time (Davidson 1925; Sayers et al. 1929). 
Vomiting has also been reported in patients as they recovered from chloroethane anesthesia (Cole 1967). It 
is not clear if gastrointestinal effects are a direct irritant effect of chloroethane or if they are secondary to 
nervous system effects. Histopathological changes in the gastrointestinal tract of animals were not 
observed in longer studies (Landry et al. 1982, 1987, 1989; NTP 1989). Gastrointestinal tract effects are 
unlikely to occur at concentrations of chloroethane normally found at occupational settings or in the 
environment, including hazardous waste sites. 
Hematological Effects. Cyanosis has been reported in humans following inhalation exposure to 
chloroethane at very high concentrations (Davidson 1925). Since this effect was observed when 
chloroethane was not mixed with oxygen, it is very likely that it was the result of a lack of oxygen rather 
than a direct effect of chloroethane. Hematological effects were not observed in mice exposed to 
chloroethane for 11 days (Landry et al. 1987, 1989) or in rats or dogs exposed to chloroethane for 2 weeks 
(Landry et al. 1982). 
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Based on the available animal data, hematological effects in humans are unlikely to occur at 
concentrations of chloroethane normally found at occupational settings or in the environment, including 
hazardous waste sites. 
Musculoskeletal Effects. No studies were located regarding musculoskeletal effects in humans following 
exposure to chloroethane. Histopathological changes in the muscle and bone have not been observed in 
animals following inhalation exposure (Landry et al. 1982, 1987, 1989; NTP 1989). Disintegration of 
muscle fibers has been observed in rats after chloroethane was applied dermally until the skin was 
blanched (Kenig 1956). This study suggests that improper use of chloroethane as a topical anesthetic could 
result in adverse effects on the underlying muscle. Musculoskeletal effects in humans are unlikely to occur 
at concentrations of chloroethane normally found at occupational settings or in the environment, including 
hazardous waste sites. 
Hepatic Effects. An enlarged liver and mild transient disturbance of liver function were reported in a 
woman who sniffed chloroethane for 4 months (Hes et al. 1979). Moderately elevated serum alanine 
aminotransferase was observed in a man who abused chloroethane for 30 years (Nordin et al. 1988). Liver 
effects reported in animals exposed to high concentrations of chloroethane include an increase in the liver 
ATP/ADP ratio (Oura et al. 1966), decreased liver glutathione (Fedtke et al. 1994b), and decreased liver 
non-protein sulfhydryl concentrations (Landry et al. 1982). Increased liver weights have also been reported 
(Landry et al. 1982,1987, 1989). These mild liver effects may be considered an adaptive response to 
chloroethane exposure rather than a toxicologic effect. Other studies have not reported liver weight 
changes or histopathological changes in the liver (Bucher et al. 1995; NTP 1989). Based on the available 
data, hepatic effects in humans are unlikely to occur at concentrations of chloroethane normally found at 
occupational settings or in the environment, including hazardous waste sites. 
Renal Effects. No studies were located regarding renal effects in humans following exposure to 
chloroethane. Mild signs of nephrotoxicity were observed in mice exposed to relatively high 
concentrations for 100 weeks (NTP 1989), while no renal effects were observed in rats exposed at the 
same concentrations for 102 weeks (NTP 1989). Additional acute- and intermediate-duration studies have 
not reported significant renal effects in animals (Fedtke et al. 1994a; Landry et al. 1982, 1987, 1989; NTP 
1989; Schmidt et al. 1972). Based on the available animal data, renal effects in humans are unlikely to 
occur at concentrations of chloroethane normally found at occupational settings or in the environment, 
including hazardous waste sites. 
CHLOROETHANE 67 
2. HEALTH EFFECTS 
Endocrine Effects. No studies were located regarding endocrine effects in humans following exposure to 
chloroethane. Endocrine gland effects have not been observed in animals exposed to chloroethane (Gohlke 
and Schmidt 1972; Landry et al. 1982, 1987, 1989; NTP 1989; Schmidt et al. 1972). Based on the 
available animal data, endocrine effects in humans are unlikely to occur at concentrations of chloroethane 
normally found at occupational settings or in the environment, including hazardous waste sites. 
Dermal Effects. No studies were located regarding dermal effects in humans following inhalation exposure 
to chloroethane. Following inhalation exposure of animals to chloroethane, dermal effects have not been 
reported (Landry et al. 1982, 1987, 1989; NTP 1989). Chloroethane has a local anesthetic effect in humans 
and animals following dermal application. It rapidly evaporates and draws heat from the skin, causing the 
skin to freeze. Application for too long a time can result in frostbite. Noble (1979) reported frostbite in 
three children sprayed with chloroethane for several minutes. Contact dermal sensitivity has also been 
reported in persons exposed to chloroethane (Bircher et al. 1994; Kriechbaumer et al. 1998; Van Ketel 
1976).  Chloroethane applied to rats until the skin was blanched caused edema in the subcutaneous tissue 
at the site of application (Kenig 1956). Because chloroethane is used as a topical anesthetic, many people 
may be at risk of developing sensitivity to chloroethane or of the hazard of freezing of the skin if 
chloroethane is used incorrectly. Sensitized individuals may react to chloroethane in the environment or at 
hazardous waste sites. 
Ocular Effects. Mild eye irritation has been reported in volunteers exposed briefly to very high 
concentrations of chloroethane (Sayers et al. 1929). Effects on the eyes have not been reported in animals 
exposed to chloroethane (Landry et al. 1982, 1987,1989). Based on the available data, ocular effects in 
humans are unlikely to occur at concentrations of chloroethane normally found at occupational settings 
and in the environment, including hazardous waste sites. 
Body Weight Effects. Body weight effects have not been reported in animals exposed to chloroethane 
(Fedtke et al. 1994a; Landry et al. 1982,1987,1989; NTP 1989; Schmidt et al. 1972; Scortichini et al. 
1986). Based on the available animal data, body weight effects in humans are unlikely to occur at 
concentrations of chloroethane normally found at occupational settings and in the environment, including 
hazardous waste sites. 
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Immunological and Lymphoreticular Effects. No immunological effects were reported in 
humans (Troshina 1966) or animals (Landry et al. 1982, 1987, 1989; NTP 1989; Schmidt et al. 1972) after 
inhalation exposure to chloroethane, but contact dermatitis has been found in humans treated dermally 
with chloroethane (Bircher et al. 1994; Van Ketel 1976). This effect is notable because of the widespread 
use of chloroethane as a topical anesthetic. Sensitized individuals may react to chloroethane in the 
environment or at hazardous waste sites. 
Neurological Effects. Chloroethane has a general anesthetic effect when inhaled at high 
concentrations by humans and animals. The severity of the effect increases with the concentration of 
chloroethane and the duration of exposure. In humans, unconsciousness was produced by inhalation of 
33,600 ppm chloroethane for approximately 15 minutes (Davidson 1925). Cbloroethaue is no longer used 
as a general anesthetic in the United States, but in the past, concentrations of approximately 40,000 ppm 
were used clinically to produce anesthesia (Lawson 1965). The gastrointestinal effects reported in patients 
as they recovered from chloroethane anesthesia (Cole 1967; Davidson 1925; Sayers et al. 1929) may be 
secondary to the neurological effects. In animals, clinically effective anesthetic concentrations range from 
30,000 to 45,000 ppm (Dobkin and Byles 1971). Induction of anesthesia using chloroethane is rapid, and 
so is recovery. The anesthetic effect is thought to be produced by the compound itself; however, its 
mechanism of action is unknown.  Balasubramanian and Wetlaufer (1966) showed that the vapors 
produced from pure liquid chloroethane and other volatile anesthetics produced reversible structural 
changes in globular proteins in vitro. They proposed that the anesthetic activity of these compounds might 
be due to their ability to produce structural changes in protein or lipoprotein structures in cell membranes. 
Following abuse of chloroethane, ataxia, nystagmus, scanning dysarthria, dysdiadochokinesia of the arm, 
and sluggish lower limb reflexes were reported (Hes et al. 1979). These effects were reversible after 1 
month without chloroethane exposure. In a second case of chloroethane abuse, neurological and mental 
changes (grand ma1 seizure, ataxia, difficulties in walking, disorientation, short-term memory impairment, 
visual hallucinations) were observed following recovery after 30 years of chloroethane abuse (Nordin et al. 
1988). The study authors indicate that it was not possible to determine whether the nervous system effects 
were toxic effects of chloroethane or withdrawal symptoms. 
Animal studies examining the histology of nervous system tissue have not revealed any adverse effects 
following inhalation exposure (Gohlke and Schmidt 1972; Landry et al. 1982, 1987, 1989; NTP 1989; 
Schmidt et al. 1972). Except for observations during exposure, neurological function has not been studied 
in animals following intermediate or chronic inhalation exposure. 
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Chloroethane is still used as a local anesthetic It is applied to the skin, and its rapid evaporation results in 
cooling. Mild pain has been reported during the dermal application of chloroethane to the skin of humans 
(Selby and Bowles 1995). Application of chloroethane to the skin of rats has been reported to result in 
thickening of nerve fibers and swelling of Schwann cell nuclei (Kenig 1956). 
The nervous system is a target of chloroethane exposure, and functional effects of chloroethane exposure 
have not been well studied. Therefore, it is not known if neurological effects may occur in humans at 
concentrations of chloroethane normally found at occupational settings and in the environment, including 
hazardous waste sites. 
Reproductive Effects. Studies of reproductive effects in humans exposed to chloroethane were not 
identified. Several studies investigated reproductive endpoints in animals. In dogs anesthetized with 
chloroethane, high concentrations resulted in decreased uterine motility and muscle tone (Van Liere et al. 
1966). Uterine weight was decreased by approximately 35% in mice exposed to high concentrations of 
chloroethane (Fedtke et al. 1994a). Significant decreases in uterine glutathione levels have also been 
reported in rats and mice exposed to chloroethane (Fedtke et al. 1994b). The decreases in glutathione in 
the uterus were greater than the decreases in glutathione observed in the liver, lungs, and kidneys. A small 
increase in the average duration of the estrous cycle was observed in mice exposed to high concentrations 
of chloroethane 6 hours/day for 2 1 days (Bucher et al. 1995). Measurement of serum estradiol and 
progesterone did not reveal any consistent statistically significant changes attributable to chloroethane 
exposure. Sperm motility in rats was reduced after exposure to chloroethane for 6 months (Troshina 1966). 
Histopathological effects have not been observed in reproductive organs of animals exposed to 
chloroethane (Landry et al. 1982, 1987, 1989; NTP 1989). No effects on the number of live and dead 
fetuses or the number and position of resorption sites were observed in mice exposed to chloroethane 
during gestation days 6-15 (Scortichini et al. 1986). Additional studies of reproductive outcome in animals 
following inhalation exposure to chloroethane were not identified. 
Based on decreases in uterine glutathione in rats and mice, decreases in uterine weight in mice, and the 
development of uterine cancer in mice exposed to chloroethane (NTP 1989) (see Cancer discussion in 
Section 2.5), the uterus appears to be a target of chloroethane exposure in mice; rats are apparently less 
sensitive to these effects. Further studies are required to determine the mechanism of uterine toxicity in 
mice and to determine the relevance of these effects to humans exposed to chloroethane at concentrations 
normally found at occupational settings and in the environment, including hazardous waste sites. 
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Developmental Effects. No studies were located regarding developmental effects in humans 
following exposure to chloroethane. Only one study of the developmental effects of chloroethane in 
animals was found.  In this mouse study, minimal evidence of fetotoxicity (increase in small centers of 
unossified bones of the skull) was observed at the highest concentration tested (Scortichini et al. 1986). 
This study serves as the basis for the acute-duration inhalation MRL. Further study is required to 
determine the relevance of developmental effects in animals to humans exposed to chloroethane at 
concentrations normally found at occupational settings and in the environment, including hazardous waste 
sites. 
Genotoxic Effects. Results of mutagenicity tests performed in vivo and in vitro are shown in Tables 
2-2 and 2-3, respectively. Chloroethane did not increase the number of micronuclei in bone marrow cells 
or affect DNA synthesis in mice exposed nose-only to 25,000 ppm chloroethane 6 hours/day for 3 days 
(Ebert et al. 1994). The investigators indicated that the exposure concentration used in this study was 
about 66% of the flammability limit and that it was the highest concentration that could be safely 
administered. Using a desiccator for exposure to the gas, positive rest&s in reverse mutation assays using 
Salmonella typhimurium strain TA1535 with and without activation were reported by NTP (1989). In 
strain TAl00, the results were positive only with metabolic activation, while the results were negative in 
strain TA98 both with and without metabolic activation. NTP (1989) indicated that the mutagenic activity 
of chloroethane in S. typhimurium was consistent with an alkylating agent. Chloroethane was positive for 
gene mutation in Chinese hamster ovary cells exposed in vitro (Ebert et al. 1994). Negative results were 
reported for chloroethane in a cell transformation assay using mouse BALB/c-3T3 cells (Tu et al. 1985). 
Although chloroethane is mutagenic in in vitro assays, negative results were observed in in vivo studies, 
and the data are insufficient to predict that chloroethane poses a genotoxic threat to humans. 
Existing data are inconclusive concerning the genotoxicity of chloroethane. Despite this lack of data, the 
volatility of chloroethane, its rapid clearance from the body, and its quick metabolism within the body 
indicate it is unlikely that it would reach germ cells to result in any potential genotoxic effect. 
Cancer. No studies were located regarding the carcinogenicity of chloroethane in humans, but 
chloroethane has been shown to be carcinogenic in animals. In a study by the NTP (1989), 86% of female 
mice chronically exposed to chloroethane vapor developed highly malignant uterine carcinomas. Uterine 
tumors were not observed in any of the control mice. The incidence of hepatocellular carcinomas also 
increased significantly in female mice. Male mice had an increased incidence of alveolar and bronchiolar 
adenomas, but because male survival was substantially reduced toward the end of the study these results 
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rats had marginally increased incidences of skin tumors, and female rats had marginally increased 
incidences of brain astrocytomas, providing equivocal evidence that chloroethane is carcinogenic in rats 
(NTP 1989).  The fact that chloroethane is carcinogenic in mice and may be carcinogenic in rats as well 
suggests the possibility that this compound may also be carcinogenic in humans. Based on limited 
evidence of carcinogenicity in animals and no human data, IARC (1991) considers chloroethane to be in 
Group 3, not classifiable as to its carcinogenicity to humans. The carcinogenicity of chloroethane has not 
been classified by EPA (IRIS 1997) or NTP (DHHS 1994). The data are not sufficient to predict whether 
chloroethane is carcinogenic at concentrations that occur in the environment or at hazardous waste sites. 
OSHA has recommended that ethyl chloride be treated in the workplace with caution because of the 
structural similarity to the four confirmed halogenated animal carcinogens: ethylene dichloride; 
hexachloroethane; 1,1,2,2-tetrachloroethane; and 1,1,2-trichloroethane (NIOSH 1997). 
2.6 CHILDREN’S SUSCEPTIBILITY 
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed. Potential 
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate due to maternal exposure during gestation and lactation. Relevant animal 
and in vitro models are also discussed. 
Children are not small adults. They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals. Children’s unique physiology and behavior can influence the extent 
of their exposure. Exposures of children are discussed in section 5.6 Exposures of Children. 
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is a 
difference depends on the chemical (Guzelian et al. 1992; NRC 1993). Children may be more or less 
susceptible than adults to health effects and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993). Vulnerability often depends on developmental stage. There are critical 
periods of structural and functional development during both pre-natal and post-natal life and a particular 
structure or function will be most sensitive to disruption during its critical period(s). Damage may not be 
evident until a later stage of development. There are often differences in pharmacokinetics and metabolism 
between children and adults. For example, absorption may be different in neonates because of the 
immaturity of their gastrointestinal tract and their larger skin surface area in proportion to body weight 
(Morselli et al. 1980; 
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NRC 1993); the gastrointestinal absorption of lead is greatest in infants and young children (Ziegler et al. 
1978). Distribution of xenobiotics may be different; for example, infants have a larger proportion of their 
bodies as extracellular water and their brains and livers are proportionately larger (Widdowson and 
Dickerson 1964; Foman et al. 1982; Owen and Brozek 1966; Altman and Dittmer 1974; Foman 1966). 
The infant also has an immature blood-brain barrier (Adinolfi 1985; Johanson 1980) and probably an 
immature blood-testis barrier (Setchell and Waites 1975). Many xenobiotic metabolizing enzymes have 
distinctive developmental patterns and at various stages of growth and development, levels of particular 
enzymes may be higher or lower than those of adults and sometimes unique enzymes may exist at 
particular developmental stages (Leeder and Kearns 1997; Komori 1990; Vieira et al. 1996; NRC 1993). 
Whether differences in xenobiotic metabolism make the child more or less susceptible also depend on 
whether the relevant enzymes are involved in activation of the parent compound to its toxic form or in 
detoxification. There may also be differences in excretion, particularly in the newborn who has a low 
glomerular filtration rate and has not developed efficient tubular secretion and resorption capacities 
(Altman and Dittmer 1974; West et al. 1948; NRC 1993). Children and adults may differ in their capacity 
to repair damage from chemical insults.  Children also have a longer lifetime in which to express damage 
from chemicals; this potential is particularly 
relevant to cancer. 
Certain characteristics of the developing human may increase exposure or susceptibility while others may 
decrease susceptibility to the same chemical. For example, the fact that infants breathe more air per 
kilogram of body weight than adults may be somewhat counterbalanced by their alveoli being less 
developed, so there is a disproportionately smaller surface area for absorption (NRC 1993). 
Children have infrequently been observed for health effects following exposure to chloroethane. Effects 
observed in humans exposed to chloroethane have resulted primarily from inhalation exposure. 
Respiratory paralysis was reported to be the cause of death of a 14-year-old child who died during 
anesthesia with chloroethane (Kuschinsky 1970); however, the concentration of chloroethane administered 
was not known.  Another study reported vagal stimulation, followed by depression of cardiac tissues in 
children exposed briefly to reportedly high concentrations of chloroethane; the specific levels were not 
indicated (Bush et al. 1952). 
Chloroethane has also been used and sometimes misused as a topical anesthetic in both children and adults 
(Nielsen 1980; Noble 1979; Ott 1969; Van Ketel 1976). Misuse occurs when excessive amounts of 
chloroethane are sprayed on the skin for long periods of time. Three children suffered frostbite on the 
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exposed skin of their ears and necks after having their earlobes sprayed with chloroethane for several 
minutes (Noble 1979). 
Effects seen in adults exposed to chloroethane are also expected in children. In particular, the nervous 
system is likely to be a sensitive target of chloroethane, as it is in adults. Since infants and young children 
have a larger proportion of their bodies as brain mass, and since blood flow is greater to this organ in 
children, one might predict on pharmacokinetic grounds that these ages of children would be more 
susceptible to the anesthetic effects of chloroethane than adults In addition, chloroethane distribution may 
be very different in children relative to adults due to the difference in fat and water content and lean body 
mass in children. 
No studies were identified that reported effects caused by chloroethane in adults exposed as children and 
there is no information on the health effects of exposures in immature animals. There are no data 
concerning the effects of chloroethane exposure on human development and there is only one 
developmental study in animals. This study (Scortichini et al. 1986) reported that at the highest 
concentration administered to mice, delayed ossification of skull bones occurred. However, no other 
developmental parameters were affected, and no maternal toxicity was reported. 
There are no data available concerning the pharmacokinetics of chloroethane in children. There are no 
human or animal studies available concerning the ability of chloroethane or its metabolites to reach and 
cross the placenta. One study determined that chloroethane can be detected in the breast milk of nursing 
mothers (Pelizzari et al. 1982), but the study was not quantitative and did not offer data concerning the 
percentage of nursing mothers that might excrete the compound in milk after exposure, nor did it provide a 
range of concentrations of the compound in this medium. No studies were identified that determined if 
chloroethane was stored in maternal tissues. However, the rapid clearance of chloroethane, as well as its 
volatility, suggest that it would not be stored within the body for an extended period of time, so pre­
conception maternal exposure is not likely to result in exposure to children during gestation or lactation. 
See Section 2.3 for further information. 
No data are currently available to indicate that the metabolism of chloroethane is different in children 
when compared to adults; however, some of the enzymes in the chloroethane metabolism scheme belong 
to enzyme families that are developmentally regulated to some extent either in humans or animals. 
Chloroethane is metabolized by both cytochrome P450 and by glutathione S-transferase. Studies have 
shown that liver glutathione S-transferase activities are low in prepubertal male and female rats, but as the 
rats reach sexual 
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maturity (at around 30-50 days of age), glutathione-conjugating activity toward dichloronitrobenzene is 
two to threefold higher in males than females (Lamartiniere and Lucier 1983). The difference in 
glutathione S-transferase activity was dependent on pituitary secretions. Further research on 
hypophysectomized male and female rats revealed that growth hormones may contribute to the 
establishment of glutathione S-transferase activities (Lamartiniere 198 1). No data are available to indicate 
that glutathione S-transferase activity is also developmentally or sexually expressed in humans. 
After glutathione conjugation of chloroethane, three other enzymes convert the conjugate to a more 
hydrophilic form to be excreted by the body. These enzymes are γ-glutamyltranspeptidase, cysteinyl 
glycinase, and N-acetyltransferase, NAT (Amdur et al. 1991). These three enzymes convert relatively 
hydrophobic glutathione conjugates to their respective mercapturic acids, which can be excreted more 
readily. There are two N-acetyltransferase enzyme families, NAT 1 and NAT2. Of these enzymes, only 
NAT2 is developmentally regulated. It is unknown which NAT enzyme metabolizes chloroethane; 
therefore, it is unknown whether chloroethane is developmentally regulated by this pathway. 
Studies have shown that cytochrome P450 IIEl is developmentally expressed in humans (Vieira et al. 
1996). This enzyme is not detectable from livers of fetuses at 14-40 gestational weeks. However, the level 
of the protein rises sharply in the first day after birth (1 unit/mg protein), and continues to increase until it 
reaches adult values of approximately 5 units/mg protein, in children from 1 to 10 years of age (Vieira et 
al 1996). 
It is unknown whether children differ from adults in their susceptibility to chloroethane, despite the 
theoretical reasons for which they might potentially differ, as discussed above. 
There are no data concerning parental exposure affecting children, including pre-conception exposure. 
There are no data concerning pre-conception exposure of either parent to germ line mutations, 
developmental defects, childhood cancer, or other health effects. Chloroethane is positive in in vitro 
mutagenicity studies in bacterial and mammalian cells, but is negative in in vivo mammalian cell tests. 
These inconclusive results do not allow the prediction of chloroethane genotoxicity in humans. 
2.7 BIOMARKERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 1989). 
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Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers 
as tools of exposure in the general population is very limited. A biomarker of exposure is a xenobiotic 
substance or its metabolite(s), or the product of an interaction between a xenobiotic agent and some target 
molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989). The 
preferred biomarkers of exposure are generally the substance itself or substance-specific metabolites in 
readily obtainable body fluid(s) or excreta. However, several factors can confound the use and 
interpretation of biomarkers of exposure. The body burden of a substance may be the result of exposures 
from more than one source. The substance being measured may be a metabolite of another xenobiotic 
substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic 
compounds). Depending on the properties of the substance (e.g., biologic half-life) and environmental 
conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the 
body by the time samples can be taken. It may be difficult to identify individuals exposed to hazardous 
substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as 
copper, zinc, and selenium). 
Biomarkers of exposure to chloroethane are discussed in Section 2.7.1. Biomarkers of effect are defined as 
any measurable biochemical, physiologic, or other alteration within an organism that, depending on 
magnitude, can be recognized as an established or potential health impairment or 
disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of tissue 
dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial cells), 
as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung capacity. 
Note that these markers are not often substance specific. They also may not be directly adverse, but can 
indicate potential health impairment (e.g., DNA adducts). Biomarkers of effects caused by chloroethane 
are discussed in Section 2.7.2. 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism’s ability 
to respond to the challenge of exposure to a specific xenobiotic substance. It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are 
discussed in Section 2.9, Populations That Are Unusually Susceptible. 
There are no known biomarkers of exposure or effect that have been validated in children or adults 
exposed as children. There are no known biomarkers of exposure and effect that are unique to children. 
Further, there are no known biomarkers of exposure and effect in adults that could identify childhood 
exposure. Since 
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chloroethane is rapidly metabolized in the body, biomarkers for adults or children would be limited to 
current exposures. 
2.7.1 Biomarkers Used to Identify or Quantify Exposure to Chloroethane 
Studies of the association of environmental concentrations of chloroethane with levels of chloroethane in 
the breath, fluids, and body tissues were not identified. Because a portion of the chloroethane inhaled is 
exhaled, measurement of chloroethane in breath may serve as a useful biomarker of exposure. In rats and 
mice, chloroethane is metabolized to acetaldehyde and the glutathione conjugates, S-ethyl-N-acetyl-L­
cysteine and S-ethyl-L-cysteine (Fedtke et al. 1994a, 1994b). Further research is required to determine if 
urinary excretion of glutathione conjugates would serve as a useful biomarker following exposure of 
humans to chloroethane.  The glutathione conjugates S-ethyl-N-acetyl-E-cysteine and S-ethyl-L-cysteine 
would not be biomarkers unique to chloroethane exposure. Acetaldehyde forms adducts with plasma 
proteins. Because ethanol is also metabolized to acetaldehyde, it has been suggested that the measurement 
of these adducts, or of antibodies produced in response to these adducts, may serve as a biomarker of 
ethanol exposure (Won-all et al. 1994).  The measurement of acetaldehyde protein adducts, or the 
associated antibodies, may also serve as a biomarker of chloroethane exposure. It should be noted that 
formation of antibodies to these compounds can result from exposure to chemicals other than 
chloroethane. 
2.7.2 Biomarkers Used to Characterize Effects Caused by Chloroethane 
Anesthesia is rapidly produced in humans by inhalation of chloroethane at a concentration of 
approximately 40,000 ppm. Other effects reported at anesthetic concentrations include cardiac 
irregularities, respiratory paralysis, and nausea. A blood concentration of 20-30 mg percent was reported 
for this exposure level (Adriani 194 1). No other studies were located regarding levels of chloroethane in 
human tissues and fluids associated with effects. Because these effects occur following exposure to many 
chemicals, they would not serve as useful biomarkers for chloroethane exposure. 
For more information on biomarkers for renal and hepatic effects of chemicals see ATSDR/CDC 
Subcommittee Report on Biological Indicators of Organ Damage (1990), and for information on 
biomarkers for neurological effects see OTA (1990). 
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2.8 INTERACTIONS WITH OTHER CHEMICALS 
The interaction between chloroethane and ethanol was studied by Schmidt et al. (1972) and Gohlke and 
Schmidt (1972), who found that chloroethane enhanced the effects of ethanol in rats. Inhalation of 
chloroethane 4 hours/day for 8 of 10 days in conjunction with ethanol treatment led to greater changes in 
liver enzyme levels (decreased succinate dehydrogenase and nonspecific esterase and increased acid 
phosphatase) than were produced by ethanol alone. In addition, inflammation of the liver and fatty 
degeneration of hepatocytes were most prominent in rats given chloroethane in addition to ethanol. These 
results, although limited, are interesting because both ethanol and chloroethane are metabolized by 
CYP2El to acetaldehyde.  Therefore, one compound could compete for active sites in CYP2E1, resulting 
in delayed metabolism of the other compound. However, ethanol, as well as chloroethane, induces 
CYP2El to expression, so more enzyme should be produced to handle a metabolic challenge (Leeder and 
Kearns 1997). 
A study in cats demonstrated that the extent of methemoglobinemia induced by intravenous administration 
of aniline was significantly reduced in cats anesthetized with chloroethane compared to unanesthetized 
cats (McLean et al. 1967). The rate at which the methemoglobin disappeared, however, was also 
significantly reduced in the anesthetized cats compared with unanesthetized cats. The results suggest that 
concurrent exposure to aniline and chloroethane may induce less methemoglobin than exposure to aniline 
alone, but the methemoglobin induced by the combined exposure would persist longer than that induced 
by exposure to aniline alone. A similar effect was not observed when cats were anesthetized with 
chloralose and treated with phenylhydroxylamine, the aniline metabolite that results in methemoglobin 
formation. Therefore, the study authors concluded that chloralose acts by inhibiting the metabolism of 
aniline. It is not known if chloroethane acts in the same manner. 
No studies were available investigating the interactions of chloroethane with other chemicals in children or 
in adults. 
2.9 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to chloroethane than will most 
persons exposed to the same level of chloroethane in the environment. Reasons may include genetic 
makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke). 
These parameters may result in reduced detoxification or excretion of chloroethane, or compromised 
function of 
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target organs affected by chloroethane. Populations who are at greater risk due to their unusually high 
exposure to chloroethane are discussed in Section 5.7, Populations with Potentially High Exposure. 
Persons with prior exposure to ethanol may be at higher risk from chloroethane exposure because 
chloroethane has been shown to enhance the effects of ethanol in rats (Gohlke and Schmidt 1972; Schmidt 
et al. 1972). Because chloroethane is metabolized by the liver (Fedtke et al. 1994a, 1994b), and minimal 
liver effects have been observed in animals following inhalation exposure (Landry et al. 1987, 1989; Oura 
et al. 1966; Sayers et al. 1929; Troshina 1966), persons with compromised liver function may be at greater 
risk following exposure to chloroethane. 
It is unknown whether children differ in their susceptibility to chloroethane from adults. This is discussed 
in detail in 2.6 Children’s Susceptibility. 
2.10 METHODS FOR REDUCING TOXIC EFFECTS 
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to chloroethane. However, because some of the treatments discussed may be experimental and 
unproven, this section should not be used as a guide for treatment of exposures to chloroethane. When 
specific exposures have occurred, poison control centers and medical toxicologists should be consulted for 
medical advice. The following texts provide specific information about treatment following exposures to 
chloroethane: Bronstein AC, Currance PL. 1988. Emergency Care for Hazardous Materials Exposure; 
Haddad LM, Winchester H. 1990. Clinical Management of Poisoning and Drug Overdose; Stutz DR, Ulin 
S. 1992. Hazardous Materials Injuries. 
There are no known pediatric-specific methods for reducing peak absorption following exposure or 
reducing body burden. None of the methods for reducing peak absorption or body burden are 
contraindicated in children. No data were available to indicate that the methods used in adults have been 
validated in children. 
2.10.1 Reducing Peak Absorption Following Exposure 
Because chloroethane is a gas, human exposure is most likely to occur by inhalation. Moving the subject 
to fresh air is the best way to reduce absorption of chloroethane following inhalation exposure (Haddad 
and Winchester 1990). 
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2.10.2 Reducing Body Burden 
Animal studies suggest that the body does not retain significant amounts of chloroethane (Fedtke et al. 
1994a, l994b). Because some of the absorbed chloroethane is exhaled, increasing the ventilation rate once 
the subject is removed from exposure may help to enhance elimination. 
2.10.3 Interfering with the Mechanism of Action for Toxic Effects 
No methods for interfering with the mechanism of action of chloroethane were identified. 
2.11 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate 
information on the health effects of chloroethane is available. Where adequate information is not available, 
ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the initiation 
of a program of research designed to determine the health effects (and techniques for developing methods 
to determine such health effects) of chloroethane. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that, if met, would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean that 
all data needs discussed in this section must be filled. In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
2.11.1 Existing Information on Health Effects of Chloroethane 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
chloroethane are summarized in Figure 2-4. The purpose of this figure is to illustrate the existing 
information concerning the health effects of chloroethane. Each dot in the figure indicates that one or more 
studies provide information associated with that particular effect. The dot does not necessarily imply 
anything about the quality of the study or studies, nor should missing information in this figure be 
interpreted as a “data need.” A data need, as defined in ATSDR’s Decision Guide for Identifying 
Substance-Specific Data Needs 
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Related to Toxicological Profiles (ATSDR 1989), is substance-specific information necessary to conduct 
comprehensive public health assessments. Generally, ATSDR defines a data gap more broadly as any 
substance-specific information missing from the scientific literature. As can be seen from the figure, 
chloroethane exposure by the inhalation route in animals has been well studied; however, there are few 
studies of the health effects of chloroethane exposure by other routes. The lack of studies of oral and 
dermal exposure is consistent with the fact that chloroethane is a gas at room temperature. 
2.11.2 Identification of Data Needs 
Acute-Duration Exposure. Tests of the acute toxicity of chloroethane by inhalation exposure have 
provided information on the levels of chloroethane that produce neurological effects in humans (Davidson 
1925; Sayers et al. 1929) and animals (Landry et al. 1982; Sayers et al. 1929) and the levels that produce 
death in animals (Sayers et al. 1929). Other toxic effects, such as those on the heart, have been reported 
(Bush et al. 1952; Haid et al. 1954), but the precise levels at which they occur have not been identified. 
Studies that carefully examine tissues histologically and look for other subtle effects are needed. They 
might provide information on the mechanisms of chloroethane lethality and neurotoxicity and provide 
further information on other toxic effects. The acute-duration inhalation MRL is based on an acute-
duration developmental study in which minimal fetotoxicity was observed in the offspring of mice 
exposed to chloroethane on gestation days 6-15 (Scortichini et al. 1986). 
No reliable studies of the oral or dermal toxicity of chloroethane were located. Reliable oral exposure 
studies are needed. Many people are exposed to chloroethane through its use as a topical anesthetic. 
Frostbite has occurred following prolonged skin application (Noble 1979). Studies of the acute dermal 
toxicity of chloroethane are needed to estimate safe application times. There is one report of eye irritation 
in humans caused by exposure to high concentrations of chloroethane vapor (Sayers et al. 1929), but skin 
irritation has not been studied for any exposure route. 
Intermediate-Duration Exposure. Repeated-dose studies of the toxicity of chloroethane by inhalation 
exposure have been performed in rats (Landry et al. 1982; NTP 1989), mice (Landry et al. 1987, 1989; 
NTP 1989), and dogs (Landry et al. 1982) at several dosage levels and for several durations of exposure. 
Reports indicate that inhalation abuse of chloroethane by adults and children may be increasing (Hersh 
199 1; Walker 1993). Human studies involving chloroethane abusers or animal studies using doses 
comparable to those sniffed from household products are needed to help elucidate the systemic effects 
caused by the compound. 
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Reliable studies of repeated-dose exposure to chloroethane are not available for other routes of exposure. 
Reliable oral exposure studies are needed. Chloroethane is also repeatedly used as a local anesthetic to 
treat sports injuries and in the treatment of musculoskeletal facial pain (Marbach 1996). Repeated-dose 
dermal studies are needed to provide information on whether repeated dermal exposure of humans is 
hazardous. 
Chronic-Duration Exposure and Cancer. A 2-year bioassay on inhaled chloroethane was 
performed in rats and mice by the National Toxicology Program (NTP 1989). Survival of mice was 
reduced compared to controls as a result of ascending urinary tract infections in males and uterine cancer 
in females. The only systemic effects noted were in the kidney (scattered foci of tubular regeneration, 
minimal glomerulosclerosis) in female mice. Female mice were also hyperactive during the exposures. 
Chloroethane was carcinogenic in female mice resulting in uterine cancer (NTP 1989). Because of reduced 
survival of male mice, the study was considered inadequate, although there was an increased incidence of 
alveolar/bronchiolar neoplasms of the lungs. In exposed rats, there was equivocal evidence of 
carcinogenicity based on skin trichoepitheliomas, sebaceous gland adenomas, or basal cell carcinomas in 
males, and malignant astrocytomas in the brain of females. A chronic study in which several exposure 
levels are tested is needed to provide more information on the danger to humans at lower exposure levels. 
Studies of chronic toxicity and carcinogenicity do not exist for other routes of exposure. Therefore, studies 
on chronic oral exposure to chloroethane are needed. 
Genotoxicity. The available genotoxicity studies indicate that chloroethane is mutagenic in bacteria 
(NTP 1989) and in mammalian cells in vitro (Ebert et al. 1994) but not clastogenic in mammalian cells in 
vivo (Ebert et al. 1994). Additional genotoxicity tests are needed to determine whether it is possible that 
chloroethane is genotoxic in humans. 
Reproductive Toxicity. Several studies investigated reproductive endpoints in animals. Uterine 
weight was decreased by approximately 35% in mice exposed to high concentrations of chloroethane 
(Fedtke et al. 1994a). Significant decreases in uterine glutathione levels have also been reported in rats and 
mice exposed to chloroethane (Fedtke et al. 1994b). A small increase in the average duration of the estrous 
cycle was observed in mice exposed to high concentrations of chloroethane (Bucher et al. 1995). 
Measurement of serum estradiol and progesterone did not reveal any consistent statistically significant 
changes attributable to chloroethane exposure. Sperm motility in rats was reduced after exposure to 
chloroethane for 6 months (Troshina 1966). Histopathological effects have not been observed in 
reproductive organs of animals 
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exposed to chloroethane (Landry et al. 1982, 1987, 1989; NTP 1989). No effects on the number of live and 
dead fetuses or on the number and position of resorption sites were observed in mice exposed to 
chloroethane on gestation days 6-15 (Scortichini et al. 1986). 
Based on decreases in uterine glutathione in rats and mice (Fedtke et al. 1994b), decreases in uterine 
weight in mice (Fedtke et al. 1994a), and the development of uterine cancer in mice exposed to 
chloroethane (NTP 1989) (see Cancer discussion in this Section 2.11.2), the uterus appears to be a target 
of chloroethane exposure in mice; rats are apparently less sensitive to these effects. The relevance of 
uterine effects in animals to human chloroethane exposure is not known, and further studies to examine the 
mechanisms of uterine effects observed in chloroethane-exposed mice are needed. A multigeneration study 
to determine if uterine effects, estrous cycle effects, and effects on sperm motility impact reproductive 
performance is also needed. 
Developmental Toxicity. Only one study of the developmental effects of chloroethane in mice 
was 
found. In this study, minimal evidence of fetotoxicity (increase in small centers of unossified bones of the 
skull) was observed at the highest concentration tested (Scortichini et al. 1986). This study serves as the 
basis for the acute-duration inhalation MRL. Additional developmental studies in other species are needed 
Because chloroethane is a neurotoxin, studies of the developmental neurotoxicity of chloroethane are also 
needed to assess the potential risk to humans. 
Immunotoxicity. Several studies included histopathological examinations of immunological organs 
and tissues following inhalation exposure to chloroethane (Landry et al. 1982, 1987, 1989; NTP 1989) but 
found no effects. Studies in which tests of immune function were performed are needed to provide more 
useful information on the immunotoxicity of chloroethane. Three reports on sensitization produced by 
dermally applied chloroethane in humans (Bircher et al. 1994; Kriechbaumer et al. 1998; Van Ketel 1976) 
were found.  Because many people are dermally exposed to chloroethane as a topical anesthetic, studies of 
this phenomenon are needed. 
Neurotoxicity. Studies of chloroethane inhalation in humans and animals have provided information 
on the neurological effects produced by acute exposure to chloroethane and the levels at which they occur. 
Most repeated-exposure studies involved only behavioral observations and histopathological examinations 
of neurological organs and tissues; one case report involved a neurological examination of an adult male, 
which revealed marked nystagmus, ataxia and vertigo, but nothing abnormal upon evaluation of the brain, 
brain 
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stem, or spine upon MRI (Walker 1993). In addition, two studies in mice (Landry et al. 1987, 1989) and 
one in dogs (Landry et al. 1982) were identified, neither of which reported signs of neurotoxicity. Reliable 
studies of neurotoxicity following exposure by other routes do not exist. Controlled studies regarding the 
neurological effects of chloroethane are needed. 
Epidemiological and Human Dosimetry Studies. No epidemiological or human dosimetry studies 
of chloroethane have been performed. High inhalation concentrations of chloroethane are anesthetic in 
humans and overdose can be lethal because of cardiovascular or respiratory effects. Chronic inhalation 
exposure has produced cancer in animals (NTP 1989). The general population might be exposed to 
chloroethane by inhalation of contaminated ambient air or intentional use as a topical anesthetic. 
Occupational exposure may occur by inhalation or dermal contact. Epidemiological studies of people who 
live near industries releasing chloroethane or near hazardous waste sites, of people who use chloroethane 
as a topical anesthetic, and of people who are occupationally exposed to chloroethane are needed to 
provide information on whether chloroethane is carcinogenic or has other toxic effects in humans at 
environmentally relevant concentrations.  If such effects are identified, human dosimetry studies may be 
able to correlate levels of chloroethane in human tissues or fluids with health effects. 
Biomarkers of Exposure and Effect 
Exposure. Studies of the association of environmental concentrations of chloroethane with levels of 
chloroethane in the breath, fluids, and body tissues were not identified. Studies examining the association 
between air and breath levels of chloroethane are needed. Further research is required to determine if 
urinary excretion of glutathione conjugate metabolites or acetaldehyde-protein adducts (Worrall et al. 
1994) would serve as a useful biomarker following exposure of humans to chloroethane. 
Effect. Unique biomarkers of effect have not been identified for exposure to chloroethane. Further 
research regarding the biochemical effects of chloroethane is needed to identify biomarkers of effect for 
chloroethane. 
Absorption, Distribution, Metabolism, and Excretion. A single breath absorption study (Morgan 
et al. 1970) is the only quantitative study regarding the absorption, distribution, metabolism, and excretion 
of chloroethane in humans. Studies in rats and mice indicate that chloroethane is readily absorbed 
following inhalation exposure and metabolized to acetaldehyde and glutathione conjugates (Fedtke et al. 
1994a, 1994b).  Additional quantitative studies of the pharmacokinetics of chloroethane are needed. 
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Comparative Toxicokinetics. A study that compares the metabolism of chloroethane in rats and 
miceindicates that mice have a greater capacity to metabolize chloroethane than rats (Fedtke et al. 1994a, 
1994b).  An in vitro study using human liver preparations to study the metabolism of chloroethane is 
needed to determine which species is the most appropriate model for the metabolism of chloroethane. 
Methods for Reducing Toxic Effects. Other than removing the subject from exposure 
(Haddad and Winchester 1990) and increasing ventilation rate to enhance elimination after the subject is 
removed from exposure, methods for reducing toxic effects were not identified. As more information is 
learned regarding the mechanism of chloroethane toxicity, methods for reducing the toxic effects of 
chloroethane can be developed. 
Children’s Susceptibility. No studies involving exposure of children or immature animals to 
chloroethane have provided quantitative doses. There are two very qualitative studies in children 
associated with the use of chloroethane as an anesthetic (Nielsen 1980; Noble 1979). There currently 
exists a need for studies with children or immature animals exposed to the compound to investigate any 
differences in dose absorption, metabolism, excretion, and presence and severity of effects, Current 
knowledge of differences in physiology and biochemistry between children and adults indicate that 
distribution and metabolism mightdiffer between children and adults. However, experiments evaluating 
qualitative and quantitative differences in these processes would greatly facilitate the understanding of 
adverse effects of chloroethane in the developing human. 
Definitive studies do not exist evaluating whether pharmacokinetics of chloroethane are different in 
children as compared with adults. Furthermore, no PBPK models exist on any age of children or adults 
that might inform the public as to the pharmacokinetics of the compound. 
Studies are needed to determine whether chloroethane or its metabolites cross the placenta and no studies 
have evaluated placental or cord blood concentrations of chloroethane or its metabolites in humans or 
animals. It is unknown whether the delayed bone development seen in the Scortichini et al. (1986) study 
was due to chloroethane or its metabolites crossing the placenta or to some indirect effect on the fetus. 
Experiments evaluating these parameters are needed, as well as experiments to determine whether 
chloroethane significantly accumulates in breast milk. One study detected the compound in breast milk 
(Pellizari et al, 1982), but neither route of exposure of the mother nor concentration of chloroethane in the 
milk was identified. In addition, studies determining whether chloroethane would be stored in maternal 
CHLOROETHANE 88 
2. HEALTH EFFECTS 
tissues would be informative, although the volatility of the compound, as well as data indicating its rapid 
clearance from the body following inhalation exposure (Morgan et al. 1970), indicate that tissue storage is 
not expected. 
Adequate data do not exist on the effect, if any, chloroethane exposure has on fetal development. The one 
available prenatal developmental study and data needs on this topic are discussed above in the 
Developmental Effects subsection. Reliable studies of this type are needed in determining the fetotoxicity 
of chloroethane, as well as the potential of the compound for disrupting normal child development. Studies 
on postnatal exposures and their influence on development in immature animals would also be useful. 
Child health data needs relating to exposure are discussed in 5.8.1 Data Needs: Exposures of Children. 
Data Needs for Modeling 
Studies which provide information on the physiological biochemical parameters specific to chloroethane 
in human and animal tissues are needed. For instance, there are no data on organ volumes, alveolar 
ventilation,cardiac output, or organ perfusion rates, among other parameters, in humans and animals. A 
PBPK model in rats exposed to chloroethane via inhalation was developed with the assumption that 
metabolism of the compound occurred exclusively in the liver (Gargas et al. 1990). The authors 
determined a Vmaxc which is the maximum velocity (Vmax) scaled for a 1 -kg animal, the Km (rate constant 
for the saturable pathway), and the first-order rate constant, Kfc, which is the rate constant (Kf) scaled for a 
l-kg animal. 
Other biochemical parameters that affect metabolism and clearance have not been investigated. Waller et 
al. ( 1996) modeled the cytochrome P450-mediated metabolism of chloroethane using three-dimensional 
quantitative structure-activity relationships (3D-QSAR). Their models have predicted a metabolic 
clearance rate for chloroethane. Other studies, involving the experimental or modeled estimation of other 
biochemical parameters, such as excretory clearance, binding and reactivity, absorption constants, 
inhibition rate constants, first pass effects, and other parameters that may influence the rate of elimination 
and bioavailability were not available. Studies investigating these parameters using human or animal 
tissues would provide much-needed information concerning the metabolism of chloroethane. 
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2.11.3 Ongoing Studies 
Ongoing studies regarding chloroethane were not identified in the CRISP (1996), FEDRIP (1998), or 
CRIS/USDA (1998) databases. 
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3.1 CHEMICAL IDENTITY 
Information regarding the chemical identity of chhloroethane is located in Table 3-l. 
3.2 PHYSICAL AND CHEMICAL PROPERTIES 





4. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
4.1 PRODUCTION 
Table 4-l lists the facilities in each state that manufacture or process chloroethane, the intended use, and 
the range of maximum amounts of chloroethane that are stored on site. There are currently 50 facilities 
that produce or process chloroethane in the United States. The data listed in Table 4-l are derived from 
theToxics Release Inventory (TRI) (TR196 1998). Only certain types of facilities were required to report. 
Therefore, this is not an exhaustive list. 
The production of chloroethane in the United States has decreased as the use of leaded gasoline has been 
regulated. In 1960, approximately 247,000 metric tons (1 metric ton = 1,000 kg) of chloroethane were 
produced, while in 1988 production of chloroethane was approximately 69,000 metric tons (IARC 1991). 
Companies on the TRI listed as producers of chloroethane include: Degussa Corporation and Huls 
America, Inc., in Theodore, AL; Monsanto Company in Muscatine, IA, and Bridgeport, NJ; Westlake 
Monomers Corporation in Calvert City, KY; BASF Corporation in Geismar, LA; Condea Vista Company 
in Westlake, LA; Dow Chemical Company in Plaquemine, LA, and Freeport, TX; Formosa Plastics 
Corporation in Baton Rouge, LA, and Point Comfort, TX; Georgia Gulf Corporation in Plaquemine, LA; 
PPG Industries in Lake Charles, LA; Vulcan Materials Company in Geismar, LA; Dow Chemical USA in 
Midland, MI; Dow Corning Corporation in Midland, MI; Akzo Nobel Chemicals, Inc., in Edison, NJ; 
Cyanamid Agricultural in Manati, PR; Lobeco Prods., Inc., in Lobeco, SC; Zeneca Specialties in Mount 
Pleasant, TN; Eastman Chemical Company in Longview, TX; Hoechst-Celanese in Bay City, TX; 
Occidental Chemical Corporation in Deer Park, TX, and Gregory, TX; Specialtychem Prods. Corporation 
in Marinette, WI; and OS1 Specialties, Inc., in Friendly, WV (TR196 1998). 
4.2 IMPORT/EXPORT 
From 1979 to 1988, chloroethane imports were significant only in 1980, 1981, and 1982. During those 
years, imported quantities were 1,270,5,030, and 2,325 metric tons, respectively (IARC 1991). From 1990 
to 1994, US. imports of chloroethane in kilograms were 3,011,432 in 1990,4,103,072 in 1991, 14,260 in 
1992,24 in 1993, and 0 in 1994 (NTDB 1996). 
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From 1979 to 1988, the United States exported 8,562-13,868 metric tons, with the maximum occurring in 
1986 and the minimum occurring in 1988 (IARC 1991). From 1991 to 1995, U.S. exports of chloroethane 
in metric tons were 11.3 in 1991, 16.8 in 1992, 15.1 in 1993,38.1 in 1994, and 5.4 in 1995 (NTDB 1996). 
4.3 USE 
In the past, the single largest use of chloroethane was in the production of tetraethyl lead. As recently as 
1984, 80% of the chloroethane consumed in the United States was used in domestic production of 
tetraethyl lead, 15% was used in the production of ethyl cellulose, and 5% was used for miscellaneous 
applications including use as a solvent, refrigerant, and topical anesthetic, and use in the manufacture of 
dyes, chemicals, and pharmaceuticals (HSDB 1997; Morris and Tasto 1979). Government-mandated 
reduction in the amount of lead additives used in gasoline in the United States and a shift to the use of 
unleaded gasoline caused a drastic reduction in the amount of chloroethane required for the production of 
tetraethyl lead (CMR 1982; EPA 1985; IARC 1991). 
Chloroethane has been used as a pulp vitality tester in dentistry, as a medication to alleviate pain 
associated with insect bums, stings, and sports injuries, as an adjunct in the treatment of tinea lesions and 
creeping eruptions, as a test for regional anesthesia before Caesarean section, and as a counterirritant and 
anesthetic for relief of myofacial and visceral pain syndromes (Adriani 1986; Boume et al. 1997; Brown 
1972; Ehrmann 1977; Marbach 1996; Ott 1969). Chloroethane has recently been used as a freezing agent 
to relieve spasms in recipient arteries in microvascular transfer (Cavadas 1996). 
Chloroethane is also used as a recreational inhalant, desired for its narcotic effects. The compound is 
manufactured in pressurized canisters and sold specifically for inhalant abuse under names such as Ethyl 
Gaz, Ethyl Four Star, Black Jac, and Maximum Impact (Hersh 199 1; Walker 1993). 
4.4 DISPOSAL 
Chloroethane is listed as a toxic substance under Section 3 13 of the Emergency Planning and Community 
Right to Know Act (EPCRA) under Title III of the Superfund Amendments and Reauthorization Act 
(SARA) (EPA 1998c). Disposal of wastes containing chloroethane is controlled by a number of federal 
regulations (see Chapter 7). 
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Chloroethane may be disposed of by controlled incineration. It is recommended that chloroethane be 
mixed with another combustible fuel prior to incineration; however, sufficient oxygen and an adequate 
operating temperature are mandatory to avoid incomplete combustion resulting in the formation of 
phosgene.  Incinerators for this compound are typically equipped with an acid scrubber to remove halo 
acids from the effluent gas (HSDB 1997; OHM/TADS 1998). In a study of the thermal destruction of 
chloroethane, the minimum temperature required for 99.99% destruction with a 1 -second residence time 
was 727 °C (Fisher and Koshland 1990). Among the chlorinated methanes and ethanes studied, 
chloroethane had the lowest temperature required for destruction. Chloroethane is also a constituent of 
some waste-water streams; it is susceptible to removal by air stripping (HSDB 1997). Placing chloroethane 
in a landfill is not recommended (HSDB 1997). 
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5.1 OVERVIEW 
Chloroethane has been ientified in at least 282 of the 1,467 current or former EPA National Priorities List 
(NPL) hazardous waste sites (HazDat 1998). However, the number of sites evaluated for chloroethane is 
not known. The frequency of these sites within the United States can be seen in Figure 5-1. 
Chloroethane is a compound that occurs in the euviroument as the result of anthropogenic activity. 
Sources of chloroethane exposure include process and fugitive emissions from its production and use as a 
chemical intermediate; evaporation from waste-water streams, landfills, solvents, refrigerants, and 
anesthetics; emissions from plastics, refuse, and biomass combustion; formation during water chlorination; 
formation via anaerobic biodegradation of some chlorinated solvents; and evaporation and leaching from 
landfills. Most chloroethane released in the environment eventually enters the atmosphere. 
When released to the atmosphere, the dominant removal mechanism is expected to be reaction with 
photochemically-generated hydroxyl radicals (half-life of 40 days). Potential exists for removal from the 
atmosphere in precipitation; however, most chloroethane removed by this mechanism is likely to reenter 
the atmosphere by volatilization. When released to surface water, volatilization is expected to be the 
primary fate process (half-life of 2.4 hours in a model river). When released to soil, chloroethane either 
volatilizes rapidly from soil surfaces or leaches through subsurface soil where it becomes a potential 
groundwater contaminant.  In groundwater, chloroethane would probably be subject to chemical 
hydrolysis. Sufficient data are not available to establish the rate of chloroethane degradation in 
groundwater. 
The general population may be exposed to low (ppt) levels of chloroethane through inhalation of 
contaminated ambient air and consumption of contaminated drinking water. Dermal contact can occur as a 
result of the intentional use of chloroethane as a topical anesthetic. Occupational exposure may occur by 
inhalation and/or dermal contact. According to a 1981-1983 NIOSH survey, an estimated 49,212 workers 
in the United States are potentially exposed to chloroethane in the workplace (NIOSH 1991). 
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5.2 RELEASES TO THE ENVIRONMENT 
According to the Toxics Release Inventory (TRI), in 1996, a total of 3,242,710 pounds (1,470,617 kg) of 
chloroethane was released to the environment from 50 large processing facilities (TR196 1998). Table 5-l 
lists amounts released from these facilities. In addition, an estimated 762 pounds (346 kg) were released 
by manufacturing and processing facilities to publicly owned treatment works (POTWs) and an estimated 
688,311 pounds (312,159 kg) were transferred offsite (TR196 1998). The TRI data should be used with 
caution because only certain types of facilities are required to report. This is not an exhaustive list. 
Chloroethane has been identified in a variety of environmental media (air, surface water, groundwater, 
soil, and sediment) collected at 282 of the 1,467 NPL hazardous waste sites. 
5.2.1 Air 
According to the Toxics Release Inventory (TRI), in 1996, the estimated releases of chloroethane of 
2553,260 pounds (1,157,941 kg) to air from 50 large processing facilities accounted for about 79% of total 
environmental releases (TR196 1998). Table 5-1 lists amounts released from these facilities. The TRI data 
should be used with caution because only certain types of facilities are required to report. This is not an 
exhaustive list. 
Chloroethane may be released to the environment through process and fugitive emissions related to its 
production and use as a chemical intermediate; through evaporative losses from waste-water streams, 
landfills, solvents, refrigerants, and anesthetics; and through emissions from combustion of plastics, 
refuse, and biomass (Graedel et al. 1986; Liepins et al. 1977; Vogt and Walsh 1985; Young and Parker 
1984).  Based on 1980 air monitoring data, it was estimated that 20 million pounds of chloroethane per 
year were being released into the atmosphere in the United States (Singh et al. 1981). Between 1980 and 
1988, production levels of chloroethane in the United States decreased by approximately 62% (IARC 
1991), and a proportional decrease in emissions related to its production and use as a chemical 
intermediate probably occurred. 
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5.2.2 Water 
According to the Toxics Release Inventory (TRI), in 1996, the estimated releases of chloroethane of 
285 pounds (129 kg) to water from 50 large processing facilities accounted for about 0.01% of total 
environmental releases (TR196 1998). Table 5-l lists amounts released from these facilities. The TRI data 
should be used with caution because only certain types of facilities are required to report. This is not an 
exhaustive list. 
Limited data are available regarding the release of chloroethane to water. This compound may be released 
to the environment as a constituent of waste-water streams from various industries, particularly those that 
use chloroethane as an intermediate. The following industries have been identified as potential sources of 
release of chloroethane: electroplating, organic chemicals, steam electric, asbestos, timber products 
processing, metal finishing, paving and roofing, paint and ink formulating, gum and wood, and carbon 
black (EPA 1988a). It is possible that chloroethane forms in some waste-water streams as a result of 
disinfection bychlorination (Gould et al. 1983; Liepins et al. 1977; Otson 1987). Because of its volatility, 
the majority of chloroethane released to surface water is expected to enter the atmosphere. This compound 
can leach into groundwater from waste disposal sites, and it may form in groundwater as an anaerobic 
biodegradation product of chlorinated solvents (e.g., 1,l ,l -trichloroethane and cis-1 ,1 -dichloroethylene) 
(Barrio-Lage et al. 1986; Vogel and McCarty 1987). 
5.2.3 Soil 
According to the Toxics Release Inventory (TRI), in 1996, there were no releases to soil from the 50 large 
processing facilities required to report (TR196 1998). 
Chloroethane can occur in soil as a result of the disposal of waste products that contain this compound and 
as a result of formation as an anaerobic biodegradation product of various chlorinated compounds (e.g., 1 
,l ,ltrichloroethane and cis- 1,2-dichloroethylene) (Barrio-Lage et al. 1986; Vogel and McCarty 1987). 
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5.3 ENVIRONMENTAL FATE 
5.3.1 Transport and Partitioning 
The relatively high water solubility of chloroethane suggests that potential exists for removal of this 
compound from the atmosphere via washout. However, most chloroethane removed by this mechanism is 
likely to reenter the atmosphere by volatilization. 
The dominant removal process for chloroethane in surface water is expected to be volatilization. Based on 
a measured Henry’s Law constant of 1 .11x10-2 atm-m3/mole at 24.8 °C, the volatilization half-life of 
chloroethane from a model river 1 m deep, flowing 1 m/second with a wind speed of 3 m/second was 
estimated to be 2.4 hours (Gessett 1987; Thomas 1982). 
Bioconcentration factors (BCF) of 7 and 5 have been estimated for chloroethane using linear regression 
equations based on a log of the octanol-water partition coefficient (Kow) of 1.43 and a water solubility of 
5,678 mg/L at 20°C, respectively (Bysshe 1982; Hansch and Leo 1985; Horvath 1982). These BCF values 
indicate that this compound would not bioconcentrate significantly in aquatic organisms. 
Adsorption coefficients (Koc) of 143 and 33 were estimated for chloroethane using linear regression 
equations based on log Kow and water solubility data, respectively (Lyman 1982). These &, values suggest 
that adsorption of chloroethane to suspended solids and sediments in water would not be a significant fate 
process. 
The likely insignificant sorption of chloroethane to soil, indicated by the relatively low Koc value for the 
compound, suggests that it would be highly mobile in soil and might undergo significant leaching (Swann 
et al. 1983). The relatively high vapor pressure of chloroethane and its volatility from water suggest that it 
would evaporate rapidly from soil surfaces, and that volatilization would probably be a major removal 
process. Washington (1996) has calculated a Kc value for chloroethane. This value is the ratio of the 
concentration of the compound in the gas phase relative to the water phase and indicates the mobility of 
the compound from water in saturated soils to vapor. The calculated value of Kc, 0.347 at 17.5 °C, 
indicates that chloroethane in soil has a propensity to become dissolved in soil water and will then enter 
soil gas. The concentrations of chloroethane in soil water and the vapor phase will approach equilibrium 
(Washington 1996). 
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5.3.2 Transformation and Degradation 
5.3.2.1 Air 
The dominant atmospheric removal process for chloroethane is predicted to be removal by reaction with 
photochemically-generated hydroxyl radicals in the troposphere. This reaction is believed to proceed via 
hydrogen abstraction (Atkinson 1985; Howard and Evenson 1976). The half-life for this reaction has been 
estimated to be 40 days based on a reaction rate constant of 4.0x10-13 m3/molecule-second at 25 °C and a 
typical hydroxyl radical concentration of 5.0x105 molecules/m3 (Atkinson 1985; Howard and Evenson 
1976).  This tropospheric half-life suggests that less than 1% of the chloroethane released to the 
atmosphere would diffuse into the stratosphere, where it would be destroyed by photolysis (Callahan et al. 
1979). Chloroethane is not expected to photolyze in the atmosphere below the ozone layer since it contains 
no chromophores that absorb light in the visible part of the spectrum (wavelengths about 400-700 nm) 
(Hubrich and Stuhl l980; Jaffe and Orchin 1962; Mabey et al. 1981). 
5.3.2.2 Water 
Chloroethane is susceptible to slow chemical hydrolysis and forms ethanol and hydrochloric acid as 
reaction products. The hydrochloric acid formed dissociates at the neutral pH of most natural waters and 
forms a chloride salt. The hydrolytic half-life of chloroethane is not known with certainty. The hydrolytic 
half-life in water at 25 °C and pH 7 was estimated to be 38 days based on a reaction rate constant 
extrapolated from experimental data at 100°C (Laughton and Robertson 1959; Mabey and Mill 1978). 
However, in another study, the hydrolytic half-life was estimated to be approximately 1.9 years based on 
an estimated first-order rate constant of 1 .18x10m-8 s-1 obtained from the analysis of chloroethane in a 
batch fermented at 20°C (Vogel and McCarty 1987). Both the neutral and alkaline reaction rates for the 
hydrolysis of chloroethane were determined by Jeffers and Wolf (1996). The neutral reaction measured in 
0.01 M hydrochloric acid at 25 °C was found to predominate, with a rate constant of 5.1 x 10-7, resulting in 
an estimated half-life for chloroethane of 2.6 years. Despite these conflicting data, chemical hydrolysis 
may be an important fate process in groundwater when losses from other degradation and transport 
processes are expected to be negligible. 
The high volatility of chloroethane indicates that this compound will volatilize from groundwater and enter 
soil as a gas. In addition, chloroethane is susceptible to biodegradation in groundwater and other media. 
Vogel and McCarty (1987) have shown that chloroethane, formed by the anaerobic biodegradation of 
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trichloroethylene in a batch fermenter, was further dechlorinated by methanogenic bacteria. This study, 
however, provided no rate constant for this reaction that could be compared to the rate for hydrolysis. 
Oxidation of chloroethane in water via reaction with singlet oxygen or peroxy radicals is too slow to be 
environmentally relevant (Mabey et al. 198 1).  Direct photolysis in surface waters is not expected to be an 
environmentally relevant fate process (Mabey et al 1981). 
5.3.2.3 Sediment and Soil 
In moist subsurface soils, chloroethane is expected to be susceptible to chemical hydrolysis. However, this 
pathway is expected to be slow and other fate and transport processes may predominate. A large body of 
data exists on the biodegradation of chlorinated alkenes and alkanes under anaerobic or aerobic conditions. 
The majority of this data, however, deals with polycblorinated compounds that are biodegraded to 
chloroethane or a structurally similar alkane or alkene (Ahlert and Enzminger 1992; Barrio-Lage et al. 
1986; Chang and Alvarez-Cohen 1996; Tabak et al. I98 1; Vogel and McCarty 1987). 
Chloroethane can undergo reductive dehalogenation by methanogenic bacteria in an anaerobic cell 
suspension or packed column environment (Baek et al. 1990; Holliger et al. 1990). Ethane and 
hydrochloric acid are formed by the reductive dechlorination of chloroethane (Holliger et al. 1990). In 
addition, chloroethane can be oxidized by aerobic nitrifying bacteria (Rasche et al. 1990). Both 
acetaldehyde and 2-chloroethanol are produced from the oxidation of chloroethane, with acetaldehyde 
predominating at more than 98% of the total product (Rasche et al. 1990). 
Although these studies provided maximum product formation rates, first-order rate constants were not 
estimated; therefore, no comparisons could be made to determine which biodegradation pathway would 
more rapidly clear chloroethane from a contaminated environment. The pathways do not directly compete, 
because they occur in different environments, one in an oxygen-deficient environment and the other in an 
oxygen-rich environment. For example, methanogenic environments are found at landfills and deep 
aquifers rich in carbohydrate-like compounds. Denitrifying environments are common to agricultural land 
use as well as areas that have on-site wastewater treatment systems (Ahlert and Enzminger 1992). 
Further, optimal biodegradation of chloroethane in aquifers or saturated sediments or soils is highly 
dependent on the presence of appropriate metabolizing bacteria, the migration of the contaminant to the 
bacteria, and the availability and concentration of necessary reactants such as carbon sources, reducers, 
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and/or oxidizers. While laboratory studies indicate that biodegradation can be a significant pathway for 
clearance of chloroethane and other contaminants from affected media, the importance of this pathway in 
the environment is still unknown. 
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT 
Reliable evaluation of the potential for human exposure to chloroethane depends in part on the reliability 
of supporting analytical data from environmental samples and biological specimens. In reviewing data on 
chloroethane levels monitored or estimated in the environment, it should also be noted that the amount of 
chemical identified analytically is not necessarily equivalent to the amount that is bioavailable. 
5.4.1 Air 
Limited data are available regarding the detection of chloroethane in air. Monitoring data from the early 
1980s indicate that levels of chloroethane in ambient air at various urban/suburban locations in the United 
States ranged from 10 to 1,248 ppt with average concentrations ranging from 41 to 140 ppt (Shepson et al. 
1987; Singh et al. 198 1). Marine air samples collected in the Northern Hemisphere during 198 1 contained 
an average concentration of 19 ppt (Singh et al. 1983). Rural air samples collected in 1974-1975 in the 
northwest United States contained less than 5 ppt chloroethane (Grimsrud and Rasmussen 1975). Current 
ambient levels of chloroethane are believed to be markedly lower than levels found during the mid 1970s 
and early 1980s because of a substantial decrease in the production of chloroethane in the United States. 
Chloroethane has been detected in the air samples of landfill gas collected from a municipal/industrial 
landfill in the United Kingdom and a municipal landfill simulator (Young and Parker 1984; Vogt and 
Walsh 1985).  These data indicate that chloroethane may be found in the air above some landfills. 
However, sufficient data are not available to determine whether elevated levels of chloroethane typically 
occur at or in the vicinity of 
waste disposal sites. 
5.4.2 Water 
Limited data are available regarding the detection of chloroethane in surface water, groundwater, drinking 
water, and waste water. Analysis of data input into the EPA STORET database during the early 1980s 
indicates that chloroethane is not a common surface water pollutant and that levels in unfiltered surface 
water samples typically fall below the detection limit (<10 mg/L) (Staples et al. 1985). Chloroethane 
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contamination of groundwater has occurred at various waste disposal sites throughout the United States 
(ATSDR 1989,199l; Cline and Viste 1985; EPA 1986a, 1987; Myers 1983; Sabel and Clark 1984). 
Groundwater and landfill leachate were the media in which chloroethane was most frequently found at 
NPL hazardous waste sites (HazDat 1998). Chloroethane was found in groundwater at 218 sites and in 
leachate at 43 NPL sites. Results of a 1982-1983 survey of 10 Canadian drinking water supplies suggest 
that trace levels (<0.1 mg/L) of chloroethane may occur in some finished drinking water supplies as a 
result of formation during the chlorination process (Otson 1987). During the 1975 EPA National Organics 
Reconnaissance Survey (NORS), chloroethane was qualitatively identified in drinking water samples from 
three of five finished drinking water supplies in the United States (EPA 1975). Without more recent or 
comprehensive data, the average daily intake of chloroethane by ingestion of drinking water cannot be 
estimated. Chloroethane is not a common constituent of treated waste water (EPA 198 1; Perry et al. 1979; 
Staples et al. 1985; Young et al. 1983). The maximum reported concentration for chloroethane in a waste 
stream was 10 mg/L in treated waste water from a paint and ink formulation industry (EPA 1981). A 
survey of storm water runoff samples collected from 15 cities located across the United States revealed 
that chloroethane is not a typical contaminant of stormwater runoff (Cole et al. 1984). 
5.4.3 Sediment and Soil 
Chloroethane was found in sediment at 10 NPL sites and in soil at 42 NPL sites (HazDat 1998). In a 
survey of U.S. waste-water treatment plants receiving both municipal and industrial waste streams, 
chloroethane was found in undigested sewage sludge from 2 of 13 plants at concentrations ranging from 
14.5 to 24 mg/kg dry weight. Assuming that the sludge was disposed of by land application, the 
application rate of chloroethane to soil was projected to be 0.16-0.17 kg/hectare  (dry weight), and the 
resulting concentration of chloroethane in the top 15 cm of soil was predicted to be 0.08-0.085 mg/kg 
(Naylor and Loehr 1982). 
5.4.4 Other Environmental Media 
Few reports are available concerning the identification of chloroethane in other media. Traces of 
chloroethane were found in two of eight human milk samples taken from women in four urban areas of the 
United States (Pellizzari et al. 1982). Chloroethane at a mean concentration of 7.6 ng/g was found in 
oysters collected from Lake Pontchartrain, LA (Ferrario et al. 1985). 
CHLOROETHANE 109 
5. POTENTIAL FOR HUMAN EXPOSURE 
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE 
According to a National Occupational Exposure Survey (NOES) conducted by NIOSH between 1981 and 
1983, an estimated 49,212 workers in the United States are potentially exposed to chloroethane (NIOSH 
1991). This was a tentative estimate and extrapolating to the present, such estimates are subject to change 
depending upon whether further information on trade name compounds containing chloroethane becomes 
available. Workers may be exposed to chloroethane by inhalation and/or dermal exposure. Chloroethane 
exposure can occur in several occupational environments including: chemical manufacturing industries; 
medical and health facilities; automotive dealerships and service stations; wholesale trade, electric, gas and 
sanitary services; companies manufacturing or using machinery (except electrical); metal production 
facilities; printing and publishing companies; paint manufacturers and painting companies; companies 
manufacturing rubber and plastic products not elsewhere classified; and companies manufacturing food 
and kindred products (Fidler et al. 1987; Parker et al. 1979). Workers who may potentially be exposed 
include physicians, nurses, and other medical workers, automobile mechanics, office machine mechanics, 
household appliance and accessory installers, assemblers, professional painters, heavy-equipment 
mechanics (including diesel mechanics), and plumbers and pipe fitters (Fidler et al. 1987; Parker et al. 
1979). Limited data indicate that the general population is exposed to very low (ppt) levels of chloroethane 
by inhalation of contaminated air and ingestion of contaminated drinking water. Apparently, people 
residing in urban/suburban areas are exposed to somewhat higher levels of chloroethane in air than people 
living in rural areas (Grimsrud and Rasmussen 1975; Shepson et al. 1987; Singh et al. 1983). Medical use 
of chloroethane as a topical anesthetic results in direct dermal exposure of the general population to this 
compound. The general population is also exposed to chloroethane by dermal contact with consumer 
products that contain this compound (i.e., various paints, solvents, refrigerants) (HSDB 1997). 
5.6 EXPOSURES OF CHILDREN 
This section focuses on exposures from conception to maturity at 18 years in humans and briefly considers 
potential pre-conception exposure to germ cells. Differences from adults in susceptibility to hazardous 
substances are discussed in 2.6 Children’s Susceptibility. 
Children are not small adults. A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, and breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume. A child’s diet often differs from that of adults. The 
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developing humans source of nutrition changes with age: from placental nourishment to breast milk or 
formula to the diet of older children who eat more of certain types of foods than adults. A child’s behavior 
and lifestyle also influence exposure. Children crawl on the floor; they put things in their mouths; they 
may ingest inappropriate things such as dirt or paint chips; they spend more time outdoors. Children also 
are closer to the ground, and they do not have the judgement of adults in avoiding hazards (NRC 1993). 
Children can be exposed inadvertently to chloroethane via household products such as paints, solvents, air 
fresheners, and refrigerants. However, children are unlikely to be exposed to a significant amount of 
chloroethane during normal use of these products by adults. Children can be exposed to chloroethane by 
intentionally sniffing household products containing the compound or sniffing packaged chloroethane that 
is sold specifically for misuse as an inhalant (Hersh 1991; Walker 1993). 
Children can also be exposed to chloroethane via contaminated drinking water or foods. Chloroethane 
concentrations in drinking water are expected to be low. One study was identified that reported 
chloroethane in small amounts (7.6 ng/g) in oysters in Lake Pontchartrain, LA (Ferrario et al. 1985). 
Because children drink more fluids and eat more food per kilogram of body weight than adults, they are 
expected to be disproportionately affected by exposure to chloroethane. However, because of the low 
concentrations of chloroethane detected in food and water, dietary exposures are not expected to be 
significant in children. 
Chloroethane has been detected in human breast milk (Pellizari et al. 1982). However, the concentrations 
of chloroethane were not determined, nor was the exposure dose. Therefore, it is not possible to determine 
how much of an absorbed chloroethane dose would be excreted in the milk and ingested by a nursing 
infant. In addition, the number of women with detectable levels of chloroethane in their milk was low; data 
do not exist that could indicate what percentage of an exposed female population could be expected to 
excrete chloroethane in their breast milk. 
Parents’ work clothes, skin, hair, tools, or other objects removed from the workplace are not likely to be a 
source of exposure to children. Chloroethane is a gas at room temperature and pressure; thus, it will not 
remain on parents’ clothes, hair, skin or other items, even for those who work with liquid chloroethane. 
Therefore, secondary exposure to children is unlikely. 
It is unknown whether children are different in their weight-adjusted intake of chloroethane. 
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5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
Humans are typically exposed to very low levels of chloroethane. Nonetheless, potentially high levels 
could result from occupational exposure, exposure at or near hazardous waste sites, and frequent contact 
with consumer products that contain chloroethane (i.e., solvents, paints, refrigerants). Inhalation and 
dermal contact are expected to be the primary routes of exposure, although ingestion via indirect contact 
(e.g., eating foods that come in contact with contaminated surfaces or swallowing mucus that becomes 
contaminated as the result of breathing air containing chloroethane) is also possible. 
5.8 ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate 
information on the health effects of chloroethane is available. Where adequate information is not available, 
ATSDR, in conjunction with the NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of chloroethane. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean that 
all data needs discussed in this section must be filled. In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
5.8.1 Identification of Data Needs 
Physical and Chemical Properties. Data on the physical and chemical properties of 
chloroethane are available (Budavari 1989; HSDB 1997). A Koc value provides a means for predicting 
whether a compound will partition significantly into suspended solids and sediments in water or adsorb 
strongly to soil. A Koc for chloroethane was estimated using regression equations based on log Kow and 
water solubility data (Lyman 1982). This estimation technique is believed to provide a reasonable 
approximation of Koc. However, additional studies are needed in which the soil adsorption coefficient of 
chloroethane is measured in order to remove any doubt concerning the reliability of the Koc. 
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Production, Import/Export, Use, Release, and Disposal. According to the 
Emergency Planning and Community Right-to-Know Act of 1986,42 U.S.C. Section 11023, industries are 
required to submit chemical release and off-site transfer information to the EPA. The Toxics Release 
Inventory (TRI), which contains this information for 1996, became available in May of 1998. This 
database will be updated yearly and should provide a list of industrial production facilities and emissions. 
Data are adequate for the production and disposal of chloroethane (IARC 199 1; TR196 1998). 
Information on the pattern of use of chloroethane is not available after 1988. Information would have to be 
supplied by the chemical industry in order to establish the percentage breakdown of the current 
chloroethane uses. This type of information is needed to establish the sources of chloroethane release and 
the potential for general population and occupational exposure. 
Environmental Fate.  Conflicting data are available concerning the hydrolytic half-life of 
chloroethane in water (Jeffers and Wolf 1996; Laughton and Robertson 1959; Mabey and Mill 1978; 
Vogel and McCarty 1987). Experimental data obtained from a hydrolysis study carried out in distilled 
water under environmental conditions (at 25 °C and pH 5-9) are needed to predict the half-life of 
chloroethane (Haider 1980; Kobayashi and Rittmann 1982) in natural water and moist soil. Available data 
regarding biodegradation of chloroethane are insufficient for predicting the importance of biodegradation 
as a removal process for chloroethane.  Natural water grab sample biodegradation studies and soil 
metabolism studies carried out under both aerobic and anaerobic conditions are needed to estimate the 
biodegradation half-life of chloroethane. Although volatilization from soil is expected to be an important 
fate process (Washington 1996), data pertaining to the rate of volatilization from soil surfaces were not 
located in the available literature. Studies involving the measurement of the volatilization rate of 
chloroethane from soil surfaces are needed to evaluate the persistence of this compound upon release to 
soil. The dominant removal mechanism for chloroethane in air is expected to be reaction with 
photochemically-generated hydroxyl radicals (Atkinson 1985; Howard and Evenson 1976). However, no 
data are available concerning the products of this reaction. These data are needed to understand the 
mechanism by which this compound degrades in the atmosphere. 
Bioavailability from Environmental Media. Chloroethane is readily absorbed following 
inhalation exposure, the major route of exposure (Konietzto 1984; Lehman and Flury 1943; Torkelson and 
Rowe 1981).  Data regarding the bioavailability of chloroethane from different media for other routes of 
exposure were not identified. Studies examining the absorption of chloroethane from various media 
following oral and dermal exposure are needed to predict exposure to chloroethane at hazardous waste 
sites. 
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Food Chain Bioaccumuiation. Based on bioconcentration factors of  7 and 5 estimated from log Kow 
and water solubility (Bysshe 1982; Hansch and Leo 1985; Horvath 1982), chloroethane is not expected to 
bioconcentrate significantly in aquatic organisms. Studies in which chloroethane is measured in biota and 
environmental media are needed to determine if the predictions are correct. 
Exposure Levels in Environmental Media. Relatively large amounts of chloroethane are released to 
the environment on an annual basis (TR196 1998). However, limited data were available concerning the 
detection of chloroethane in the environment, particularly in ambient air (Shepson et al. 1987; Singh et al. 
198 1), air in the vicinity of waste disposal sites (Vogt and Walsh 1985; Young and Parker 1984), drinking 
water, groundwater downgradient from waste disposal sites (HazDat 1998), and soil at waste disposal sites 
(HazDat 1998; Otson 1987). Reliable monitoring data for the levels of chloroethane in contaminated 
media at hazardous waste sites are needed so that the information obtained on levels of chloroethane in the 
environment can be used in combination with the known body burdens of chloroethane to assess the 
potential risk of adverse health effects in populations living in the vicinity of hazardous waste sites. 
Exposure Levels in Humans. Despite the fact that chloroethane is a fairly large volume commercial 
compound, limited data are available concerning occupational exposure. Tentative results of the National 
Occupational Exposure Survey are indicative of the number of workers potentially exposed to 
chloroethane in industry (NIOSH 1991). However, there are no quantitative data relating type of 
occupation to level and route of exposure. Available data indicate that the general population may be 
exposed to chloroethane by inhalation, ingestion of drinking water, and dermal contact (HSDB 1997). 
However, data were insufficient for estimating average daily intake by these routes. Up-to-date 
comprehensive monitoring data for air, water, and soil are needed to determine the typical amount of 
chloroethane to which the general population is exposed. 
This information is necessary for assessing the need to conduct health studies on these populations. 
Exposures of Children. Children are exposed to chloroethane via many different exposure pathways. 
However, to date no studies have provided information on adverse effects observed in children as a result 
of exposure to a specific dose of the compound. Reliable exposure and body burden studies in children are 
needed to relieve this data gap. In addition, because many older children may be exposed to chloroethane 
through sniffing the compound directly, there is a need to explore the prevalence of this behavior, the 
frequency of the abuse, and resulting exposure doses. 
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It is currently unknown whether children differ from adults in their weight-adjusted intake of chloroethane. 
Therefore, studies investigating this issue are needed. 
Exposure Registries. No exposure registries for chloroethane were located. This substance is not 
currently one of the compounds for which a subregistry has been established in the National Exposure 
Registry. The substance will be considered in the future when chemical selection is made for subregistries 
to be established. The information that is amassed in the National Exposure Registry facilitates the 
epidemiological research needed to assess adverse health outcomes that may be related to exposure to this 
substance. 
5.8.2 Ongoing Studies 
Ongoing studies regarding the environmental fate of chloroethane were not identified in the CRISP (1996), 
PEDRIP (1998), or CRIS/USDA (1998) databases. 
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The purpose of this chapter is to describe the analytical methods that are available for detecting, and/or 
measuring, and/or monitoring chloroethane, its metabolites, and other biomarkers of exposure and effect to 
chloroethane. The intent is not to provide an exhaustive list of analytical methods. Rather, the intention is 
to identify well-established methods that are used as the standard methods of analysis. Many of the 
analytical methods used for environmental samples are the methods approved by federal agencies and 
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH). Other 
methods presented in this chapter are those that are approved by groups such as the Association of Official 
Analytical Chemists (AOAC) and the American Public Health Association (APHA). Additionally, 
analytical methods are included that modify previously used methods to obtain lower detection limits, 
and/or to improve accuracy and precision. 
6.1 BIOLOGICAL SAMPLES 
The analytical methods for the determination of chloroethane in biological matrices are given in Table 6-1. 
The purge and trap method used for environmental samples is also commonly used for biological samples. 
The discussion regarding the methods that may be most sensitive for determining chloroethane levels in 
environmental samples and the advantages and disadvantages of the commonly used methods as given in 
Section 6.2 are also applicable for biological samples. 
6.2 ENVIRONMENTAL SAMPLES 
Analytical methods for the determination of chloroethane in environmental samples are presented in 
Table 6-2. The two common methods used for preconcentrating chloroethane in air samples are adsorption 
on a sorbent column and collection in a cryogenically cooled trap. The disadvantages of cryogenic cooling 
are that the method is cumbersome and condensation of moisture in air may block the passage of further 
air through the trap. The disadvantages of the sorption tubes are that the sorption and desorption 
efficiencies may not be 100% and that the background impurities in the sorbent tubes may interfere with 
the detection of samples containing low concentrations of chloroethane (Cox 1983). The most common 
method for determining chloroethane levels in water, sediment, soil, and aqluatic species is purging 
chloroethane vapor from the sample or its solution in water using an inert gas and then trapping the 
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trap. Subsequent thermal desorption is used for the quantification of its concentration. The two analytical 
instruments that provide the lowest detection limits are the halide-specific detectors (e.g., Hall electrolytic 
conductivity detector) and the mass spectrometer (see Table 6-2). The advantages of halide-specific 
detectors are that they are not only very sensitive, but they are also specific for halide compounds. The 
mass spectrometer, however, provides an additional confirmation of the presence of a compound through 
the ionization patterns and is desirable when a variety of compounds are to be quantified. High-resolution 
gas chromatography with capillary columns is a better method for volatile compounds than 
chromatography with packed columns because capillary columns provide better resolution of closely 
eluting compounds and increase the sensitivity of detection. In addition, purge and whole column 
cryotrapping eliminates the need for the conventional purge and trap unit and reduces the time of analysis 
(Pankow and Rosen 1988). The plugging of the trap by the condensation of moisture during cryotrapping 
may be avoided by using a wide bore capillary column, although the chromatographic resolution of such a 
column is inferior to narrow bore capillary columns (Mosesman et al. 1987; Pankow and Rosen 1988). 
6.3 ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate 
information on the health effects of chloroethane is available. Where adequate information is not available, 
ATSDR, in conjunction with the NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of chloroethane. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean that 
all data needs discussed in this section must be filled. In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
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6.3.1 Identification of Data Needs 
Methods for Determining Parent Compounds and Metabolites in Biological Materials. 
There is a relative paucity of data on the analytical methods for the determination of chloroethane levels, 
as well as levels of its metabolites, in biological matrices. Most of the limited number of publications that 
discuss the methods for the determination of organic volatiles in biological matrices (Michael et al. 1989; 
Pellizzari et al. 1979) are not specific for chloroethane. These studies analyze other structurally-similar 
chlorinated hydrocarbons and discuss the applicability of the techniques for measuring other 
hydrocarbons. Therefore, it is believed that these techniques would be useful for the detection of 
chloroethane in certain biological matrices.  However, recovery data and detection limits have not been 
conclusively determined for chloroethane at this time. Further studies to develop analytical methodologies 
for the determination of chloroethane in biological matrices are needed. 
One study was identified which described the assay of a chloroethane metabolite in human urine (ESkinja 
et al. 1997). This study measured the concentration of ethylmercapturic acid (EMA), a metabolite of 
glutathione conjugation of chloroethane, in urine from subjects presumably exposed to chloroethane. 
Themethod is fairly sensitive, with detection limits in the ppb range. 
Methods for Determining Biomarkers of Exposure and Effect. No known biomarker for this 
chemical in human tissue or body fluids has been identified. Ethylmercapturic acid, a metabolite of 
glutathione conjugation of chloroethane, can be detected in human urine. However, this metabolite can be 
formed by glutathione conjugation to other structurally-similar compounds and is not specific to 
chloroethane exposure. The potential usefulness of this compound as an indicator of exposure needs to be 
investigated further. Additional studies to identify specific biomarkers and to develop analytical 
monitoring methodologies for the determination of chloroethane exposure are needed. One breath 
absorption study using inhaled radiolabeled chloroethane quantitatively measured absorption of the 
compound (Morgan et al. 1970). However, the analytical technique used is not applicable for widespread 
use because it involved quantitative analysis of the radiolabel, not the compound itself. 
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Methods for Determining Parent Compounds and Degradation Products in 
Environmental Media.  Analytical methods with adequate sensitivity and specificity are available 
for the quantification of chloroethane in environmental samples (Driscoll et al. 1987; EPA 1982a, 1986b; 
Ferrario et al. 1985; Hiatt 1983; Lopez-Avila et al. 1987; Otson and Ghan 1987; Shepson et al. 1987; Vogt 
and Walsh 1985). The degradation products of chloroethane are ethanol and chloride salts (the 
hydrochloric acid initially formed dissociates to form chloride salts at the neutral pH values in most 
environmental media). Analysis for these compounds in environmental media would provide little or no 
information about chloroethane. 
6.3.2 Ongoing Studies 
No significant ongoing studies are in progress for the development of analytical methodologies for 




7. REGULATIONS AND ADVISORIES
 
The international, national, and state regulations and guidelines regarding chloroethane in air and water are 
summarized in Table 7-l. 
IARC considers chloroethane to be a Group 3 carcinogen, not classifiable (IARC 1991). A carcinogenic 
assessment of chloroethane has not been completed by the EPA (IRIS 1997). ACGIH considers 
chloroethane to be an animal carcinogen of unknown relevance to humans (ACGIH 1998). 
Toxicity data for chloroethane are limited to inhalation data. Therefore, estimates of safe exposure 
concentrations are only available for air. The QSHA permissible exposure limit (PEL) for chloroethane is 
1,000 ppm (OSHA 1998). ACGIH recommends an occupational exposure threshold limit value 
timeweighted average (TLV-TWA) of 100 ppm (skin) (ACGIH 1998). 
ATSDR has derived an acute-duration inhalation MRL of 15 ppm with an uncertainty factor of 100, based 
on a NOAEL of 1,504 ppm for fetotoxicity in mice that was observed at 4,946 ppm (Scortichini et al. 
1986). The EPA reference concentration (RfC) of 10 mg/m3 (4 ppm) is based on the same study. EPA used 
uncertainty factors of 10 to account for sensitive populations, 3 for interspecies extrapolation with 
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Adsorption Coefficient (Koc)-The ratio of the amount of a chemical adsorbed per unit weight of organic
 
carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.
 
Adsorption Ratio (Kd)-The amount of a chemical adsorbed by a sediment or soil (i.e., the solid phase)
 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a
 




Bioconcentration Factor (BCF)-The quotient of the concentration of a chemical in aquatic organisms at a
 
specific time or during a discrete time period of exposure divided by the concentration in the surrounding
 
water at the same time or during the same period.
 
Cancer Effect Level (CEL)-The lowest dose of chemical in a study, or group of studies, that produces
 




Carcinogen-A chemical capable of inducing cancer.
 
Ceiling Value-A concentration of a substance that should not be exceeded, even instantaneously.
 
Chronic Exposure-Exposure to a chemical for 365 days or more, as specified in the Toxicological Profiles.
 
Developmental Toxicity-The occurrence of adverse effects on the developing organism that may result
 
from exposure to a chemical prior to conception (either parent), during prenatal development, or
 
postnatally to the time of sexual maturation. Adverse developmental effects may be detected at any point
 
in the life span of the organism.
 
Embryotoxicity and Fetotoxicity-Any toxic effect on the conceptus as a result of prenatal exposure to a
 
chemical; the d istinguishing feature between the two terms is the stage of development during which the
 




EPA Health Advisory-An estimate of acceptable drinking water levels for a chemical substance based on
 
health effects information. A health advisory is not a legally enforceable federal standard, but serves as
 
technical guidance to assist federal, state, and local officials.
 
Immediately Dangerous to Life or Health (IDLH)-The maximum environmental concentration of a
 










Immunologic Toxicity-The occurrence of adverse effects on the immune system that may result from
 
exposure to environmental agents such as chemicals.
 
In Vitro-Isolated from the living organism and artificially maintained, as in a test tube.
 
In Vivo-Occurring within the living organism.
 
Lethal Concentratioq(LO) (LCLO)-The lowest concentraGon of a chemical in air which has been reported to
 
have caused death in humans or animals.
 
Lethal Concentration (50) (LC50) - A calculated concentration of a chemical in air to which exposure for a 
specific length of time is expected to cause death in 50% of a defined experimental animal population. 
Lethal Dose(50)_(LD50)-The lowest dose of a chemical introduced by a route other than inhalation that 
isexpected to have caused death in humans or animals. 
Lethal Dose(50) (LD50)-The dose of a chemical which has been calculated to cause death in 50% of a 
defined experimental animal population. 
Lethal Time(50) (LT50)-A calculated period of time within which a specific concentration of a chemical is 
expected to cause death in 50% of a defined experimental animal population. 
Lowest-Observed-Adverse-Effect Level (LOAEL)-The Aowest dose of chemical in a study, or group of 
studies, that produces statistically or biologically significant increases in frequency or severity of adverse 
effects between the exposed population and its appropriate control. 
Malformations-Permanent structural changes that may adversely affect survival, development, or function. 
Minimal Risk Level-An estimate of daily human exposure to a dose of a chemical that is likely to be 
without an appreciable risk of adverse noncancerous effects over a specified duration of exposure. 
Mutagen-A substance that causes mutations. A mutation is a change in the genetic material in a body cell. 
Mutations can lead to birth defects, miscarriages, or cancer. 
Neurotoxicity-The occurrence of adverse effects on the nervous system following exposure to chemical. 
No-Observed-Adverse-Effect Level (NOAEL)-The dose of chemical at which there were no statistically or 
biologically significant increases in frequency or severity of adverse effects seen between the exposed 
population and its appropriate control. Effects may be produced at this dose, but they are not considered to 
be adverse. 
Octanol-Water Partition Coefficient (Kow) -The equilibrium ratio of the concentrations of a chemical in n­
octanol and water, in dilute solution. 




q1*-The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure. The ql* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually µL for water, mg/kg/day for food, and µg/m3 
for air). 
Reference Dose (RfD)-An estimate (with uncertainty spanning perhaps an order of magnitude) of the daily 
exposure of the human population to a potential hazard that is likely to be without risk of deleterious 
effects during a lifetime. The RfD is operationally derived from the NOAEL (from animal and human 
studies) by a consistent application of uncertainty factors that reflect various types of data used to estimate 
RfDs and an additional modifying factor, which is based on a professional judgment of the entire database 
on the chemical. The RfDs are not applicable to nonthreshold effects such as cancer. 
Reportable Quantity (RQ)-The quantity of a hazardous substance that is considered reportable under 
CERCLA. Reportable quantities are (1) 1 pound or greater or (2) for selected substances, an amount 
established by regulation either under CERCLA or under Sect. 311 of the Clean Water Act. Quantities are 
measured over a 24-hour period. 
Reproductive Toxicity-The occurrence of adverse effects on the reproductive system that may result from 
exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the related 
endocrine system. The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of this 
system. 
Short-Term Exposure Limit (STEL)-The maximum concentration to which workers can be exposed for up 
to 15 mm continually. No more than four excursions are allowed per day, and there must be at least 60 min 
between exposure periods. The daily TLV-TWA may not be exceeded. 
Target Organ Toxicity-This term covers a broad range of adverse effects on target organs or physiological 
systems (e.g., renal, cardiovascular) extending from those arising through a single limited exposure to 
those assumed over a lifetime of exposure to a chemical. 
Teratogen-A chemical that causes structural defects that affect the development of an organism. 
Threshold Limit Value (TLV)-A concentration of a substance to which most workers can be exposed 
without adverse effect. The TLV may be expressed as a TWA, as a STEL, or as a CL. 
Time-Weighted Average (TWA)-An allowable exposure concentration averaged over a normal g-hour 
workday or 40-hour workweek. 
Toxic Dose (TD50)-A calculated dose of a chemical, introduced by a route other than inhalation, which is 
expected to cause a specific toxic effect in 50% of a defined experimental animal population. 
Uncertainty Factor (UF)-A factor used in operationally deriving the RfD from experimental data. UFs are 
intended to account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from 
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using LOAEL data 
rather than NOAEL data. Usually each of these factors is set equal to 10. 
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ATSDR MINIMAL RISK LEVELS AND WORKSHEETS 
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 
994991, requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly 
with the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances 
most commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances. 
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance. During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a given 
route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance that is 
likely to be without appreciable risk of adverse noncancer health effects over a specified duration of 
exposure.  MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or 
action levels. 
MRLs are derived for hazardous substances using the no-observed-adverse-effect 1eveVuncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects. MRLs are derived for acute (1-14 days), intermediate (15-364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure. Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans. Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs. Exposure to a level above 
the MRL does not mean that adverse health effects will occur. 
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MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely. They may also be viewed as a mechanism to identify those hazardous waste sites that 
are not expected to cause adverse health effects. Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances. ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention. Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive. Thus, the resulting MRL may be as much as a hundredfold below levels that 
have been shown to be nontoxic in laboratory animals. 
Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the 
Division of Toxicology, expert panel peer reviews, and agencywide MRL Workgroup reviews, with 
participation from other federal agencies and comments from the public. They are subject to change as 
new information becomes available concomitant with updating the toxicological profiles. Thus, MRLs in 
the most recent toxicological profiles supersede previously published levels. For additional information 
regarding MRLs, please contact the Division of Toxicology, Agency for Toxic Substances and Disease 
Registry, 1600 Clifton Road, Mailstop E-29, Atlanta, Georgia 30333. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Chloroethane 
CAS Number: 75-00-3 
Date: November 1998 
Profile Status: Post-Public 
Route: [x] Inhalation [ ] Oral 
Duration: [x] Acute [] Intermediate [ ] Chronic 
Graph Key: 30 
Species: Mice (CF-1) 
Minimal Risk Level:  15 [ ] mg/day [x] ppm 
Reference:  Scortichini et al. 1986 
Experimental design: Groups of 23-26 pregnant mice were exposed to 99.9% pure chloroethane at 0,49 1, 
1504, or 4,946 ppm 6 hours/day on gestation days 6-15. Body weights were recorded on gestation days 
6,9, 12, 15, and 18, and food and water intakes were measured. The animals were sacrificed on gestation 
day 18 and the following data were recorded: maternal liver weight; number and position of fetuses in 
utero; number of live and dead fetuses; number and position of resorption sites; weight and sex of each 
fetus; gross externalalterations. Half of each litter was examined for visceral alterations, half for skeletal 
alterations. 
Effects noted in study and corresponding doses: No maternal toxicity (body weight, food and water 
intake,liver weight) was observed. There were no effects on reproductive parameters, fetal body weight, or 
malformations. A small increase in the incidence of foramina of the skull bones (small centers of 
unossified bone) was observed at the high dose that was statistically significant (p = 0.05) (percent of 
litters affected 5%, 4%, 4%, 23%; percent of fetuses affected l%, l%, l%, 4% at 0,491, 1,504, and 4,946 
ppm, respectively). An increase in supernumerary ribs was also found, although the effect was not 
indicated as statistically significant. The incidence of fetuses with supernumerary ribs was 2/257 (1%) 
controls, and in increasing concentrations l/299 (0.3%), 6/311 (2%), and 2/242 (2%). The incidence in 
litters was 2/22 (9%) controls, l/25 (4%), 5/26 (19%), and 4/22 (18%). The authors indicate that the effect 
was “suggestive of, at most, very slight fetotoxicity” at the high dose. 
Dose and end point used for MRL derivation: 
[x] NOAEL [ ] LOAEL 
1,504 ppm 
Uncertainty Factors used in MRL derivation: 
[ ] 10 for use of a LOAEL 
[x] 10 for extrapolation from animals to humans 
[x] 10 for human variability 
Was a conversion used from ppm in food or water to a mg/body weight dose? No. 
If so, explain: 
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If an inhalation study in animals. list the conversion factors used in determining human equivalent dose: 
Because fetotoxic effects may result from peak concentrations rather than total duration of exposure, the 
NOAEL was not adjusted for intermittent exposure. 
Because chloroethane is lipid soluble it is reasonable to assume that periodicity was attained. Therefore, a 
human equivalent concentration (HEC) could be calculated by multiplying the NOAEL by the ratio of the 
human/mouse blood gas partition coefficients. The value for humans is 2.69 (Gargas et al. 1989). The 
value for mice is not known. Since the human/mouse ratio is unknown, a default value of 1 is used. 
Other additional studies or uertinent information which lend support to this MRL: 
There are no additional developmental or reproductive studies of chloroethane. A study by Bucher et al. 
(1995) reported a small increase in the average duration of the estrous cycle in female mice exposed to 
chloroethane at 15,000 ppm 6 hours/day for 21 days. No consistent effects on estradiol or progesterone 
effects were noted. No other exposure concentrations were used in this study. 
Other studies have not identified clear dose-related effects of chloroethane in animals at concentrations up 
to 19,000 ppm (Landry et al. 1982, 1987, 1989; NTP 1989). Because of an explosion hazard (chloroethane 






Public Health Statement 
This chapter of the profile is a health effects summary written in non-technical language. Its intended 
audience is the general public especially people living in the vicinity of a hazardous waste site or chemical 
release. If the Public Health Statement were removed from the rest of the document, it would still 
communicate to the lay public essential information about the chemical. 
The major headings in the Public Health Statement are useful to find specific topics of concern. The topics 
are written in a question and answer format. The answer to each question includes a sentence that will 
direct the reader to chapters in the profile that will provide more information on the given topic. 
Chapter 2 
Tables and Figures for Levels of Significant Exposure (LSE) 
Tables (2-1,2-2, and 2-3) and figures (2-l and 2-2) are used to summarize health effects and illustrate 
graphically levels of exposure associated with those effects. These levels cover health effects observed at 
increasing dose concentrations and durations, differences in response by species, minimal risk levels 
(MRLs) to humans for noncancer end points, and EPA’s estimated range associated with an upper- bound 
individual lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. Use the LSE tables and figures for a 
quick review of the health effects and to locate data for a specific exposure scenario. The LSE tables and 
figures should always be used in conjunction with the text. All entries in these tables and figures represent 
studies that provide reliable, quantitative estimates of No-Observed-Adverse- Effect Levels (NOAELs), 
Lowest-Observed-Adverse-Effect Levels (LOAELs), or Cancer Effect Levels (CELs). 
The legends presented below demonstrate the application of these tables and figures. Representative 
examples of LSE Table 2-l and Figure 2-l are shown. The numbers in the left column of the legends 
correspond to the numbers in the example table and figure. 
LEGEND 
See LSE Table 2-l 
(1) 	 Route of Exposure One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. When 
sufficient data exists, three LSE tables and two LSE figures are presented in the document. The 
three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, and 
dermal (LSE Table 2-1,2-2, and 2-3, respectively). LSE figures are limited to the inhalation (LSE 
Figure 2-l) and oral (LSE Figure 2-2) routes. Not all substances will have data on each route of 
exposure and will not therefore have all five of the tables and figures. 
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(2)	 Exposure Period Three exposure periods - acute (less than 1.5 days), intermediate (15-364 days), 
and chronic (365 days or more) are presented within each relevant route of exposure. In this 
example, an inhalation study of intermediate exposure duration is reported. For quick reference to 
health effects occurring from a known length of exposure, locate the applicable exposure period 
within the LSE table and figure. 
(3)	 Health Effect The major categories of health effects included in LSE tables and figures are death, 
systemic, immunological, neurological, developmental, reproductive, and cancer. NOAELs and 
LOAELs can be reported in the tables and figures for all effects but cancer. Systemic effects are 
further defined in the “System” column of the LSE table (see key number 18). 
(4)	 Key to Figure  Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure. In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the 2 “18r” data points in Figure 2-l). 
(5)	 Species The test species, whether animal or human, are identified in this column. 
“Relevance to Public Health,” covers the relevance of animal data to human toxicity and Section 
2.3, “Toxicokinetics,” contains any available information on comparative toxicokinetics. 
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL. 
(6)	 Exposure Frequency/Duration The duration of the study and the weekly and daily exposure 
regimen are provided in this column. This permits comparison of NOAELs and LOAELs from 
different studies. In this case (key number 18), rats were exposed to 1,1,2,2-tetrachloroethane via 
inhalation for 6 hours per day, 5 days per week, for 3 weeks. For a more complete review of the 
dosing regimen refer to the appropriate sections of the text or the original reference paper, i.e., 
Nitschke et al. 1981. 
(7)	 System This column further defines the systemic effects. These systems include: respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular.  “Other” refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems. In the example of key number 18, 1 systemic effect (respiratory) was 
investigated. 
(8)	 NOAEL A No-Observed-Adverse-Effect Level (NOAEL) is the highest exposure level at which 
no harmful effects were seen in the organ system studied. Key number 18 reports a NOAEL of 3 
ppm for the respiratory system which was used to derive an intermediate exposure, inhalation 
MRL of 0.005 ppm (see footnote “b”). 
(9)	 LOAEL A Lowest-Observed-Adverse-Effect Level (LOAEL) is the lowest dose used in the study 
that caused a harmful health effect. LOAELs have been classified into “Less Serious” and 
“Serious” effects. These distinctions help readers identify the levels of exposure at which adverse 
health effects first appear and the gradation of effects with increasing dose. A brief description of 
the specific endpoint used to quantify the adverse effect accompanies the LOAEL. The respiratory 
effect reported in key number 18 (hyperplasia) is a Less serious LOAEL of 10 ppm. MRLs are not 
derived from Serious LOAELs. 
(10) 	 Reference The complete reference citation is given in chapter 8 of the profile. 
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(11) 	 CEL A Cancer Effect Level (CEL) is the lowest exposure level associated with the onset of 
carcinogenesis in experimental or epidemiologic studies. CELs are always considered serious 
effects, The LSE tables and figures do not contain NOAELs for cancer, but the text may report 
doses not causing measurable cancer increases. 
(12)	 Footnotes Explanations of abbreviations or reference notes for data in the LSE tables are found in 
the footnotes. Footnote “b” indicates the NOAEL of 3 ppm in key number 18 was used to derive 
an MRL of 0.005 ppm. 
LEGEND 
See Figure 2-1 
LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
(13)	 Exposure Period The same exposure periods appear as in the LSE table. In this example, health 
effects observed within the intermediate and chronic exposure periods are illustrated. 
(14) 	 Health Effect These are the categories of health effects for which reliable quantitative data e 
exists. The same health effects appear in the LSE table. 
(15)	 Levels of Exposure concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log 
scale “y” axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day. 
(16)	 NOAEL In this example, 18r NOAEL is the critical endpoint for which an intermediate inhalation 
exposure MRL is based. As you can see from the LSE figure key, the open-circle symbol 
indicates to a NOAEL for the test species-rat. The key number 18 corresponds to the entry in the 
LSE table. The dashed descending arrow indicates the extrapolation from the exposure level of 3 
ppm (see entry 18 in the Table) to the MRL of 0.005 ppm (see footnote “b” in the LSE table). 
(17)	 CEL Key number 38r is 1 of 3 studies for which Cancer Effect Levels were derived. The diamond 
symbol refers to a Cancer Effect Level for the test species-mouse. The number 38 corresponds to 
the entry in the LSE table. 
(18)	 Estimated Upper-Bound Human Cancer Risk Levels This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are derived 
from the EPA’s Human Health Assessment Group’s upper-bound estimates of the slope of the 
cancer dose response curve at low dose levels (ql *). 
(19)	 Key to LSE Figure The Key explains the abbreviations and symbols used in the figure. 
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Chapter 2 (Section 2.5) 
Relevance to Public Health 
The Relevance to Public Health section provides a health effects summary based on evaluations of existing 
toxicologic, epidemiologic, and toxicokinetic information. This summary is designed to present 
interpretive, weight-of-evidence discussions for human health end points by addressing the following 
questions. 
1. What effects are known to occur in humans? 
2. What effects observed in animals are likely to be of concern to humans? 
3. What exposure conditions are likely to be of concern to humans, especially around 
hazardous waste sites? 
The section covers end points in the same order they appear within the Discussion of Health Effects by 
Route of Exposure section, by route (inhalation, oral, dermal) and within route by effect. Human data are 
presented first, then animal data. Both are organized by duration (acute, intermediate, chronic). In vitro 
data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also considered in 
this section. If data are located in the scientific literature, a table of genotoxicity information is included. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer potency 
or perform cancer risk assessments. Minimal risk levels (MRLs) for noncancer end points (if derived) and 
the end points from which they were derived are indicated and discussed. 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Data Needs section. 
Interpretation of Minimal Risk Levels 
Where sufficient toxicologic information is available, we have derived minimal risk levels (MRLs) for 
inhalation and oral routes of entry at each duration of exposure (acute, intermediate, and chronic). These 
MRLs are not meant to support regulatory action; but to acquaint health professionals with exposure levels 
at which adverse health effects are not expected to occur in humans. They should help physicians and 
public health officials determine the safety of a community living near a chemical emission, given the 
concentration of a contaminant in air or the estimated daily dose in water. MRLs are based largely on 
toxicological studies in animals and on reports of human occupational exposure. 
MRL users should be familiar with the toxicologic information on which the number is based. Chapter 2.5, 
“Relevance to Public Health,” contains basic information known about the substance. Other sections such 
as 2.8, “Interactions with Other Substances,” and 2.9, “Populations that are Unusually Susceptible” 
provide important supplemental information. 
MRL users should also understand the MRL derivation methodology. MRLs are derived using a modified 
version of the risk assessment methodology the Environmental Protection Agency (EPA) provides (Barnes 
and Dourson 1988) to determine reference doses for lifetime exposure (RfDs). 
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To derive an MRL, ATSDR generally selects the most sensitive endpoint which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration. ATSDR cannot make 
this judgement or derive an MRL unless information (quantitative or qualitative) is available for all potential 
systemic, neurological, and developmental effects. If this information and reliable quantitative data on the 
chosen endpoint are available, ATSDR derives an MRL using the most sensitive species (when information 
from multiple species is available) with the highest NOAEL that does not exceed any adverse effect levels. 
When a NOAEL is not available, a lowest-observed-adverse-effect level (LOAEL) can be used to derive an 
MRL, and an uncertainty factor (UF) of 10 must be employed. Additional uncertainty factors of 10 must be 
used both for human variability to protect sensitive subpopulations (people who are most susceptible to the 
health effects caused by the substance) and for interspecies variability (extrapolation from animals to humans). 
In deriving an MRL, these individual uncertainty factors are multiplied together. The product is then divided 
into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used in developing 
a substance-specific MRL are provided in the footnotes of the LSE Tables. 







